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II. ABSTRACT 
Hepatitis B Virus (HBV) leads to chronic infection of the liver and is a risk factor for the 
development of cirrhosis and hepatocellular carcinoma. Virus persistence requires the 
establishment and maintenance of covalently closed circular (ccc)DNA, serving as the episomal 
template for transcription of viral genes in the nucleus of infected hepatocytes. Viral cccDNA-
dependent gene expression requires HBV X protein (HBx) and HBx-mediated degradation of 
the host restriction factors structural maintenance of chromosome 5/6 (SMC5/6). A prerequisite 
for SMC5/6 ubiquitination and degradation is that HBx binds DNA damage-binding protein 1 
(DDB1) and further recruits Cullin 4A ring ligase complex, which requires neddylation for its 
activation. 
After the establishment of a reliable quantitative PCR, the kinetics of cccDNA formation 
in four in vitro infection systems and the effect of drugs (interferon-a, nucleos(t)ide analogues, 
entry inhibitors, and capsid inhibitors) on cccDNA were analyzed. Compared to replicative 
relaxed circular (rc)DNA, copy numbers of cccDNA in infected hepatocytes are unexpectedly 
low (1~6 copies per infected cell). Entry inhibitor, Myrcludex B, efficiently blocked cccDNA 
formation. Interferon-a reduced cccDNA level at high dose, whereas nucleos(t)ide analogues 
did not reduce it. Treatment with capsid inhibitors during the infection phase but not afterward 
led to a decline of cccDNA levels.  
Using HBx-minus virion for infection, we verified HBx as a key controller of cccDNA 
transcription. HBx expressed by its authentic promoter showed nuclear localization. Using 
lentiviral-based transcomplementation assay to restore the transcription of HBx-minus virus to 
the wild-type level, key fragments and residues of HBx were identified. The whole C-terminus 
of HBx (51~154 amino acids) was sufficient and indispensable to enhance transcription of 
HBx-minus virus, whereas N-terminal HBx (1~50 amino acids) displayed no transactivation. 
In addition, two shorter truncations (51~142 and 58~142 amino acids) showed residual function. 
Remarkably, the HBx(R96E) mutant with impaired binding activity to DDB1 totally abolished 
its transactivation activity, supporting that foundation of the HBx-DDB1 complex is required 
for maximal transcription from cccDNA. 
We further investigated whether blockage of neddylation hampers transcription. 
MLN4924, a specific NEDD8-activating enzyme 1 inhibitor, was identified to notably possess 
antiviral potential. MLN4924 potently reduced HBV transcription and viral antigen expression 
at nanomolar doses. After the establishment of cccDNA, the drug profoundly suppressed 
transcription from cccDNA without affecting cccDNA levels. Withdrawal of MLN4924 did not 
lead to restoration of cccDNA transcription in HepaRGhNTCP cells, however fast HBV rebound 
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was observed in infected HepG2hNTCP cells. Peculiarly, transcription from cccDNA of HBx-
minus virus was not significantly affected, suggesting that MLN4924 effect on wild-type virus 
replication is HBx dependent. MLN4924 selectively reduced transcription from all HBV 
promoters on cccDNA but not integrants. MLN4924 prevented SMC6 from degradation and 
the restoration of SMC6, in turn, silenced transcription from cccDNA. 
Taken together, nuclear HBx binds DDB1, induces SMC6 degradation and thereby 
promotes transcription from cccDNA. Targeting neddylation blocks transcription from 
cccDNA and restores SMC6 restriction on cccDNA. Therefore, MLN4924 treatment traps 
cccDNA in “transcriptional silence”. Small molecules that target the HBx-DDB1-Cullin 
complex might be foresight as the next possible therapeutic option combating HBV. 
Zusammenfassung 
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III. ZUSAMMENFASSUNG 
Das Hepatitis B Virus (HBV) kann zu chronischer Leberinfektion führen und ist ein 
Risikofaktor für die Entstehung von Leberzirrhose und dem hepato-zellulären Karzinom. Für 
die Persistenz des Virus ist die Bildung und die Aufrechterhaltung der kovalent geschlossenen 
zirkulären DNS („covalently closed circular“ (ccc)DNS) zwingend notwendig, da sie als 
episomale Matrize für die Transkription im Kern der infizierten Hepatozyten dient. Die an 
cccDNS gebundene virale Transkription hängt vom HBV X Protein (HBx) sowie den durch 
HBx initiierten Abbau des wirtsspezifischen Restriktionsfaktors „structural maintenance of 
chromosome 5/6“ (SMC5/6) ab. Eine Grundvoraussetzung für die Ubiquitinierung und den 
Abbau von SMC 5/6 ist, dass HBx das Protein “DNA damage-binding protein1“ (DDB1) bindet 
und somit den Cullin 4A Ringligasekomplex rekrutiert, welcher für seine Aktivierung 
neddyliert werden muss. 
Nachdem eine verlässliche quantitative PCR etabliert wurde konnte die Kinetik der 
cccDNS Bildung in vier verschiedenen in vitro Infektionsmodellen sowie der Einfluss von 
Medikamenten (Interferon-α, Nukleos(t)id-Analoga, Inhibitoren des viralen Zelleintritts 
(„entry Inhibitor“) und Kapsid-Inhibitoren) auf die cccDNS untersucht werden. Im Vergleich 
zum Replikationsintermediat der gelockerten zirkulären („relaxed circular“; (rc)DNS) sind die 
Kopienzahlen der cccDNS in infizierten Hepatozyten niedrig (1-6 Kopien/infizierter Zelle). Der 
„entry Inhibitor“ Myrcludex B unterband effizient die (ccc)DNS Bildung. Hohe Interferon-α 
Dosen verringerten die cccDNS Menge während Nukleos(t)id-Analoga diese nicht vermindern 
konnten. Die Gabe von Kapsid Inhibitoren während der Infektionsphase, aber nicht zu einem 
späteren Zeitpunkt, führte zu einer Verringerung der cccDNS Menge. 
Indem wir HBx negative Virionen für die Infektion verwendet haben, konnten wir die 
Schlüsselrolle von HBx in der Kontrolle der cccDNS Transkription verifizieren. Wird HBx 
transient von einem authentischen Promotor exprimiert befindet es sich im Zellkern. Mit Hilfe 
eines lentiviral basierten Transkomplementationsansatzes, in dem die Transkription von HBx 
defizienten Virionen auf das Level von Wildtypviren gehoben wurde, konnten 
Schlüsselfragmente und -bereiche des HBx bestimmt werden. Der gesamte C-Terminus von 
HBx (Aminosäuren 51-154) war sowohl ausreichend als auch unentbehrlich um die Replikation 
HBx-defizienter Viren wieder herzustellen während der N-Terminus (Aminosäuren 1-50) keine 
transaktivierende Funktion aufzeigte. Zusätzlich waren zwei kürzere Fragmente (Aminosäure 
51-142 und 58-142) teilweise funktional. Bemerkenswerterweise wies die HBx Mutante 
(R96E), welche nur noch eine geringe Bindeaktivität zu DDB1 aufweist, überhaupt keine 
Transaktivierungsaktivität mehr auf, was darauf hindeutet, dass die Bildung des HBx-DDB1 
Komplexes für die maximal mögliche Transkription der cccDNS nötig ist. 
Zusammenfassung 
VI 
Des Weiteren untersuchten wir ob eine Hemmung der Neddylierung die Transkription 
erschwert. MLN4924, ein spezifischer Inhibitor des NEDD8-aktivierenden Enzyms 1 zeigte ein 
bemerkenswertes antivirales Potenzial. MLN4924 verringerte die HBV Transkription und 
virale Antigenexpression wirksam in nanomolarer Dosierung. Nach der Bildung der cccDNS 
unterdrückte das Medikament hochgradig die Transkription selbiger ohne dabei die cccDNS 
Menge zu beeinflussen. Die Unterbrechung der MLN4924 Gabe führte in HepaRGNTCP Zellen 
nicht zu einer Reaktivierung der cccDNS Transkription, wohingegen in HepG2NTCP Zellen eine 
schnelle Erholung von HBV beobachtet wurde. Bemerkenswerter Weise wurde die 
Transkription der cccDNS HBx-defizienter Viren nicht signifikant beeinfluss, was darauf 
schließen lässt, dass der MLN4924 Effekt auf das Wildtypvirus HBx-abhängig ist. MLN4924 
verringert dabei selektiv die Transkription aller HBV Promotoren im Kontext der cccDNS, 
jedoch nicht bei integrierter viraler DNA. MLN4924 verhinderte der Abbau von SMC6, 
förderte dessen Wiederherstellung und unterband somit die Transkription der cccDNS. 
Zusammenfassen lässt sich sagen, dass nukleäres HBx DDB1 bindet, den Abbau von 
SMC6 induziert und so die Transkription der cccDNS fördert. Ein Angriff auf die Neddylierung 
unterbindet die Transkription der cccDNS und stellt die SMC6-abhängige Restriktion der 
cccDNS wieder her. Somit friert eine MLN4924 Behandlung die cccDNS in einem Zustand der 
„transkriptionellen Stille“ ein. Kleine Moleküle, die auf den HBx-DDB1-Cullin Komplex 
zielen könnten somit eine Vorausschau auf die nächstmögliche Therapie für HBV sein. 
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1. INTRODUCTION 
1.1. Hepatitis viruses 
According to WHO’s statistics, annually killing more people than HIV, tuberculosis and 
malaria, viral hepatitis has become the seventh leading cause of death and disability worldwide 
(Stanaway et al., 2016). Viral hepatitis is acute or chronic liver inflammation induced by viral 
infection. Most of common causes of viral hepatitis are one of the five hepatotropic viruses as 
shown in Table 1.1.: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), 
hepatitis D virus (HDV), and hepatitis E virus (HEV) (Zuckerman, 1996). It can not be 
neglected that a number of new-class hepatitis viruses discovered later (HGV, TT, SEN) may 
also lead to viral hepatitis (Reshetnyak et al., 2008). In addition, other viruses including herpes 
simplex virus, Epstein-Barr virus, and cytomegalovirus also cause local liver inflammation. 
Although all the five hepatitis viruses induce liver damage, they are genetically unrelated to 
each other and classified in distinct genera. A myriad of basic and clinical features of these 
viruses are summarized as shown. 
Table 1.1. Hepatitis viruses.  
 HAV HBV HCV HDV HEV 
Classification Picornavirus Hepadnavirus Hepacivirus Deltavirus Hepevirus 
Genome +ssRNA dsRNA-RT +ssRNA -ssRNA +ssRNA 
Incubation (d) 20~40 45~160 15~150 30~60 15~60 
Transmission 
route 
Fecal-oral Parenteral 
Perinatal 
Sexual 
Parenteral 
Perinatal 
Sexual 
Parenteral 
Sexual 
Fecal-oral 
Chronicity Acute 5-10% chronic1 
80% neonates 
70% chronic Chronic with 
HBV 
Acute2, # 
Carcinogenesis – + + – – 
Prophylaxis vaccine vaccine NA HBV vaccine vaccine3 
Therapy NA IFN, NUCs DAAs IFN RBV 
15~10% in immunocompetent adults; 2mild in normal adults and severe in pregnant women; 
3licensed in China. #: chronic in immunocompromised patients. ss: single stranded, ds: double 
stranded, RT: reverse transcriptase, IFN: interferon-a, NUC: nucleos(t)ide analogue, DAA: 
direct-acting antiviral, RBV: ribavirin; NA: therapy not required. 
Leading to acute hepatitis in most cases, HAV and HEV are usually fecal-oral transmitted 
through either person-to-person communication or ingestion of contaminated foods. Decades 
ago, both viruses caused outbreaks in the Third World countries (central Africa, southern Asia 
and southern America) where hygiene conditions were bad. Until 2012, HAV prevalence was 
only high in India, south-Sahara Africa and moderate in the Middle East, North Africa and 
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Latin America. For pre-exposure prevention, the application of HAV vaccines worldwide is 
highly effective in protecting healthy people for ten years. However, HEV is highly endemic in 
the whole Asia, northern and eastern Africa, Mexico and also present in the whole Europe, USA 
and South America, threatening more people in larger geographic regions. The first HEV 
vaccine was approved in China in 2011, yet it is not available in other countries (Tahaei et al., 
2012). 
One the other hand, HBV, HCV and HDV cause chronic infection and lead to a more 
serious global burden of public health. In 2013, HBV and HCV accounted for more than 95% 
of viral hepatitis-related mortality. By the year 2018, it was estimated that chronically infected 
people worldwide are 240 million (caused by HBV mono-infection), approximate 15~20 
million (by HBV/HDV co-infection) and 75 million (by HCV infection) (WHO’s statistics 
2018). Recent estimates have ranked viral hepatitis and associated clinical manifestations that 
account for more than 1 million death cases every year (Stanaway et al., 2016). 
HCV is a blood-borne hepatitis virus and prevalent all over the world. In 70% of HCV-
infected patients, HCV develops persistent infection and gradually leads to cirrhosis and 
hepatocellular carcinoma over the years. Because of its high mutation rate during replication, 
HCV vaccine is still not available. Combinational therapy of interferon and ribavirin was not 
efficient enough to control the virus. However, 25 years after its characterization, interferon-
free direct-acting antivirals have been developed. Antiviral medication using inhibitors 
targeting two or three HCV viral enzymes at the same time was approved and this therapy 
resulted in sustained virological response (SVR) rate to above 90% in patients. Reduced therapy 
duration and side effects of direct-acting antivirals allow a cure of HCV within 8 or 12 weeks 
(Asselah et al., 2016). 
In contrast to HCV, HBV and HDV chronic infections are not curable by the approved 
drugs. HBV is commonly transmitted from mother to neonate during birth delivery, as well as 
in adults through contact with blood or other body fluids. In immunocompetent adults, acute 
HBV infection is self-cleared and resolved in 90~95% of infected individuals, 80% of the 
neonates, however, can not naturally eliminate the virus. 5% of infected adults and 80 % of 
infected newborns develop chronic infection and are, similar to HCV chronic infection, at a 
very high risk of developing liver cirrhosis and hepatocellular carcinoma over decades. 
Therefore, among hepatitis viruses, HBV is the major health problem. HDV, a satellite virus of 
HBV, requires HBV envelope proteins for entry, assembly and spread. Patients with HBV and 
HDV coinfection show the most severe live injury and are with the highest risk to develop liver 
diseases. 
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1.2. Hepatitis B virus 
Hepadnaviridae is a collection of viruses with natural hosts, humans, apes and birds. Belonging 
to the Hepadnaviridae, all the viruses are divided into two genera: Avihepadnavirus that infects 
avian hepatocytes, and Orthohepadnavirus, with the best-known member the hepatitis B virus 
(HBV), which merely infects humans and chimpanzees (International Committee on Taxonomy 
of Viruses, 2018). HBV is a hepatotropic, small DNA virus in size and genome length, which 
is categorized into four serotypes (adw, ayw, adr, ayr) and into at least eight genotypes (A 
through H). Diseases and complications associated with chronic HBV infection contain 
hepatitis, liver cirrhosis and hepatocellular carcinomas. 
Three centuries ago, there were epidemic outbreaks of jaundice and of serum hepatitis 
after receiving vaccination in civilians, although people did not know what caused hepatitis. 
Later on, it was postulated that this infectious jaundice was caused by an unknown virus. In 
1946, MacCallum classified “infectious hepatitis” termed hepatitis A and “serum hepatitis” as 
hepatitis B (Mac, 1946). Using molecular biology that was further developed, Blumberg et al 
discovered the “Australia antigen” (HBsAg) among Australian aborigines and characterized a 
new pathogen, HBV. A few years later Dane et al observed the “dane” particle (complete HBV 
particle) isolated in the serum of infected patients (Blumberg et al., 1965, Dane et al., 1970). 
After HBV characterization, researchers started to seek preventive and therapeutic options. 
In the early 70s, Blumberg and his colleagues developed the first HBV vaccine that was a heat 
inactivation of the virus. In 1981, a plasma-derived HBV vaccine produced by inactivating 
pooled blood of HBsAg-positive donors by formaldehyde and pasteurization was approved. 
Merck further developed this inactivated type of vaccine as “Hepavax”. Nowadays safer, more 
effective and genetically engineered recombinant HBV vaccines have completely replaced the 
old ones (Hepatitis B Foundation, 2019). On the other hand, Interferon-a-2b (Intron A) as the 
first drug was approved by the FDA in 1981. In recent 25 years, Lamivudine (1998), Adefovir 
dipivoxil (2002), peginterferon (2002), Entecavir (2005), Telbivudine (2006), Tenofovir (2008) 
were one-by-one approved for treating chronic HBV infection as shown in Figure 1.1 (Thomas 
et al., 2015). The prodrug of tenofovir, Tenofovir alafenamide, was approved in 2016. 
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Figure 1.1. Timeline of HBV virologic characterization and therapeutic development. 
Events in discovery history and early HBV science (right upper, 1885~1970) and treatment 
options (1981~2012). (Emmanuel Thomas, 2015) with permission. 
1.2.1. Epidemiology 
In the global regions, WHO estimates that there are 240 million people with chronic HBV 
infection, which is defined as HBsAg positive. HBsAg prevalence is highest in Southeast Asia 
and Middle Africa (> 6%) and China (> 5%) in all-aged individuals. Prevalence is moderate in 
East Europe and South-East Asia (China excluded)(2.6~5%). HBsAg positive rate is pretty low 
in Australia, Western Europe (< 1%) and the whole America (0.7%) (Polaris Observatory, 2018) 
(Figure 1.2.). 
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Figure 1.2. HBsAg prevalence estimates in all-aged individuals in 2016. Estimated for 
countries with data and data extrapolated from countries in the same global burden of diseases 
with available data (all ages). Rates of HBsAg prevalence are shown in colors as indicated. 
Circles show absolute infection numbers (millions) (The Polaris Observatory Collaborators, 
Lancet, 2018) with permission. 
The epidemiological study also showed HBsAg prevalence in children at 5 years old. This 
value reveals preventive efforts in the regions by vaccination since mother-to-child 
transmission is one of the major routes accounting for HBV prevalence. Initiated a national 
vaccination program for 30 years, nowadays China has controlled HBsAg prevalence rate down 
to < 0.5% in children aged at 5 years, compared to 10~50 fold higher prevalence in all-age 
people (> 5%) (Polaris Observatory, 2018) (Figure 1.3.), however, China still has more than 
100 million chronic HBV carriers in the elders, waiting for a curative therapy (Figure 1.2). In 
contrast, rates of HBsAg prevalence in children aged at 5 year in India and Indonesia are 
ascending compared to the rates in all-aged individuals, which may be due to unstable 
vaccination programs towards newborns under high birth rate. 
Figure 1.3. HBsAg prevalence estimates in children aged at 5 years in 2016. Estimated 
for countries with data and data extrapolated from countries in the same global burden of 
diseases (children only aged at 5 years). Colors: HBsAg prevalence. Circles: total infected 
numbers. (The Polaris Observatory Collaborators, Lancet, 2018) with permission. 
 
1.2.2. Genomic organization 
Inside equipped capsid, HBV has a small but compact genome, which is a single copy of relaxed 
circular (rc)DNA with the length of 3182~3248 bp among genotypes (3182 bp, genotype D as 
shown in Figure 1.4.). Every rcDNA is covalently bound to one viral polymerase (P). Double-
stranded rcDNA consists of an entire minus strand and one partial plus strand. The minus-strand 
DNA is not covalently closed but covers the entire genome, while the plus strand starts from 
direct repeat 2 (DR2) and has variable 3’ ends at 50~80% of the whole genome (Lutwick and 
Robinson, 1977). 5’ plus strand terminates with a short RNA oligo that is derived from the 5’ 
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end of pregenomic RNA (pgRNA), the template for reverse transcription of the minus strand. 
Minus strand is covalently bound to polymerase via phosphotyrosine and has a short nucleotide 
terminus, which is essential for the formation of rcDNA, when sequences of DR1 and DR2 are 
identical (Seeger et al., 1986). In addition to rcDNA, approximate 10% of HBV genomes 
contain double-stranded linear DNA (dslDNA) generated from in situ priming of plus strand 
synthesis when DR1 and DR2 share mismatches (Staprans et al., 1991). After infection, 
dslDNA is the major component for HBV integration by homologous recombination (Tu et al., 
2017). 
The circular HBV genome contains four authentic promoters (core/preS1/preS2/X) and 
two enhancers (Enh1/Enh2). All transcripts have the same polyadenylation signal at their 3’ 
ends. Accordingly, open reading frames (precore-core/P/preS1-preS2-S/X) are under the four 
promoters. RcDNA and dslDNA are genomes in virus, however in cell rcDNA is converted 
into another type of genome, covalently closed circular (ccc)DNA by host DNA repair 
machinery including a/k/l polymerases, ligases and topoisomerases (Nassal, 2008, Qi et al., 
2016, Long et al., 2017, Sheraz et al., 2019, Tang et al., 2019). CccDNA serves as the major 
template of viral transcription and all transcripts can be expressed by the minus strand on the 
same cccDNA genome, then capped at their 5’ ends and polyadenylated at 3’ ends. At RNA 
level, HBV expresses preC/C (3.5 kb), preS1 (2.4 kb), S (2.1 kb), X transcripts (0.6~0.8 kb) 
and spliced RNA. They mostly share the same 3’ ends by the polyadenylation signal (Cattaneo 
et al., 1983b, Cattaneo et al., 1984). Furthermore, pgRNA (the shorter 3.5 kb) is -as a replicative 
pre-genome- encapsidated in infected cells as the template for rcDNA synthesis via reverse 
transcription but also is translated to core protein (HBcAg) and polymerase, whereas non-
genomic precore mRNA (the longer 3.5 kb) is translated and processed to HBeAg (Figure 1.4.). 
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Figure 1.4. HBV genomic structure. In the center, it shows the genomic scale (3182/1: EcoRI 
cutting site). The HBV genome is composed of a circular and double-stranded rcDNA. rcDNA 
is repaired to form cccDNA with both strands entired and closed that serves as the template 
for viral transcription to generate viral RNAs with 3.5 kb (two, different starting points), 2.4 kb, 
2.1 kb and 0.6~0.8 kb (uncertain) in size. Among these transcripts, the longer 3.5 kb PreC 
mRNA is translated to a pre-core protein and cleaved to HBeAg, whereas the shorter 3.5 kb 
pgRNA is translated to HBcAg and polymerase. The 2.4 kb mRNA is translated to the large 
surface antigen (L) and the 2.1 kb mRNA is responsible for the middle (M) and small (S) 
envelope proteins. The smallest mRNA encodes HBx protein. PreC: precore; pol: polymerase; 
DR1: direct repeat 1; DR2: direct repeat 2; Enh: enhancer; AAAA: polyadenylation ends. 
(Robert Gish, Antiviral Res, 2015) with permission. 
 
1.2.3. Structure and viral proteins 
Infectious virions (Dane particles) are made of 120 dimers of core proteins (T=3 or T=4 
symmetry) with an inner size of 22 nm (Dryden et al., 2006). The capsids are surrounded by a 
lipid membrane containing three viral envelopes, large (L), middle (M) and small proteins (S). 
Outer size of the enveloped particle is 47 nm. Molecular ratio of the L, M, and S proteins are 
1:1:4 (Heermann et al., 1984). Every nucleocapsid contains one copy of rcDNA genome that 
covalently links to one viral polymerase at 5’ end of its minus-strand. The virion has a density 
of 1.24~1.26 g/mL in CsCl gradients. Besides, non-infectious subviral particles, spheres and 
filaments, are also generated during HBV replication. Spheres with a size of 22 nm contain M 
and S proteins at a ratio of 1:2 and very little amount of L protein (Heermann et al., 1987). 
However, filaments are organized as a rod-like structure with variable length and contain L, M, 
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and S proteins at the same ratio of 1:1:4, similar to virion (Short et al., 2009). These subviral 
particles do not contain any viral rcDNA genomes and stay at a density of 1.18 g/mL in CsCl 
gradients (Figure 1.5.). 
HBV encodes seven viral proteins, five of which are structural (polymerase, core, L, M 
and S proteins) and two are non-structural (HBeAg and HBx protein) (Gish et al., 2015).  
Core protein has 183 amino acids with a molecular weight of approximate 21 kD. Within 
it, 45 amino acids in the center form a spike (Bringas, 1997). Carboxyl amino acids are arginine-
rich and this domain is required for pgRNA encapsidation and productive rcDNA synthesis 
(Nassal, 1992). It was further demonstrated that arginines in the SPRRR motif help pgRNA 
packaging and DNA replication (Lewellyn and Loeb, 2011). The C-terminus of core protein 
also contains three serine sites (Ser 155/162/170) that are phosphorylated and overlapped with 
the arginine-rich SPRRR motif. Phosphorylation of core protein is responsible for its nuclear 
localization (Eckhardt et al., 1991, Kann et al., 1999, Lan et al., 1999, Li et al., 2010a, Liao and 
Ou, 1995, Yeh et al., 1990). 
The HBeAg precursor is translated from precore mRNA with an upstream start codon in 
the frame of the core ORF. After translation, HBeAg precursor undergoes a cleavage of its C-
terminal 34 amino acids and anchors to the ER membranes via its signal peptide, before it is 
secreted as a 15 kD mature HBeAg from infected cells (Bruss and Gerlich, 1988, Garcia et al., 
1988, Ou et al., 1986, Ou et al., 1989, Standring et al., 1988, Zhou and Standring, 1991). 
Secreted HBeAg suppresses host immune response and increases the frequency of chronic 
infections. However, HBV mutations that lead to devoid of HBeAg expression have been 
frequently identified in long-term chronic infection in HBeAg negative patients (Brunetto et al., 
1999). 
L (preS1-preS2-S) and M proteins (preS2-S) are N-terminally longer than S protein. All 
three proteins share the same C-terminus. They also share topogenic signal I and II and 
hydrophobic C-terminus that direct these proteins to the ER membranes. L protein is N-
terminally myristoylated (glycine 2) and M protein is acetylated (Persing et al., 1987, Schmitt 
et al., 1999). N-terminus of L protein is crucial to capsid binding and is exposed on the surface 
of the virion and initiates effective infection of hepatocytes (Prange and Streeck, 1995). Another 
region located at transmembrane domain II and hydrophobic C-terminus of S contains a second 
infectivity determinant (Le Duff et al., 2009, Salisse and Sureau, 2009). M protein is 
dispensable for infectivity but acts as a spacer for virus assembly (Ni et al., 2010). M and S 
proteins containing export signals can be assembled and independently secreted as subviral 
particles as described in Figure 1.5.. 
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HBV polymerase with a size of 90 kD consists of three domains: terminal protein (TP) for 
the priming of minus-strand synthesis, reverse transcriptase (RT) for DNA synthesis and RNase 
H region for pgRNA degradation. Spacer with unclear function is a flexible region between the 
TP and RT domains (Bartenschlager and Schaller, 1988, Chang et al., 1990). The viral 
polymerase is specific to pgRNA template, utilizes itself to bind the e packaging signal at the 
5’ end of pgRNA and results in the priming of reverse transcription in the TP domain (tyrosine 
65) (Lanford et al., 1997, Wang and Seeger, 1992, Weber et al., 1994). Once encapsidated, one 
single polymerase catalyzes a complete round of DNA synthesis. Polymerase and pgRNA 
template co-exist at similar amounts but the molar ratio of polymerase molecules per virion 
DNA is approximate 0.7 in each virion (Bartenschlager et al., 1992, Bartenschlager and Schaller, 
1992, Zhang and Tavis, 2006). Owing to its enzymatic activity, reverse transcriptase becomes 
an antiviral target of approved nucleos(t)ide inhibitors. RNase H is also a target of potential 
inhibitors in development. Moreover, the polymerase may regulate host responses. Uncoupled 
from its function in DNA synthesis, polymerase anchors to the mitochondria via mitochondrial 
targeting signal in its TP domain (Unchwaniwala et al., 2016). Via its RT domain, polymerase 
interacts with the stimulator of interferon genes (STING), blocks its polyubiquitination and 
thereby suppresses interferon production (Liu et al., 2015) 
The other non-structural protein encoded by HBV is HBx, which has 154 amino acids 
(16.5 kD). HBx was identified to bind many cellular proteins and involved in multiple host 
processes. In terms of its high importance in this thesis, the biological functions of HBx were 
separately introduced in session 1.3.2.. 
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Figure 1.5. Structure of virions and subviral particles. Infectious virions (Dane particles) 
are composed of envelopes (L (preS1-preS2-S): M (preS2-S): S = 1:1:4) embedded with 
nucleocapsids (black). Polymerase (TP-RT-RNase H) and its associated rcDNA (dslDNA is 
not shown in this scheme) are located inside the nucleocapsid. Non-infectious subviral 
particles, spheres with mostly M and S proteins, filaments with L, M and S proteins (1:1:4), are 
made up by envelope proteins but do not contain any DNA genomes. TP: terminal protein; RT: 
reverse transcriptase. Adapted from an internal scheme in Urban’s laboratory. 
 
1.2.4. Overview of the HBV life cycle 
HBV infection initiates with an L envelope-dependent binding to heparan sulfate proteoglycans 
(HSPG) on the cellular membrane (Schulze et al., 2007). After attachment, myristoylated N-
terminal preS1 domain via the NPLGFFP motif binds the bona fide receptor, sodium 
taurocholate cotransporting polypeptide (NTCP) (Yan et al., 2012). Reconstitution of human 
NTCP but not rodent NTCP renders human hepatoma cells susceptible to HBV infection (Ni et 
al., 2014). After membrane fusion and uncoating, nucleocapsids are transported into the nuclear 
periphery, where capsids move into the nucleus in an importin a/b-dependent manner (Rabe et 
al., 2006, Schmitz et al., 2010). In the nucleus, rcDNA genome is released (Rabe et al., 2003, 
Rabe et al., 2009). How rcDNA is converted to cccDNA is not fully understood, it is likely that 
tyrosyl-DNA-phosphodiesterase 2 (TDP2) specifically cleaves the viral polymerase out of 
rcDNA (Koniger et al., 2014), and DNA polymerase k/l and ligases 1 and 3 are involved in 
rcDNA-to-cccDNA conversion (Qi et al., 2016, Long et al., 2017). 
Once cccDNA is formed, it serves as a template for viral transcripts, including pregenomic 
RNA (pgRNA), subgenomic RNAs, preCore mRNA and HBx mRNA. pgRNA acts as the 
template for translation of core and polymerase proteins and for the generation of new rcDNA. 
When translated, viral polymerase binds the epsilon signal e of pgRNA, this ribonucleoprotein 
complex further recruits HBcAg and is packaged into nucleocapsids (Bartenschlager and 
Schaller, 1992, Hirsch et al., 1990, Huang and Summers, 1991). Within capsids, minus-strand 
DNA is firstly synthesized by reverse transcription complementary to pgRNA and the 
polymerase remains covalently bound to the minus-strand (Gerlich and Robinson, 1980, 
Molnar-Kimber et al., 1983, Molnar-Kimber et al., 1984). Then pgRNA template is degraded 
by the RNase H activity of viral polymerase (Chen and Marion, 1996, Radziwill et al., 1990, 
Summers and Mason, 1982). Plus-strand DNA synthesis always starts after complete synthesis 
of minus-strand DNA and is primed via the remaining RNA oligomer of pgRNA. To prime it, 
the RNA oligomer anneals with DR2 that is identical to DR1 (Lien et al., 1986, Seeger et al., 
1986, Will et al., 1987, Staprans et al., 1991). If DR1 and DR2 are not exactly the same, their 
mismatches block rcDNA formation but promote an in situ DNA priming leading to the 
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formation of dslDNA that can be integrated into host genomes (Figure 1.6.) (Staprans et al., 
1991, Condreay et al., 1992, Yang and Summers, 1998). 
Nucleocapsids gain the opportunity to interact with envelopes (Huovila et al., 1992, 
Lenhoff and Summers, 1994, Patzer et al., 1984). Through the ER-Golgi apparatus, it is 
plausible that ubiquitin ligase Nedd4, g2-adaptin and thioredoxin-related transmembrane 
protein 2 (Rost et al., 2006, Hartmann-Stuhler and Prange, 2001, Toh et al., 2005) help virions 
locating at the ESCRT vesicles (endocytic sorting complexes required for transport) in which 
supports virus budding. Virions are secreted by multivesicular bodies. Alternatively, non-
enveloped nucleocapsids can be secreted as naked capsids. 
Figure 1.6. Overview of the HBV life cycle. HBV entry begins with a reversible attachment 
to HSPG (not drawn in the scheme) and a preS1 protein-mediated specific interaction with 
hepatocyte-specific bile acid cotransporter NTCP. After membrane fusion and uncoating, the 
nucleocapsid is either assembled out or transported into the nucleus to release viral rcDNA 
genome. rcDNA afterward is repaired by cellular proteins to convert to cccDNA, which is 
coupled with histones and core proteins and forms a mini-chromosome. RNA polymerase II-
driven transcription of cccDNA produces five capped and polyadenylated transcripts (PreC 
mRNA, pgRNA, preS, S and X mRNA) that are exported into cytoplasm where they are 
translated to seven viral proteins. One of these proteins, viral polymerase, binds the e signal 
region of the pgRNA. This ribonucleoprotein complex is encapsidated with phosphorylated 
core proteins. In most nucleocapsids, reverse transcription of pgRNA generates a complete 
minus-strand DNA and further pgRNA is degraded and partial plus-strand DNA is synthesized. 
In a minority of nucleocapsids, dslDNA is formed and responsible for HBV integration. rcDNA-
containing nucleocapsids are either recycled into the nucleus, directly secreted as naked 
capsids (not shown), or enveloped in the ER membrane and secreted as virions. Virions are 
secreted by multivesicular bodies. Spheres and filaments (see 1.1.4.) are secreted via the 
classical secretory pathway. (Tong et al. 2016) with permission. 
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1.3. cccDNA, HBx and HBx-mediated transcription of cccDNA 
1.3.1. cccDNA and mini-chromosome 
CccDNA plays a central role in HBV replication. Nucleocapsids in the cytoplasm either enter 
the nucleus to release rcDNA genome or being assembled with envelopes and secreted as 
virions. In the first option, released rcDNA is converted to cccDNA (Tuttleman et al., 1986). 
As a non-integrated circular genome, the cccDNA is not replicative as genomic DNA by host 
DNA synthesis system, however it produces all viral transcripts essential for protein production 
(Mason et al., 1982). In a non-dividing hepatocyte, cccDNA formation occurs early when viral 
envelope expression is low in DHBV infection (Summers et al., 1990). Once formed, the 
cccDNA pool is relatively stable and cccDNA copy number per cell is 1~50 (Jilbert et al., 1987, 
Kajino et al., 1994, Miller and Robinson, 1984, Zhang et al., 2003). The pool has a long half-
life comparable to its host in non-dividing cells (Levrero et al., 2009) but during mitosis loss of 
cccDNA was observed in in vivo experiments (Lutgehetmann et al., 2010, Allweiss et al., 2018). 
Due to its stability, cccDNA is also the key factor responsible for chronic HBV infection. 
For transcription, nuclear episomal cccDNA is bound to histones and transcriptional 
regulators. They organize into a chromatin-like structure termed “mini-chromosome”, which 
recruits also liver-specific nuclear proteins and viral HBcAg (Bock et al., 1994, Bock et al., 
2001, Newbold et al., 1995). The organization of viral DNA and nucleosomal proteins is usual 
for human papillomavirus and adenovirus (Favre et al., 1977, Tate and Philipson, 1979). Unlike 
latent DNA viruses, HBV replication requires a minichromosome composed of 
transcriptionally active chromatin. It is believed that RNA polymerase II binds cccDNA, 
bypasses the polyadenylation signal located in the core region and continues transcription for 
another 3.2 kb to generate 3.5 kb pre-C/C transcripts (Russnak, 1991). In addition to RNA 
polymerase and histones, under physiological situation, many liver-specific (HNF1, HNF3, 
HNF4a) and non-specific host factors (RARa/b, RXRa, PPARa, C/EBP, etc.) may be 
involved in transcription of cccDNA (Quasdorff and Protzer, 2010, Courtois et al., 1988, Guo 
et al., 1993, Lopez-Cabrera et al., 1990, Raney et al., 1995, Chen et al., 1994, Ori and Shaul, 
1995). Besides, two enhancers EnhI and EnhII, regulate the transcription from all four 
promoters and enhance the expression amounts of pgRNA, PreC, preS/S and HBx mRNA 
(Trujillo et al., 1991). 
 
1.3.2. Multi-functional HBx 
HBx is a multifunctional protein of all orthohepadnaviruses and essential to initiate infection 
and maintain replication in vivo and in vitro (Zoulim et al., 1994, Lucifora et al., 2011). Early 
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conceptions were established by overexpression analysis of HBx in various hepatoma and 
HEK293T cells, using these systems HBx was identified to interact with more than fifty host 
factors, including transcriptional factors and co-activators, key proteins in DNA damage, 
ubiquitin-proteasome pathway, mitochondrial components and effectors in signaling cascades 
(Bouchard and Schneider, 2004, Murakami, 2001). Transfection studies without HBV infection 
suggested that HBx is involved in various cellular processes (transcription, cell cycle, cell 
adhesion, DNA repair, apoptosis, protein stability). However, most functions were not further 
characterized in authentic infection systems. 
HBx is encoded by all orthohepadnaviruses. Although DHBV genome has a hidden open 
reading frame (ORF) as X-like encoding region and the putative protein expressed by a 
construct activated mitogen activated protein kinase (MAPK) pathway and was localized in the 
cytoplasm (Chang et al., 2001), a follow-up study showed that DHBV with a stop codon in the 
X-like ORF showed similar infectivity and replication level in vivo compared to the WT DHBV, 
questioning whether DHBV HBx-like protein really exists (Meier et al., 2003). Functional X 
proteins have been identified in infected mammals (humans, chimpanzees, woodchucks [WHx], 
ground squirrels [GSHx], horseshoe and tent-making bats [bat X] and so on). HBx protein has 
154 amino acids. WHx, GSHx and bat X have between 139~142 amino acids and a shorter C-
terminus compared to the HBx (Figure 1.7.). The additional C-terminal HBx (143~154 amino 
acids) is essential for its stability, transcriptional activation and replication stimulation (Lizzano 
et al., 2011, Luo et al., 2012, Li et al., 2016b).  
Figure 1.7. Alignment of HBx, WHx, GSHx and two bat X. Representative HBx proteins 
from all genotypes (A2, B2, C2, D, E2, F, G2, H) and WHx, GSHx, X from horseshoe and tent-
making bat were aligned using VectorNTI software. Homology was shown in different colors 
(yellow: the same residues; green: high conserved; blue: moderate conserved; white: not 
conserved). 
Full-length HBx protein has been divided into five regions based on their sequence 
homologies among eight genotypes. Three of the five regions (1~20, 58~84 and 120~154 amino 
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acids) are conserved and contain eight conserved cysteines (C7, C17, C61, C69, C115, C137, 
C143, C148) and two histidines (H52, H139), the other two (21~57 and 85~119 amino acids) 
however are less conserved (Kumar et al., 1996). This similarity suggests that HBx among all 
eight genotypes have common biochemical features. Purified recombinant HBx protein 
(genotype D) contained metal ions in particular zinc and iron (Jiang et al., 2016). Further 
characterization showed that zinc binding activity through conserved CCCH motif (C61, C69, 
C137 and H139) is required for its function (Ramakrishnan et al., 2019) (Figure 1.8.) 
Figure 1.8. Alignment of HBx from eight genotypes. HBx proteins among eight genotypes 
(A2, B2, C2, D, E2, F, G2, H) were aligned using VectorNTI software. Conserved domains: 
1~20 aa, 58~84 aa and 120~154 aa. Conserved C61, C69, C137 and H139 residues are 
shown in yellow. Variable domains: 21~57 aa and 85~119 aa. Yellow: the same residues; 
green: high conserved; blue: moderate conserved; white: not conserved. 
Figure 1.9. Scheme of the HBx protein. HBx has 154 amino acids and 17 kD in size. This 
scheme presents identified HBx domains. For transcriptional regulation, a negative regulatory 
domain (light purple) is located at the N-terminus (1~50 aa) and C-terminal HBx (51~154 aa) 
is the trans-activation region (brown). Highly variable disordered region (red) is overlapping 
with the dimerization region (Serine and proline rich). Other regions are responsible for binding 
of 14-3-3 protein (white) (26~31 aa), DDB1 (dark purple) (88~100 aa), p53 binding (light blue) 
(101~154 aa) and mitochondrial targeting (light green) (111~116 aa). The scheme is adapted 
from the ExPASy database. 
As shown in Figure 1.9., modulating transcription is one of the major functions of HBx. 
The N-terminal domain (1~50 amino acids) was firstly identified as a transcriptional repressor 
in trans (Murakami et al., 1994) and this repression was further mapped to the conserved 1~20 
amino acids (Misra et al., 2004). The N-terminal one third (1~50 amino acids) is not required 
but the whole C-terminal two-thirds (51~154 amino acids) is the trans-activation domain, which 
was confirmed using alanine scanning mutagenesis assay (Tang et al., 2005). Specifically, two 
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regions (52~65 and 88~154 amino acids) are crucial for the augmentation function of HBx. 
This finding showed similar findings as the earliest report presenting that HBx C-terminus 
(58~140 amino acids) retained trans-activation and was indispensable. In the nucleus, HBx 
promotes transcription from cccDNA, presumably associated with DNA-damage binding 
protein 1 (DDB1) by binding the motif (88~101 amino acids) (Li et al., 2010c). Although the 
association of HBx and DDB1 is not sufficient for maximal HBV replication (Hodgson et al., 
2012), this complex recruits host ubiquitin machinery and promotes degradation of SMC5/6 
restrictive on cccDNA to enhance HBV replication (Decorsiere et al., 2016) (Murphy et al., 
2016, Livingston et al., 2017). These findings provided concrete evidence that HBx in an 
authentic infection system enhances transcription of cccDNA. C-terminal HBx also binds p53 
and inhibits p53-mediated transcriptional trans-activation, apoptosis and DNA-specific binding 
(Elmore et al., 1997).  
HBx is primarily located in the nucleus and also accumulates in the cytoplasm (Cha et al., 
2009). Since HBx has a nuclear export signal (key residues L98 and L100) that is overlapping 
with DDB1 binding domain, the interaction of HBx and nuclear export receptor Crm1 allow 
cytoplasmic trans-localization of HBx (Forgues et al., 2001). When HBx is located in the 
cytoplasm, it forms a complex with MEKK1, SEK1, SAPK/JNK and 14-3-3 proteins (Diao et 
al., 2001). These interactions result in prolonged cell survival and maintain a cellular 
environment favorable to HBV replication. 
Besides nuclear localization, a proportion of HBx is transported to the mitochondria via 
its six amino acids at the C-terminus (111~116 amino acids). When cysteine 115 was mutated 
to alanine, mitochondria targeting of HBx was lost (Li et al., 2008). Mitochondrial HBx disrupts 
innate immunity by binding and down-regulating mitochondrial antiviral signaling protein 
(MAVS) and inhibits the activation of interferon regulatory factor 3 (IRF3) and b-interferon in 
vitro and in vivo (Wei et al., 2010, Wang et al., 2010, Kumar et al., 2011). On the mitochondria, 
HBx also binds the anti-apoptotic Bcl-2 protein to increase intracellular calcium level for virus 
replication and induces cell death (Bouchard et al., 2001, Chami et al., 2003, McClain et al., 
2007, Gearhart and Bouchard, 2010, Yang and Bouchard, 2012, Casciano and Bouchard, 2018). 
Similarly, HBx interacts directly with the Bcl-2 homolog CED-9 through Bcl-2 homology 3 
(BH3)-like motif, and as a result, trigger cytosolic calcium increase and cell death (Geng et al., 
2012a, Geng et al., 2012b). Later on, a structural study confirmed the binding of a synthesized 
BH3-like HBx peptide (110~135 amino acids) with recombinant Bcl-2 protein. Remarkably, 
the binding of HBx peptide and Bcl-2 required iron and zinc for its stability (Jiang et al., 2016). 
HBx also interacts with Bcl-xL with a similar structure as Bcl-2 via the same motif (Zhang et 
al., 2019). Nevertheless, most findings were based on the overexpression of HBx using 
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transfection. Due to its low expression level during HBV replication, it is unclear whether HBx 
displays the same functions in infection models. 
 
1.3.3. HBx-mediated transcription of cccDNA 
Efficient transcription from cccDNA requires a collection of transcriptional factors and co-
factors, including ubiquitous factors and liver-specific factors (Quasdorff and Protzer, 2010). 
Chromatin immunoprecipitation method (ChIP) allows the identification of the DNA binding 
sites of these factors. Using this technique, H3 and H4 Histones were identified to bind cccDNA 
and transcription from cccDNA was enhanced when the histones are acetylated (Pollicino et al., 
2006). ChIP-seq analysis further identified that high levels of methylated and acetylated 
histones associate with active transcription occurring at specific regions on the cccDNA, 
whereas low levels of modified histones correlate with transcriptional repression (Tropberger 
et al., 2015). HBcAg and HBx are also associated with the minichromosome by direct or 
indirect binding (Belloni et al., 2009). 
HBx protein associates with the ubiquitin-proteasome system (Minor and Slagle, 2014, 
Slagle and Bouchard, 2016, Slagle and Bouchard, 2018). Twenty years ago, HBx was firstly 
reported to interfere with cellular DNA repair (Becker et al., 1998). DDB2 directly binds 
damaged DNA and the whole DDB1-DDB2 complex is required for repair. HBx associates 
with DDB1 but not DDB2 and induces cell death, but this function is antagonized by DDB2 
(Bontron et al., 2002). In turn, DDB2 induces nuclear accumulation of HBx that is independent 
of its DDB1 binding, and HBx protein is stabilized by the DDB1-DDB2 complex (Nag et al., 
2001, Bergametti et al., 2002). However, HBx protein stimulates HBV replication via a DDB1-
dependent manner distinct from that leading to cell death, when DDB2 is also required (Leupin 
et al., 2003, Leupin et al., 2005). Binding of HBx and DDB1 affects the cell cycle and causes 
chromosome segregation defects (Martin-Lluesma et al., 2008).  
There are two predicted roles of the HBx-DDB1 complex in cccDNA transcription. The 
first model suggested that HBx does not directly bind cccDNA but associates with cccDNA via 
DDB1 binding, and the C-terminal HBx recruits transcriptional factors. However, so far no 
evidence using ChIP method supports the DDB1-cccDNA binding. The second model predicted 
HBx to recruit the whole DDB1 and ubiquitin ligases to “degrade a host restriction factor” or 
“prevent degradation of a dependency factor in transcription from cccDNA” (Hodgson et al., 
2012). Later, such restriction factors were identified. HBx binds DDB1 and hijacks the Cullin 
4A, an E3 ubiquitin ligase (Li et al., 2010c, Guo et al., 2014). HBx therefore bridges Cullin 4A 
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and ubiquitin-proteasome complex and promotes degradation of SMC5/6 and Talin-1 proteins 
that are all host restriction factors suppressing transcription from cccDNA (Decorsiere et al., 
2016, Murphy et al., 2016, van de Klundert et al., 2016a).  
 
1.4. Neddylation 
Post-translation modification of proteins enlarge biological utilization efficacy of each protein 
and enable degradation of proteins when they are redundant. Proteins can be modified in 
different ways, such as ubiquitination, sumoylation and neddylation involving conjugation of 
small messenger proteins.  
Ubiquitin is a well-characterized modifier required in many cellular processes that link to 
the ubiquitin-proteasome machinery (Ravid and Hochstrasser, 2008). Ubiquitination requires 
either one ubiquitin connected to the target protein (monoubiquitination) or -in most cases- a 
chain of multiple ubiquitins (polyubiquitination). Secondary ubiquitins are linked to one of the 
lysine residues or the first methionine of the primary ubiquitin that couples to the target protein 
and that number referring to the residues is defined for instance as “K48”, “M1”. Most K29 and 
K48 ubiquitination recruits the proteasome and initiates degradation of the target protein, 
whereas monoubiquitination and M1 and K63 polyubiquitination may regulate the protein but 
not mediate its degradation (Miranda and Sorkin, 2007). Of another ubiquitin-like messenger, 
SUMO (small ubiquitin-like modifier) labeling regulates protein aggregation, DNA repair and 
transcription (Gareau and Lima, 2010), Coupling of ATG8 and ATG12 regulates autophagy 
(Schreiber and Peter, 2014).  
NEDD8 (neural precursor cell expressed developmentally downregulated protein 8) has 
been characterized as a modifier of its major target, the E3 ubiquitin ligase family of Cullin-
ring ligases (CRL) (Enchev et al., 2015). NEDD8 is a conserved nuclear protein (Kamitani et 
al., 1997) and usually overexpressed with other neddylation enzymes in human cancers (Hori 
et al., 1999). Despite sharing 59 % similarity, NEDD8 and ubiquitin have no interchangeable 
functions because of their structural differences (Whitby et al., 1998). Mature NEDD8 protein 
is transferred by specific E1 and E2 enzymes and finally conjugated by E3 enzymes to a specific 
lysine in a targeted substrate protein. 
 
1.4.1. NAE1 mediated NEDD8 transfer cascade 
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As shown in Figure 1.10.., the NEDD8 transfer cascade begins with one of the E1 activating 
enzymes (NAE1 in this thesis as an example), which is a heterodimer composed of amyloid-b 
precursor protein binding protein 1 (APPBP1) and ubiquitin activating enzyme 3 (UBA3) 
subunits. Binding NEDD8, ATP and magnesium at the adenylation site of UBA3 subunit is 
followed by AMP binding to the NEDD8 and leads to a  pyrophosphate release. Therefore, 
NEDD8 is activated and attacked by the catalytic domain of the NAE1. At this step, the ATP 
binding of NEDD8 and NAE1 can be chemically blocked by a small molecule, termed 
MLN4924, which is an ATP competitor (Zhao et al., 2014). NAE1 restructures itself to be a 
closed confirmation that allows thiolation of the NEDD8 to the NAE1 active site and AMP 
release. NAE1 afterward recovers to its open confirmation and adenylates a second NEDD8 
leading to conformational rearrangement again. Dual NEDD8-loaded NAE1 binds specific E2 
enzymes, like UBE2M and UBE2F (not shown in the scheme). They catalyze a thiolation 
reaction and the transfer of NEDD8 from the active site of NAE1 onto the active site of the E2 
enzyme (Huang et al., 2005). In addition, UBE2M directly binds the NEDD8 conjugated with 
the NAE1 (Huang et al., 2007). In both cases, NEDD8 is transferred from NAE1 to UBE2M or 
UBE2F in close proximity. Furthermore, E3 ligases catalyze the transfer of NEDD8 from the 
E2 enzymes onto the substrate protein. The well-characterized E3 ligases are the ring domain 
subunit ring-box protein 1 (RBX1), one of the components of CRL1~4, and their close 
homologue CRL5 complex (Walden et al., 2003, Huang et al., 2007, Huang et al., 2009, Olsen 
et al., 2010). Fully validated neddylation substrates are the cullin members that nucleate the 
largest class of ring ligases, CRLs. CRL neddylation leads to the activation of ubiquitin transfer 
activity by alternative conformations of RBX1 and the CRLs (Duda et al., 2008, Saha and 
Deshaies, 2008, Yamoah et al., 2008). 
 
Figure 1.10. Scheme of the NEDD8 transfer cascade. The C-terminus of progenitor NEDD8 
protein is cleaved to generate mature NEDD8 messenger. One of eight host enzymes, NAE1, 
couples NEDD8 protein to the E1 enzyme in an ATP-dependent manner. NEDD8 protein is 
further loaded on the E2 enzyme, the E3 enzyme and finally substrates (mostly Cullin-ring 
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ligases). Neddylation of the substrates is reversible by cleaving NEDD8 out of the targets by 
the NEDD8 isopeptidase. Adapted from (Zhao et al., 2014) with permission. 
 
1.4.2. NAE1 inhibitor MLN4924 and its antiviral potential 
HBx enhances HBV replication in vivo and in vitro (Balsano et al., 1993, Lucifora et al., 2011). 
HBx induces degradation of host restriction factor(s) (Minor and Slagle, 2014) that were 
identified as SMC5/6 proteins, which are ubiquitin labelled and degraded in an HBx-dependent 
manner (Decorsiere et al., 2016, Murphy et al., 2016), raising up the opportunity that this 
function of HBx may become a drug target. A prerequisite of SMC5/6 degradation is the HBx 
binding of DDB1 and recruitment of host E3 ubiquitin ligase CRL4A. As depicted above, to be 
fully activated, CRL4A neddylation is mandatory, and thereby neddylation inhibitor MLN4924 
may result in the unavailability of the HBx-DDB1-CRL4A complex. 
Pharmacologic inhibition of CRL4A neddylation is thus practical. MLN4924 is a first-in-
class NAE1 inhibitor being tested in phase III clinical trial towards patients with melanoma and 
lymphoma, since it selectively and potently inhibits catalytic activity of NAE1 at EC50 value of 
nanomolar concentration (EC50 = 4 nM in biochemical analysis) (Soucy et al., 2009, Brownell 
et al., 2010). MLN4924 resembles AMP and binds the adenylation site of NAE that competes 
for loading of NEDD8. MLN4924 also forms a sulphamate adduct and inhibits CRL4A 
neddylation and activity (Embade et al., 2012). From the virological point of view, it has been 
reported that MLN4924 blocks simian immunodeficiency virus and lentiviral infections by 
disrupting Vpx-mediated neddylation-dependent SAMHD1 degradation, suggesting that host 
neddylation signaling is hijacked by retrovirus and the inhibition of neddylation restricts 
lentivirus replication (Hofmann et al., 2013, Wei et al., 2014). Furthermore, a recent study 
extends MLN4924 application to broader and more potent antiviral activities against human 
and mouse cytomegalovirus, and herpes simplex virus (Le-Trilling et al., 2016). Taking that 
HBx also hijacks host CRLs in the context of transactivation into account, it is reasonable to 
speculate that MLN4924 may have an antiviral effect on HBV replication. 
 
1.5. Antivirals for HBV 
Vaccines and antivirals are two major ways of preventing or controlling viral infection. 
Although HBV vaccines are safe and effective, they have no effect against established chronic 
HBV infection. Potential therapeutic vaccines that may stimulate the host immune system for 
HBV clearance are far from being approved. Moreover, some people who do not generate 
protective anti-HBsAg antibodies after complete vaccinations are deemed “non-responders”. It 
is estimated that 5% of people who are at elder age or have cigarette smoking, alcohol drinking, 
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obesity, chronic illness and other factors might not respond to vaccines. HBV vaccine non-
responsiveness also varies among each subject population (Saco et al., 2018). In addition, a 
small proportion of people are responders but have a rapid decline of anti-HBsAg titer over 2~3 
years after successful vaccination (Propst et al., 1998). Therefore, antivirals with curative 
potential are required. 
 
1.5.1. Overview of anti-HBV agents 
 
Figure 1.11. Antiviral targets on HBV replicative steps in development. Listed entry 
inhibitors interfere with HBV entry via NTCP. rcDNA-to-cccDNA conversion can be affected by 
sulfonamides. cccDNA can be degraded by specific CRISPR or transcriptionally silenced by 
histone deacetylase inhibitors. Transcription of cccDNA is hampered by specific siRNA. 
Reverse transcription is blocked by nucleos(t)ide analogues (NUC). Capsid assembly is 
targeted by capsid modulator (CpAM). Assembly ad secretion of HBsAg is blocked by nucleic 
acid polymers. Adapted from (Durantel and Zoulim, 2016) with permission. 
As shown in Figure 1.11., except HBx, most of the viral proteins and replicative steps have 
been targeted with approved drugs or investigational inhibitors. Targeting viral entry, entry 
inhibitors Myrcludex B and cyclosporine derivatives interfere with preS1-mediated NTCP 
binding. How virus trafficking after its entry is largely unknown, but the rcDNA-to-cccDNA 
conversion has been tested as an in vitro drug target. Two disubstituted sulfonamides, termed 
CCC-0346 and CCC-0975 and selected from a small molecule library with 85,000 compounds, 
affect rcDNA conversion to cccDNA without inhibiting viral polymerase and rcDNA 
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replication (Cai et al., 2012). Decomposition of established cccDNA can be induced not only 
by cytokines (IFN-a, IFN-g, and TNF-a) (Xia et al., 2016) but theoretically also by exogenous 
engineered nucleases (ZFNs, TALENs, and CRISPR/Cas9) (Bloom et al., 2013, Weber et al., 
2014, Seeger and Sohn, 2014, Seeger and Sohn, 2016). In the next step, cccDNA transcription 
may be silenced by epigenetic modifiers targeting cccDNA methylation, histone methylation 
and acetylation (e.g. HDAC inhibitors). Host nuclear receptors (e.g. retinoid X receptor a) 
seems to positively regulate cccDNA transcription. RXRa-specific agonist Bexarotene was 
found to inhibit HBV replication and silencing of RXRa led to evaluated cccDNA formation 
and antigen production (Song et al., 2018). 
Whether HBx will be a pharmacologic target? It may be an ideal target of blocking 
transcription of cccDNA that requires HBx. Although one of the FDA-approved drugs, 
terbinafine, specifically and potently inhibits HBx-mediated HBV RNA transcription in 
HepG2.2.15 and transfected HepG2 cells, it is unclear whether it inhibits transcription from 
authentic cccDNA in de novo infection (van de Klundert et al., 2016b).  
Many silencing RNAs (siRNA) induce degradation of viral transcripts without specificity. 
Among them (ARB-1467, ARB-1740, ARC-520, RG6004, ARO-HBV, ALN-HBV, etc.), 
ARC-520 consists of two siRNAs conjugated to cholesterol and shows favorable tolerability in 
phase I clinical trial (Schluep et al., 2017). In the phase II trial, HBsAg is strongly suppressed 
in treatment-naïve HBeAg positive patients but less significantly reduced in patients who are 
either HBeAg negative or received long-term NUC treatment (Wooddell et al., 2017). 
For the next step, NUCs are approved as first-line drugs. As HBV polymerase is a reverse 
transcriptase with ribonuclease H activity, the latter is also a target of specific RNase H 
inhibitors (Tavis et al., 2013, Hu et al., 2013, Cai et al., 2014, Lu et al., 2015, Tavis and 
Lomonosova, 2015, Lomonosova et al., 2017, Tavis et al., 2018).  
Disturbing nucleocapsid formation and assembly, at least three classes of capsid inhibitors 
are in development. However, neither NUCs nor capsid modulators induces HBsAg reduction. 
Nucleic acid polymers (NAPs) are first-in-class HBsAg secretion inhibitors, which interfere 
with the formation of subviral particles and prevent the release of them from infected 
hepatocytes. Two of the NAPs, REP 2139 and REP 2165, are well tolerated and have substantial 
antiviral activity in patients in phase I/II trials. REP 2139 administration leads to rapid 
elimination of HBsAg and reduction of viral load in patient sera (Roehl et al., 2017, Bazinet et 
al., 2017). Recently, a small molecule, RG7834, belonging to the dihydroquinolizinones, was 
discovered by screening a small molecule library with one million compounds. RG7834 
Introduction 
 
 
22 
profoundly reduced HBsAg as well as viral load in infected PHH and humanized mice. 
Moreover, Entecavir and pegylated IFN-a-2a when treated in combination with RG7834 
resulted in more potent reductions of HBsAg and DNA levels in humanized mice (Mueller et 
al., 2018). 
Taken together, small molecule inhibitors in development have targeted most of the 
intracellular steps in HBV replication. However, elimination of cccDNA or silence of HBx-
mediated transcription from cccDNA (one way of functional cure) is still not possible. In the 
following table, all compounds approved and in development for chronic hepatitis B are 
summarized (Table 1.4.). 
Table 1.2. Compounds approved and in development for therapeutic use (updated July 
2019). 
Name                 Brand Name    Nature     Mechanism                   Company             Status 
IFN-a-2b               Intron A        cytokine   immunomodulator         Merck                   Approved 
Pegylated IFN       Pegasys       cytokine   immunomodulator        Genentech            Approved 
Lamivudine            Epivir               NUC         inhibits polymerase       GlaxoSmithKline   Approved 
Adefovir dipivoxil  Hepsera         NUC       inhibits polymerase       Gilead                   Approved 
Entecavir              Baraclude      NUC       inhibits polymerase       Bristol-Myers        Approved 
                                                                                                        Squibb 
Telbivudine           Tyzeka          NUC       inhibits polymerase        Novartis               Approved 
Tenofovir               Viread           NUC       inhibits polymerase        Gilead                  Approved 
Tenofovir               Vemlidy         NUC      inhibits polymerase        Gilead                  Approved 
alafenamide          
ANA 380               Besivo           NUC       inhibits polymerase       Ildong Pharma     Approved§ 
Myrcludex B         Bulevirtide     peptide               NTCP                  MYR GmbH         Phase III 
Cyclosporin A      Sandimmune peptide               NTCP                  Norvatis              Approved# 
HBIG                    HepaGam B   antibody            L/M/S                  Aptevo Bio          Approved 
BAY 41-4109                              HAP        capsid assembly           Bayer GmbH       Preclinical 
GLS4 (morphothiadin)                HAP        capsid assembly            HEC Pharma        Phase II 
NVR 3-778                                  SBA        capsid assembly           Janssen                Phase II 
JNJ 56136379                            CpAM      capsid assembly            Janssen               Phase II 
ABI-H0731                                  CpAM      capsid assembly            Assembly Bio.     Phase II 
AB-506                                        SBA        capsid assembly            Arbutus Bio.         Phase I 
RG7907                                      CpAM      capsid assembly            Roche                  Phase I 
VIR-2218                                    siRNA      RNAi silencer                 Vir Biotech           Phase II 
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RG6004                                      siRNA      RNAi silencer                 Roche                  Phase II 
ARO-HBV                                   siRNA      RNAi silencer                 Janssen               Phase II 
AB-729                                      siRNA      RNAi silencer                 Arbutus Bio.         Phase I 
DCR-HBVS                               siRNA      RNAi silencer                 Arbutus Bio.         Phase II 
EBT106                                     sgRNA     CRISPR/Cas                  Excision Bio.      Preclinical 
RNase H inhibitor                                      inhibits polymerase        Arbutus Bio.       Preclinical 
ccc_R08                                                    cccDNA decay                Roche                Preclinical 
RG7834                         carboxylic acid    HBsAg inhibitor               Roche                  Phase I 
REP 2139                                     NAP      HBsAg inhibitor              Replicor               Phase II 
REP 2165                                     NAP      HBsAg inhibitor              Replicor               Phase II 
EYP001                                 unknown      FXR agonist                   Enyo Pharma       Phase I 
NUC: nucleos(t)ide analogue, NTCP: sodium taurocholate cotransporting polypeptide, HAP: 
heteroaryldihydropyrimidines, SBA: sulfamoyl benzamides, CpAM: core protein allosteric 
modifiers. NAP: nucleic acid polymer.  
§: approved outside USA, #: approved for other diseases. Adapted from the Hepatitis B 
Foundation. 
 
1.5.2. Interferon-a and pegylated interferon-a 
Interferon-a (IFN-a) is the first drug, which was approved by the FDA in 1991. As a natural 
first-line defense against viruses, IFN-a with interferon-stimulated genes (ISG) has a broad 
antiviral activity. Later on, polyethylene glycol was conjugated to IFN-a and this modification 
allows interferon lasting longer in vivo. Pegylated IFN-a was licensed in 1995. Both pegylated 
IFN-a and IFN-b are medically used, yet only pegylated IFN-a-2a (PegaSys) and IFN-a-2b 
(IntronA/PegIntron) given by subcutaneous injection are currently used for chronic HBV 
treatment. However, the response rate of pegylated interferons remains low (5~20%) and side 
effects are common including influenza-like symptom, headache and fatigue (Janssen et al., 
2005, Xia and Protzer, 2017). 
IFN-a and ISG play pleiotropic roles in counteracting HBV replication. Firstly, IFN-a-
treated HBV-infected HepaRG cells release soluble factors that compete with the virus for 
HSPG binding and restrict HBV spread to neighbor cells. The interferon-induced secreted 
factors inhibited HBV binding to heparin. Size exclusion purification showed that they are 
larger than 100 kD, although the nature of these factors was never characterized (Xia et al., 
2017b). Secondly, high doses of IFN-a mediate non-cytolytic clearance of cccDNA in infected 
PHH and HepaRG cells. To be specific, IFN-a specifically induces nuclear deaminase 
APOBEC3A, which is also an ISG and binds nuclear HBcAg to tether on cccDNA (Lucifora et 
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al., 2014). Deaminated cccDNA by APOBEC3A becomes prone to be degraded by hydrolysis 
of another nuclease ISG20 (personal communications with Daniela Stadler). IFN-a upregulates 
APOBEC3A level in vitro and in the livers of treated patients and chimpanzees, the response 
to IFN-a treated patients correlates with IFN-mediated base excision repair that leads to 
cccDNA decay (Li et al., 2017). Thirdly, IFN-a inhibits transcription of viral RNA from 
cccDNA minichromosome by regulating its epigenetic modification in vitro and in humanized 
mice. IFN-a leads to histone hypo-acetylation (via reducing the H3K9 and H3K27 acetylation) 
and recruitment of transcriptional repressors such as histone deacetylase 1 (HDAC1) on 
cccDNA (Belloni et al., 2012, Liu et al., 2013). The reduction of histone activity by IFN-a in 
HBV-infected PHH can be recapitulated by an epigenetic modulator, C646, which inhibits 
histone acetyltransferases (Tropberger et al., 2015). Fourthly, IFN-induced tripartite motif 22 
protein (TRIM22) inhibits HBV core promoter activity and gene expression in vitro and in vivo 
(Gao et al., 2009). Fifthly, many ISGs restrict viral transcription. For instance, zinc finger 
proteins trigger viral RNA decay in vitro and in vivo (Mao et al., 2013, Chen et al., 2015). 
Myeloid differentiation primary response protein 88 (MyD88) facilitates this decay (Li et al., 
2010b). Myxoma resistance protein 1 (Mx1) impedes pgRNA encapsidation (Gordien et al., 
2001, Li et al., 2012). APOBEC3G induces genome hyper-mutation and it is incorporated into 
cytosolic nucleocapsids to inhibit viral DNA replication (Noguchi et al., 2005, Nguyen et al., 
2007, Nguyen and Hu, 2008). Sixthly, IFN-a upregulates RNA-dependent protein kinase (PKR) 
that inhibits the synthesis of viral proteins. Consequently, the intracellular level of capsid 
proteins is reduced (Park et al., 2011). Finally, IFN-a treatment enhances tetherin expression 
that blocks the egress of HBV particles. Tetherin colocalizes with virions at the multivesicular 
bodies and therefore reduces virus budding without affecting intracellular viral replication (Yan 
et al., 2015). In sum, IFN-a and ISGs almost target all the replicative steps in the HBV life 
cycle. Besides, IFN-a is a strong immunomodulator that stimulates adaptive immune responses. 
Recruited cytotoxic T cells are able to kill the HBV infected hepatocytes. 
 
1.5.3. Nucleos(t)ide analogues 
Beside IFN-a and pegylated IFN-a, six nucleoside and nucleotide analogues (NUCs) are 
licensed by FDA for treating chronic hepatitis B: Epivir (Lamivudine, approved in 1998), 
Hepsera (Adefovir dipivoxil, 2002), Baraclude (Entecavir, 2005), Tyzeka (Telbivudine, 2006), 
Viread (Tenofovir, 2008), and Vemlidy (Tenofovir alafenamide or TAF, November 2016). 
Lamivudine, Telbivudine and Entecavir are nucleoside analogues containing a nucleic acid 
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analogue and a sugar, whereas Adefovir dipivoxil, Tenofovir disoproxil fumarate and Tenofovir 
alafenamide are nucleotide analogues that contain a nucleic acid, a sugar and 1~3 phosphate 
groups (Fung et al., 2011, Lo and Wong, 2014). All six NUCs target the viral polymerase and 
potently inhibit minus-strand DNA synthesis by reverse-transcription mediated by the viral 
polymerase. However, they have their specific features. 
Lamivudine (3TC, LAM), used to treat HIV infection, was the first nucleoside analogue 
approved for the treatment of chronic hepatitis B at a dose of 100 mg/day by oral administration. 
It is a broad reverse transcriptase inhibitor acting at HBV polymerase as well as HIV reverse 
transcriptase. It reduces viral DNA load, improves HBeAg seroconversion, normalizes ALT 
level and reverses fibrosis (Lai et al., 1998, Dienstag et al., 1999). Upon treatment, Lamivudine 
decreases the risk of hepatocellular carcinoma in cirrhotic patients when compared with the 
patients without treatment (Liaw et al., 2004, Yuen et al., 2007). However, the major drawback 
of Lamivudine therapy is frequent drug resistance mutation at the tyrosinemethionine-aspartate-
aspartate (YMDD) motif in the catalytic domain of the viral polymerase. Emergence frequency 
of YMDD mutants arises from 15~32 % in the first year to 69 % in the fifth year of treatment 
(Lai et al., 2003). Other mutations responsible for drug resistance include rtM204V 
concomitantly occurring with rtL180M and rtM204I occurring alone or together with rtL180M 
(Allen et al., 1998). Nevertheless, Lamivudine is safe, moderately effective and improves liver 
function in patients (Kapoor et al., 2000, Yao et al., 2001). 
Adefovir dipivoxil (ADV) was the second nucleotide analogue, approved for treating 
chronic hepatitis B at a dose of 10 mg/day. Adefovir leads to a thousand-fold reduction on HBV 
DNA titer, frequent HBeAg seroconversion, and normalization of ALT concentration compared 
with the placebo (Marcellin et al., 2003), although at 10 mg/day dose the speed of viral 
suppression was slow (>48 weeks). One great significance of Adefovir is that Lamivudine 
resistant rtM204V/I mutant is sensitive to Adefovir (Lampertico et al., 2005). However, upon 
Adevovir treatment two major mutations of viral polymerase rtA181V/T and rtN236T are 
emerging (Angus et al., 2003). 29 % resistance rate occurs in the fifth year of its treatment 
(Hadziyannis et al., 2006). Increased nephrotoxicity is associated with Adefovir treatment at 
higher doses. This nephrotoxicity with a decrease in serum phosphate and an increase in serum 
creatinine levels started from 4~12 months after therapy. Toxicity was disappeared when the 
treatment was terminated (Marcellin et al., 2008). 
Entecavir (ETV) was licensed at a dose of 0.5 mg/day for treatment naïve patients and 1 
mg/day for Lamivudine ineffective patients. As a guanosine analogue, Entecavir inhibits 
priming of viral polymerase involving guanosine and allows several additional nucleotides to 
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be incorporated prior to termination, in contrast to other NUCs that are obligate terminators 
(Langley et al., 2007, Tchesnokov et al., 2008). Compared to Lamivudine, Entecavir showed 
up to two thousand-fold efficacy in viral DNA reduction in vitro. The drug resistance of 
Entecavir was rare and only 1.2 % after 5-year treatment (Tenney et al., 2009, Chang et al., 
2010), because three mutations are required before virus develops resistance. In addition to 
rtL180M and rtM204V mutations responsible for Lamivudine resistance, a third mutation of 
rcI169T, rcT184G, rtS202I or rtM250V is required (Baldick et al., 2008a, Baldick et al., 2008b).  
Telbivudine (LdT), a thymidine analogue, was approved for treating chronic hepatitis B at 
a dose of 600 mg/day. Telbivudine has stoichiometric L-configuration opposite to natural 
nucleosides. It is incorporated into premature chain termination and competes with 5’-
triphosphate thymidine and thereby inhibits viral polymerase. Telbivudine was much superior 
to Lamivudine in HBV suppression with the relative lower opportunity of drug resistance (Lai 
et al., 2007). After 24-week treatment, Telbivudine also showed better HBV suppression 
compared with Adefovir. However, mutations are high-frequent rtM204I with or without 
concomitant rtL180M and rtL80I/V and rare rtA181T/V and rtL229W/V. For side effect, 
peripheral neuropathy was also reported when patients have received a combination of 
Telbivudine and IFN-a, thus this combination is forbidden. 
Tenofovir disoproxil fumarate (TDF) and its prodrug Tenofovir alafenamide (TAF) were 
approved for the treatment of chronic HBV infection at 300 mg/day and 25 mg/day, respectively. 
As chain terminator, both drugs compete for the natural substrate of deoxyadenosine 5’-
triphosphate and inhibit viral polymerase, as a result, mediate HBV DNA reduction, HBeAg 
seroconversion and ALT normalization (Marcellin et al., 2008, Heathcote et al., 2011). So far, 
the sole documented primary resistance to Tenofovir occurred in two patients. A quadruple 
mutation of rtS106C, rtH126Y, rtD134E and rtL269I confers Tenofovir resistance (Park et al., 
2019). Nephrotoxic side effect appears to be mild and less severe compared to Adefovir 
(Heathcote et al., 2011, Patterson et al., 2011). 
Taken together, all approved inhibitors are potent in HBV DNA reduction and ALT 
normalization. However, long-term treatment of most of them leads to multiple drug resistance, 
except Tenofovir and Tenofovir alafenamide. This class inhibitors specifically target viral 
polymerase but not cccDNA. Therefore, they can suppress HBV replication but none of them 
is curative. 
 
1.5.4. Entry inhibitors 
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The human NTCP gene is one of the members in the SLC10A family. NTCP protein is a 34 kD 
that can shift to 56 kD upon glycosylation.  NTCP is mainly localized on the basolateral 
membrane of hepatocytes and it is a transporter of bile salts into hepatocytes (Hagenbuch and 
Meier, 1994). In 2012, human NTCP was identified as the HBV entry receptor (Yan et al., 
2012). Constitutive expression of human NTCP renders non-susceptible hepatoma cells 
susceptible to HBV and HDV infections (Yan et al., 2012, Ni et al., 2014). Within NTCP, a key 
region (157~165 amino acids) is crucial for the binding of HBV preS1 protein and another 
region (84~87 amino acids) is responsible for post-binding processes (Yan et al., 2014, Ni et 
al., 2014). Later NTCP becomes a drug target. 
Before the characterization of NTCP, Urban et al. identified that recombinant DHBV preS 
polypeptide inhibits DHBV infection in a dose-dependent manner. An 85-amino-acid preS 
peptide showed maximal inhibition (Urban et al., 1998). HBV infection also depends on the N-
terminus of preS1 (3~77 amino acids) (Le Seyec et al., 1999). In the initial test, a myristoylated 
preS1 peptide at the large surface protein bound hepatocytes and blocked DHBV infection in 
vitro (Urban and Gripon, 2002). In the same year, differentiated HepaRG cell line was 
established as an in vitro HBV infection system (Gripon et al., 2002). Using PHH and HepaRG 
cultures, the myristoylated N-terminal 47 amino acids (2~48) of the HBV preS1 domain 
(genotype D) was found to specifically inhibit HBV infection with the EC50 value of 8 nM 
(Gripon et al., 2005). Amino acids (2~18) of the N-terminal preS1 efficiency blocked HBV 
infection and the amino acids (28~48) enhanced the inhibitory effect. Myristoylated 2~48 
amino acids selectively bound primary tupaia hepatocytes (Glebe et al., 2005). Deletions and 
mutations between 11~21 amino acids led to the loss of inhibitory activity and finally key 
residues (amino acids 9~15, NPLGFFP) were confirmed. The peptide (2~48 amino acid) 
derived from the preS1 was further used to identify NTCP (Yan et al., 2012). Similarly, HDV 
infection is inhibited by the same peptide with the same specificity (Engelke et al., 2006, 
Schulze et al., 2010, Meier et al., 2013). 
Myristoylated preS1-derived lipopeptides are promising candidates for antiviral therapy. 
In the preclinical study, the peptides permit subcutaneous delivery, accumulate in the liver and 
prevent HBV entry in vivo, when urokinase-type plasminogen activator and severe 
immunodeficient mice (USB) were repopulated with PHH or tupaia hepatocytes (Petersen et 
al., 2008). One of the peptides was officially designated as “Myrcludex B” (the myristoylated 
peptide excludes hepatitis B). Myrcludex B was solid-phase synthesized for preclinical use 
(Schieck et al., 2010). In HBV-infected USB mice that were superinfected with HDV, 
Myrcludex B treatment efficiently hinders the establishment of HDV infection (Lutgehetmann 
et al., 2012). Furthermore, in HBV mono-infection, Myrcludex B efficiently blocks HBV 
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spreading from initial infected human hepatocytes to naïve hepatocytes. Strikingly, Myrcludex 
B hinders amplification of the cccDNA pool (Volz et al., 2013). 
In phase Ia clinical trial, Myrcludex B showed well tolerability and mild adverse effects at 
a dose of 20 mg by intravenous injection in healthy volunteers. Given by subcutaneous injection, 
10 mg and higher doses reached a target saturation for at least 15 h (Blank et al., 2016). In phase 
Ib/IIa trials, 24 chronic hepatitis D patients were equally randomized (1:1:1) and received 
Myrcludex B, pegylated IFN-a-2a, or both. HDV RNA level is dramatically declined after 24-
week treatment. HDV RNA becomes negative in two of eight patients that received either 
Myrcludex B or pegylated IFN-a, and in five of seven patients who have received both drugs. 
ALT levels are normalized in six of eight patients in the Myrcludex B group. Virus kinetic 
analysis suggests a synergistic effect of Myrcludex B and pegylated IFN-a on HDV 
(Bogomolov et al., 2016). Furthermore, a phase IIb trial compares Myrcludex B with Tenofovir 
and applies for co-treatment in chronic HDV patients. Another phase IIb trial with larger cohort 
amount confirms that HDV is eliminated in 40 % of the HBV/HDV co-infected patients upon 
co-treatment of Myrcludex B and IFN-a (Wedemeyer et al., AASLD Meeting 2018 & EASL 
ILC Meeting 2019). Besides its therapeutic potential, unlabelled and fluorescein-labeled 
Myrcludex B also serve as decent tools to study virus-receptor interaction after hNTCP 
identification (Ni et al., 2014, Urban et al., 2014, Li and Urban, 2016). 
With weaker activity than Myrcludex B, small molecules can also inhibit HBV and HDV 
entry by targeting hNTCP. Cyclosporin A and its derivative SCYX1454139 show some NTCP-
binding affinity (Nkongolo et al., 2014, Watashi et al., 2014, Shimura et al., 2017). Ezetimibe 
inhibits HBV entry (Lucifora et al., 2013) and lipase inhibitor Orlistat targets an early step in 
the HBV life cycle (Esser et al., 2018). However, none of them is as potent as Myrcludex B and 
has respective EC50 values at the micromolar range. HBV attachment before NTCP binding 
also becomes a drug target of surimin and heparin (Petcu et al., 1988, Schulze et al., 2007).  
Table 1.3. Attachment and entry inhibitors. 
Class             Name               Nature                 Target       Clinical status            EC50 value*  
Attachment   suramin            small molecule     L/M/S           approved§                      25 µM 
Inhibitor         heparin            glycoglycan          L/M/S           approved§                 9.4 µg/mL 
Entry             Myrcludex B     peptide                NTCP           phase III                           8 nM 
Inhibitor        Cyclosporin A   peptide                NTCP           approved§                        1 µM 
                     SCYX1454139  peptide               NTCP           preclinical                    0.17 µM  
                     Ezetimibe          small molecule   NTCP           approved§                       18 µM  
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                     Orlistat              small molecule   unknown       approved§                       50 µM 
§: approved for other diseases but not chronic hepatitis B.  
*: PHH or HepaRG cells. Adapted from (Lempp and Urban, 2014) 
 
1.5.5. Capsid inhibitors 
Core protein assembles with viral polymerase and pgRNA to form the nucleocapsid shell in 
which reverse transcription occurs as long as polymerase-bound pgRNA is encapsidated 
(Fletcher and Delaney, 2013). Interaction between core proteins or interference with core 
assembly is a target of capsid inhibitors. It has been shown that truncated core protein lacking 
its C-terminus retains the ability to assemble (Nassal, 1992). Therefore, mutants of the assembly 
domain have been used in vitro to screen modulators of capsid formation and assembly (Stray 
et al., 2006, Zlotnick et al., 2007). 
Characterized capsid inhibitors are classified as heteroaryldihydropyrimidines (HAP), 
phenylpropenamides (AT) and sulfamoyl benzamides (SBA). The earliest HAP inhibitor is 
BAY 41-4109, which has an EC50 value of 120 nM and reduces the amounts of core protein in 
HepG2.2.15 cells (Deres et al., 2003, Klumpp et al., 2015). In HBV transgenic mice (Tg 
HBV1.3 fsX(-)3’5’), oral administration of BAY 41-4109 at 15 mg/kg for 28 d induced a 
significant reduction of viral DNA and cytoplasmic HBcAg levels in the liver (Weber et al., 
2002). Moreover, BAY 41-4109 at 25 mg/kg for 5 d in humanized mice transplanted with PHH 
and infected with HBV led to a 10-fold drop in viral load (Brezillon et al., 2011). BAY 41-4109 
has dual effects on capsid assembly. One BAY 41-4109 molecule is sufficient to induce every 
five capsid dimers to form non-capsid polymers (BAY: dimer = 1:5), and the formed capsids 
are stabilized by BAY 41-4109 at a ratio of one molecule per two dimers (BAY: dimer = 1:2). 
However, capsids are destroyed to generate large non-capsid polymers, when the ratio of BAY 
41-4109 and capsid dimer is 1:1 or higher (BAY: dimer > 1:1). BAY 41-4109 may induce 
aberrant assembly at low concentrations when in excess misdirects assembly by reducing the 
stability of capsids (Stray et al., 2005, Stray and Zlotnick, 2006). HAP molecule binds the 
pocket of core protein at the dimer-dimer interface. Hence, a V124W core mutation at this 
pocket results in HAP resistance and confers HAP-like behaviors (Bourne et al., 2006, Tan et 
al., 2013). Further structural modification of the BAY 41-4109 identifies GLS4 
(morphothiadine mesilate) which is more potent than BAY 41-4109 in vitro (Wang et al., 2012, 
Klumpp et al., 2015). GLS4 is 10-fold more potent with mean EC50 values of 15 nM (Klumpp 
et al., 2015). Compared to BAY 41-4109, GLS4 has no cytotoxicity up to 25 µM and shows a 
sustained decline of viral DNA in nude mice injected with HepAD38 cells. So far, GLS4 is in 
clinical evaluation in China (Wu et al., 2013). 
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The second class of capsid inhibitors is the AT series. AT-61 is a potent inhibitor of HBV 
replication in vitro (King et al., 1998) and its derivative AT-130 shows enhanced potency (Perni 
et al., 2000). Both derivatives are very effective against WT and NUC-resistant HBV mutants 
(Delaney et al., 2002). AT-130 blocks replication on the step of pgRNA packaging and 
nucleocapsid forming (Feld et al., 2007). Although structural studies have shown some 
differences between AT-130-bound and free capsids, co-structure of the capsid and AT-130 
complex reveal that AT-130 binds the capsid and leads to tertiary and structural changes without 
disrupting the capsid structure (Katen et al., 2013). AT-130 locates mainly in the B-subunit 
pocket at the dimer-dimer interface, whereas HAP resides in the pocket of the C-subunit, which 
differs the two classes. 
A third-class nucleocapsid assembly modulator is SBA, originally identified from high 
throughput screening using a murine AML12HBV10 cell line with stable HBV integration and 
pgRNA transcription (Campagna et al., 2013). Direct comparison of the SBA with BAY 41-
4109 and AT-61 has shown that SBA inhibits HBV replication in a manner to form capsids 
devoid of nucleic acids. Interestingly, SBA showed selectivity against HBV, but not WHV or 
DHBV replication in HepG2 cells (Campagna et al., 2013). One of the representative SBA 
compounds, NVR 3-778, is the most advanced in development. Six-week NVR 3-778 treatment 
in humanized mice leads to the reduction of viral DNA that is comparable to Entecavir treatment. 
NVR 3-778 also shows a synergistic effect in combination with pegylated IFN-a and inhibits 
DNA levels to an undetectable level (Klumpp et al., 2018). NVR 3-778 is well-tolerated, 
pharmacologically effective and as efficient in phase Ia trial as in vitro. In phase Ib clinical trial, 
NVR 3-778 shows a marginal reduction in viral load when daily given at 400 mg. A 1.7-log 
decline in HBV DNA level, however, was observed at a higher dose of 600 mg/day (Yuen et 
al., 2019). 
 
1.6. In vitro cell culture models 
HBV has a narrow species and tissue tropism and thereby HBV study relies on a few in vitro 
cell culture models. Although hepatoma cell lines are widely used that support HBV replication 
and assembly, when they are transfected with cloned HBV genomes (Sells et al., 1988), 
transfection systems have no real cccDNA and thereby transcription from authentic cccDNA 
can not be studied (Slagle et al., 2015). 
It was a long history when only PHH and primary tupaia hepatocytes (PTH) support the 
“pre-transcription” steps in the HBV life cycle that include receptor-mediated entry, uncoating, 
import of nucleocapsid in the nucleus, rcDNA repair, cccDNA formation (Gripon et al., 1988, 
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Kock et al., 2001). Gripon et al. demonstrated that the supplement of 1.5% DMSO in the culture 
medium efficiently enhanced HBV replication in PHH (Gripon et al., 1988). They further 
illustrated that the addition of polyethylene glycol increased viral adsorption and penetration 
(Gripon et al., 1993). So far PHH is still the gold model. However, once isolated and plated, 
primary hepatocytes ex vivo rapidly lose the differentiation state and HBV susceptibility. PHH 
also have a short life span of 1~2 weeks in vitro and it is not practical to study chronic HBV 
infection. In this year, the long-term functional maintenance of PHH over 4 weeks was achieved 
by using a combination of five chemicals in culture medium, whether this new system is the 
best physiologically relevant is under debate (Xiang et al., 2019). 
In 2002, HepaRG, a progenitor cell line, which was isolated and colonized from the liver 
of a female HCV-infected patient, supported efficient de novo HBV infection when fully 
differentiated and infected. Cellular metabolism and innate immune responses in HepaRG cells 
are close to PHH. Similar to PHH, HepaRG cells show undetectable expression level of a-
fetoprotein (AFP) but high levels of aldolase B, Cyp 2E1 and 3A4 liver enzymes (Gripon et al., 
2002, Ni et al., 2014). However, a disadvantage of HepaRG cells includes low infectivity rate 
as only 5~10 % hepatocyte-like cells in the total cells could be infected. After differentiation 
processes, a majority of co-existing biliary cells are not susceptible to HBV and HDV infection. 
Besides, long-term maintenance of HepaRG cells is not available, as all viral markers including 
cccDNA stay stable up to 3 weeks p.i.. 
After another ten years, the HBV receptor NTCP was discovered (Yan et al., 2012), which 
provides a new direction to generate hepatoma cell lines reconstituted with human NTCP 
(hNTCP). Stable expression of hNTCP renders HepG2 and Huh7 hepatoma cells fully 
susceptible to HBV and HDV infection and enhances the infectivity rate in HepaRG cells (Ni 
et al., 2014). Different from Huh7hNTCP cells with rather low infection rate (5 %) of HBV and 
deficiency in innate immunity, HepG2hNTCP cells are more robust and supportive of high HBV 
infectivity (20~80 %). Moreover, HepG2hNTCP cells are suitable for long-term cultivation after 
infection (eight weeks). Yet low levels of HBsAg secretion is a characteristic in HepG2hNTCP 
cells when infected with cell culture (cc)-derived HBV. This low HBsAg level is partially 
caused by hNTCP overexpression and specific for HBV genotype D (Li et al., 2016a). Of 
special note, a slow proliferating HepG2hNTCP cell clone, HepG2-NTCPsec+, supports viral 
spread to neighbor non-infected cells and multiple rounds of HBV infection (Konig et al., 2019) 
Ectopic expression of hNTCP in cynomolgus macaque, rhesus macaque and swine 
hepatocytes permits HBV infection with comparable replication efficiencies to human 
hepatocytes, suggesting that hNTCP is the only limiting host factor in macaques and pigs 
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(Lempp et al., 2017). However, reconstitution of hNTCP did not provide HBV susceptibility in 
primary mouse, rat and dog hepatocytes, probably due to lack of other human-specific factors 
(Lempp et al., 2016a). Remarkably, the first and only mouse cell line, AML12, gains HBV 
susceptibility upon hNTCP expression, although the infection rate is rather low (<1 %) (Lempp 
et al., 2016b). In this special case, it is plausible that mature nucleocapsids are unstable in the 
AML12hNTCP cells and aberrantly released rcDNA converts to cccDNA (Cui et al., 2013, Cui et 
al., 2015, Cui et al., 2016). 
To closer imitate the liver environment, hepatic co-culture systems have been established 
to allow more accurate and physiologically relevant HBV infection and virus-host interactions. 
Micropatterned co-culture of PHH and stromal cells support higher productive HBV infection 
that can be enhanced by blocking interferon-stimulated genes (e.g. using JAK inhibitor). This 
model offers a prolonged and productive infection and represents a new platform for 
investigating virus-host interactions and developing antiviral agents (Shlomai et al., 2014). 
Furthermore, the co-culture of PHH with mouse stromal cells delays PHH de-differentiation 
and thereby supports persistent infection for over 40 days. The platform can be miniaturized to 
96-well plate format and also amenable to high throughput screening (Winer et al., 2017). 
Avoiding PHH de-differentiation seems important for its long-term infection, as shown in 
recent study PHH cultured with the five chemicals efficiently recapitulated HBV infection with 
constant levels of cccDNA and other viral markers (Xiang et al., 2019). 
Stem cell-derived hepatocyte-like cells have been developed as a new model for viral 
hepatitis research (Wang et al., 2019). Pluripotent stem cells can be reprogrammed by co-
expression of the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc) in human fibroblasts 
(Takahashi and Yamanaka, 2006). The induced pluripotent stem cells (iPSC) can further be re-
differentiated into hepatocyte-like cells (Sullivan et al., 2010). Similar to iPSC, human 
embryonic stem cells (hESC) resided in the liver or bone marrow can also be differentiated 
(Lavon et al., 2004). For both iPSC and hESC, the endodermal state is at first induced by 
introduction of Wnt3 and Activin A and finished by the expression of transcriptional factors 
FOX A2, GATA4 and Sox17. Secondly, DMSO and fibroblast growth factor are added to 
express hepatocyte markers, a-fetoprotein (AFP), cytokeratin 19 (CK19), hepatocyte nuclear 
factor (HNF) and epithelial cell adhesion molecules (EpCAM). During this process, 
endodermal culture turns to be the next state of the hepatic specification. Thirdly, these 
hepatoblasts are incubated with dexamethasone and hepatocyte growth factor. Hepatocyte 
maturation is associated with the expression of albumin, cytokeratin 18 (CK18) and Cyp 2E1 
and 3A4 liver enzymes as shown in Figure 1.12. (Vosough et al., 2013). 
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Figure 1.12. Stem cell-derived hepatocyte-like cells. The differentiation steps of iPSC or 
hESC contain definitive endoderm induction, hepatic specification, hepatoblast expansion and 
hepatic maturation to become HLC that is permissive for HBV infection. The cells are treated 
with activin A and Wnt-3A enhancer for 4 days, and HGF and Rock inhibitor Y-27632 for 1 day. 
Definitive endoderms are incubated with HGF alone for 1 week. Hepatoblast cells are treated 
with dexamethasone (DEX) for 3 days and can be infected with HBV at d 15 p.i.. Infected cells 
can be maintained in the presence of insulin, hydrocortisone (HC) and DMSO for another 1 
month until d 45 post differentiation. Adapted from (Wang et al. 2019) with permission. 
iPSC-derived hepatocyte-like cells support HBV replication, which is further enhanced by 
blocking the induction of interferon-stimulated genes (Shlomai et al., 2014). Compared to 
iPSC-derived hepatocyte-like cells (iPSC-HLC), immature proliferating hepatic progenitor-like 
cells (iPSC-HPC) are less efficient in HBV infection and the infection is dependent on the 
expression levels of human NTCP. Since long-term culture of iPSC-HLC is difficult, the 
persistence of cccDNA is established in iPSC-HPC further overexpressing human NTCP and 
down-regulating Janus kinase signaling (Kaneko et al., 2016). iPSC-HLC is further validated 
by antiviral agents Entecavir and Myrcludex B (Sakurai et al., 2017). Notably, both iPSC-
derived and hESC-derived HLC gain efficient HBV infectivity. Xia et al. used an optimized 
protocol to differentiate the non-colony type monolayer culture of hESC and iPSC to HLC in 
15 d. The HLC maintained its differentiated state and allowed HBV infection for more than 4 
weeks. Importantly, the authors demonstrated that the optimized protocol for HLC 
differentiation provided the model capable of supporting HBV spread. Notably, the de-
differentiation process occurred at a slower rate in HLC than PHH, as high expression levels of 
proviral factors including hNTCP, HNF4a and RXRa for more than 3 weeks, which makes 
HLC a suitable model for long-term HBV infection (Xia et al., 2017a). Taken together, all 
above in vitro models for HBV infection are summarized in Table 1.2.. 
In addition to the models that support de novo HBV infection, HepG2.2.15 cells are widely 
used in virion production and antiviral studies, despite HBV production is limited (Sells et al., 
1987). Moreover, HepAD38 and HepG2.117 cells were generated. In both cells, the 
transcription of pgRNA is induced in a tetracycline-dependent manner (Ladner et al., 1997, Sun 
and Nassal, 2006). HBeAg production is cccDNA-dependent in HepAD38 cells, it is difficult 
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to reliably quantify HBeAg among excessive HBcAg from nucleocapsids during virus 
production. To solve this problem, a second-generation cccDNA reporter cell line, termed 
HepBHAe82, was developed in the principle that an HA tag was introduced into the N-terminus 
of PreCore ORF, so that only HBeAg generated from an HA encoding cccDNA but not HBcAg 
is tagged. The model is amenable to assess antiviral agents and identify host factors that regulate 
transcription from cccDNA (Cai et al., 2016). 
Table 1.4. Feasible cell culture models for HBV infection.  
Model       Infectivity rate   HBsAg    HBeAg   Advantages                     Disadvantages 
PHH                100%         ++++       ++++     the most physiological      donor variability, high 
                                                                       commercially available     cost, limited spread, 
                                                                       support innate sensing     short-term infection                                                     
HepaRG          5~10%        +++         ++         close to PHH                    long differentiation 
                                                                       support innate sensing     biliary cells included 
                                                                                                                short-term infection 
                                                                                                                low infectivity 
HepaRGhNTCP  10~20%      ++++       +++       close to PHH                    biliary cells included 
                                                                       support innate sensing    short-term infection 
                                                                                                                long differentiation 
HepG2hNTCP     >50%         +             ++++     robust, high throughput    very low HBsAg 
                                                                       long-term infection           secretion 
Huh7hNTCP        5%             +              ++        support integration            low infectivity, unstable 
                                                                                                                NTCP, deficient in  
                                                                                                                innate sensing 
AML12hNTCP     1%             +              –          the sole mouse model       very low infectivity 
iPSC-derived   25~90%    +++          +++      physiological, close to       ethical issue, high cost 
HLC                                                               PHH, support spread,  
                                                                      long-term infection, 
                                                                      personalized       
hESC-derived  50~90%    ++++        ++++    physiological, close to        ethical concern, limited 
HLC                                                              PHH, support spread,        cell number, not 
                                                                      long-term infection,           available from adults 
                                                                      personalized 
PHH: primary human hepatocytes; HLC: hepatocyte-like cells; iPSC: induced pluripotent stem 
cells; hESC: human embryonic stem cells. Antigen expression levels: ++++ high; +++ 
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moderate; ++ low; + very low; - undetectable. NA: not applicable. Adapted from (Ni and Urban, 
2017) with permission. 
It is noteworthy to point out that most in vitro infection models support the formation of 
cccDNA, expression of HBx protein and show HBx-dependent HBV replication. All the models 
are listed in Table 1.3.. 
Table 1.5. Models for HBx-dependent HBV replication.  
Model             Entry     cccDNA     assembly   secretion    HBx dependency§   Viremia       Immunity 
PHH               +              +                +                +         Yes                         NA            NA 
HepaRG         +              +                +                +         Yes                         NA            NA 
HepG2hNTCP    +              +                +                +         Yes                         NA            NA 
HepAD38       NA            +                +                +         ND                         NA             NA 
Transfected 
HepG2/Huh7  NA            No             +                +         Yes                         NA            NA 
NA: not applicable, ND: not determined. §: Efficient HBV replication in this model depends on 
HBx. Adapted from (Slagle et al., 2015) with permission. 
 
1.7. Rationale and aims 
The majority of HBx studies have been performed under experimental conditions in which 
hepatoma cells were transfected with plasmids encoding more-than-full-length HBV. Authentic 
functions of HBx on cccDNA could not be attained in this model, since the transcriptional 
template is plasmid but not cccDNA. Consistently, it has been studied that HBx stimulates HBV 
replication to less extent: when HBx is expressed from more-than-full-length constructs in 
transfected cells, HBV replication in the absence of HBx (introduction of two stop codons in 
the HBx ORF) is 2~3 fold reduced, which allows comparable production of Xd virions in these 
hepatoma cells with Xd plasmid in the absence of a helper HBx-encoding plasmid. This finding 
indicates that HBx is minimally required for transcription from a plasmid template. However, 
when susceptible cells (primary hepatocytes, etc.) were infected with Xd virus compared to an 
equal amount of WT virus, 50~100 fold weaker replication of Xd virus was observed. Indeed, 
replication of Xd virions are severely impaired in woodchucks (Zoulim et al., 1994) and bona 
fide infection in PHH and HepaRG cells (Lucifora et al., 2011)(Sonnabend J, thesis, 2013). 
The pronounced effect observed in infection models compared to transfection systems can 
be hypothesized that a preference of functional HBx is selective on the cccDNA-dependent 
transcription of viral genes. The major differences between plasmid and cccDNA templates are 
that cccDNA may have relative low-copy numbers per cell, based on the knowledge of DHBV, 
and cccDNA has a tremendous transcriptional activity over time. Accurate quantification of 
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cccDNA copy number in infection models will provide new understandings on the nature of 
cccDNA. Using HBx-minus virus and HBx-encoding lentivirus, the effects of HBx on 
formation and transcription of cccDNA can be monitored. 
 
Specific aim 1: Establishment of quantitative analysis of cccDNA numbers in its formation, 
maintenance and stability in in vitro infection systems. 
To obtain a comprehensive overview, all susceptible hepatocytes and hepatoma cell lines will 
be infected with HBV. Except for HBx, all viral markers will be measured. cccDNA levels will 
be accurately quantified by reliable qPCR approach, which is specific for cccDNA. Referring 
to the percentage of infected cells,  cccDNA numbers per infected cell are calculated. 
 
Specific aim 2: Functional analysis of a minimal active domain and key residues for HBx 
transactivation in authentic infection. 
Previous studies in our laboratory have shown that arginine-proline insertions into the HBx 
ORF resulted in significant loss of its transactivation activity. Lentiviral transcomplementation 
assay and extended mutational strategy using more truncations and deletions will be used to 
define key fragments. Whether HBx function is dependent on some binding proteins will be 
also investigated. 
 
Specific aim 3: HBx-mediated formation and transcription of cccDNA and its inhibition.  
Previous studies have shown that knockout of HBx within the viral genome profoundly 
impaired vial gene expression after infection with Xd virus. My early studies using stable DDB1 
knockdown cells also showed that DDB1 plays an essential role and promotes transcription of 
cccDNA. Targeting the HBx-DDB1-CRL complex, new-class inhibitors will be identified and 
evaluated. Therapeutic perspectives of neddylation inhibition on HBV replication will be 
discussed. 
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Organisms 
2.1.1.1. Viruses 
HBV:  
Three types of HBV virions were prepared from (1) HepAD38, (2) HepG2-H1.3, and (3) Huh7 
cells.  
(1) HBV (subtype ayw) was isolated and originally cloned into plasmid pBR322 (pHBV-1) 
(Hirschman et al., 1980). Complementary DNA was subcloned at 3’ terminus of the 
CMV-IE promoter of ptetHBV plasmid and stabilized in virus-producing HepAD38 cells 
(Ladner et al., 1997). The supernatant was collected from HepAD38 cells with the 
removal of doxycycline in culture medium and virus was further purified by heparin-
affinity chromatography. 
(2) A wild-type (WT) 1.3-fold-overlength HBV genome (subtype ayw) was PCR amplified 
from pHBV1.3 plasmid and subcloned in pTH1.3 plasmid (Sprinzl et al., 2001, Jost et 
al., 2007). In parallel, two stop codons within HBx opening reading frame were 
introduced in pTH1.3 to generate pTH1.3-DX. pTH1.3 or pTH1.3-DX together with 
pSV2neo plasmids were stably transfected in HepG2 cells and thereby HepG2-H1.3 and 
HepG2-H1.3-DX cell lines were generated (a kind gift from Ulrike Protzer). Secreted 
virions were PEG precipitated and 100-fold enriched. 
(3) WT 1.1-fold-overlength HBV genome was cloned in pCHT-9/3091(WT) plasmid as 
previously described (Nassal, 1992). pCHT-9/3091(Xd) plasmid was generated by 
introducing two stop codons of Q8stop and Q87stop (C22T and C259T of the HBx coding 
region) within HBx opening reading frame without changing core and polymerase 
proteins (Jessica Sonnabend, unpublished). Huh7 hepatoma cells were transfected with 
pCHT-9/3091(WT) or pCHT-9/3091(Xd), and secreted WT and Xd virions were PEG 
precipitated and enriched. Section 2.2.2.2 describes more details of (2) and (3). 
HDV: 
HDV genomic-encoding plasmid pSVLD3 (genotype 1) (provided from John Taylor) and 
HBV envelope encoding pT7HB2.7 (a kind gift from Camille Sureau) plasmid were co-
transfected in Huh7 cells. Secreted HDV viruses were purified by heparin affinity 
chromatography. 
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Lentivirus: 
Second-generation recombinant lentiviruses were produced by a triple-transfection of 
HEK293T cells with pWPI-HBx/pInducer20-HBx, psPAX2 (expressing Gag and Pol of HIV) 
and pMD2.G (expressing VSV-G envelopes) (weight: weight: weight = 3: 3: 1). Supernatant 
between 24~72 hours post transfection was collected, pooled, filtered through 0.45 µM filter, 
ultracentrifuged, and resuspended. Section 2.2.2.5 describes more details. 
 
2.1.1.2. Prokaryotic bacteria 
E.coli strains DH5a and Top10 were used for molecular cloning. Competent cells for high-
efficient transformation were home-made using rubidium chloride chemical sensitization 
according to Promega Protocols and Applications Guide. 
 
2.1.1.3. Eukaryotic cell lines 
Cell line                             Description 
Huh7                                  Differentiated hepatocyte-derived carcinoma cell line  
                                           originally from a 57-year-old Japanese male HCC patient in 1982 
HepG2                               ATCC® HB-8065, a human hepatoma cell line from a 15-year-old   
                                           Caucasian adolescent in 1979 
HepG2hNTCP                        HepG2 cells stably expressing hNTCP (Ni et al., 2014) 
HepaRG                             Human hepatoma cell line isolated from a liver tumor of a female  
                                           HCV and HCC patient (Gripon et al., 2002) 
HepaRGhNTCP                     HepaRG cells stably expressing hNTCP (Ni et al., 2014) 
HepAD38                           HepG2-derived cell line with a tet-inducible integrate allowing           
pgRNA transcription and virus assembly in a tet-off manner 
(Ladner et al., 1997) 
HepG2-H1.3(WT)               HepG2-derived cell line with an HBV 1.3-mer supporting  
                                           constitutive pgRNA transcription and virus assembly  
                                           (Jost et al., 2007) 
HepG2-H1.3(DX)                HepG2-derived cell line with two stop codons in HBx ORF 
                                           supporting generation of Xd virions (Lucifora et al., 2011) 
HBx(WT)-HepG2hNTCP        HepG2hNTCP-derived cell line with an HA-tagged HBx for  
                                           HBx(WT) expression in a tet-on manner (this thesis) 
HBx(R96E)-HepG2hNTCP    HepG2hNTCP-derived cell line with an HA-tagged HBx for  
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                                           HBx(R96E) expression in a tet-on manner (this thesis) 
HBx(WT)-HepaRGhNTCP      HepaRGhNTCP-derived cell line with an HA-tagged HBx for  
                                            HBx(WT) expression in a tet-on manner (this thesis) 
HBx(R96E)-HepaRGhNTCP   HepaRGhNTCP-derived cell line with an HA-tagged HBx for  
                                            HBx(R96E) expression in a tet-on manner (this thesis) 
PLC/PRF5                          ATCC® CRL-8024, a human hepatoma cell line with natural HBs  
                                            integrates and continuous HBsAg production 
                                            (Daemer et al., 1980) 
HEK293T                            Human embryonic kidney cell line derived from HEK293 cell line 
                                            expressing a mutated SV40 large T antigen (DuBridge et al.,  
                                            1987). 
 
2.1.1.4. Primary human hepatocytes (PHH) 
PHH were isolated from liver specimens obtained after partial hepatectomy and following 
written informed consent of the patients (provided by Florian W.R. Vondran). The whole 
process was approved by the ethics commission of Hannover Medical School/Ethik-
Kommission der MHH, no. 252-2008. 
 
2.1.2. Inorganic consumables 
2.1.2.1. Chemicals and compounds 
Chemical                                                    Provider                                      Catalog number 
[a-32P]-deoxyxytidine 5’-triphosphate (dCTP)   Hartmann Analytic GmbH                  SRP-205(9.25 MBq) 
Acetic acid (Ph.Eur.,>99.8%)                            Sigma-Aldrich                                  33209-2.5L 
Acrylamide/Bisacrylamide(30% w/v, 3.3% C)   Serva Electrophoresis GmbH          10687.01 
Agarose, high melting temperature                   Biozym Diagnostic GmbH               840004 
Ampicillin                                                           Life Technologies, Invitrogen          11593-027 
Ammonium persulfate (AP)                               Fisher Scientific GmbH                   10744171 
Bacto-Agar                                                         Becton-Dickinson                            214050 
Bacto-Trypton                                                    Becton-Dickinson                            211705 
Bacto-Yeast extract                                           Becton-Dickinson                            212720 
BAY41-4109                                                      Bayer AG 
B.Braun Aqua (ddH2O), injektionszwecke        University Hospital Heidelberg 
Beta-Mercaptoethanol (2-ME)                           Sigma-Aldrich GmbH                      M6250-250ML 
Blasticidin S                                                       Life Technologies, Invitrogen          R210-01 
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Bovine serum albumin fraction V (>98%)           Carl Roth GmbH                            Nr.8076.2 
Caesium chloride (ultrapure)                              Invitrogen                                       15507-023 
Coelenterazine                                                   PJK GmbH                                     102171 
Diethyl pyrocarbonate (DEPC)                           Sigma-Aldrich GmbH                     D5758-50ML 
Dimethylsulfoxide (DMSO)                                 EMD Millipore                                1.02950.0500 
Dithiothreitol (DTT) (>98%)                                Sigma-Aldrich GmbH                     D0632-1G 
dNTPs (100 mM)                                                New England Biolabs                    N0446S 
Dulbecco’s Modified Eagle Medium (DMEM)    Life Technologies, Invitrogen         41965-039 
DMEM/F12 medium (v/v 1:1)                             Life Technologies, Invitrogen         31330-038 
Dulbecco’s PBS (w/o Ca2+ and Mg2+)                Sigma-Aldrich GmbH                     D8537-500ML 
DNA loading dye (6×)                                        Fermentas                                      R0611 
Doxycycline                                                       Sigma-Aldrich GmbH                      Y0001714 
DRAQ5                                                              Life Technologies, Invitrogen         62254 
Ethanol absolute (Ph. Eur.,>99.8%)                  Sigma-Aldrich GmbH                     32205-2.5L-M 
Ethidium bromide (EB)                                      Sigma-Aldrich GmbH                     E7637-1G 
Ethylenediaminetetraacetic acid (EDTA)          Serva Electrophoresis GmbH         39760.01 
Fetal bovine serum gold (FBS)                         PAA, GE Healthcare GmbH            A15-151 
Fluoromount-G                                                  Life Technologies, Invitrogen         00-4958-02 
Formaldehyde (36.5-38%)                                Sigma-Aldrich GmbH                      F8775-500ML 
GeneRuler 1kb DNA ladder                              Fermantas                                       SM0312 
GLS4 (morphothiadin)                                      Sunshine Lake Pharma Co., Ltd. 
Glycerol (99.9%)                                               Fisher Scientific                               G/0650/15 
Glycine                                                              Sigma-Aldrich GmbH                      G8898-1KG 
Guanidine hydrochloride                                   Sigma-Aldrich GmbH                      50950-1KG 
Hank’s balanced salt solution (HBSS)              Life Technologies, Invitrogen          14170-112 
HEPES (1 M)                                                    Life Technologies, Invitrogen          15630-080 
Hydrochloric acid (>37% fuming)                      Sigma-Aldrich GmbH                      30721-2.5L 
Hydrocortisone hemisuccinate                          Sigma-Aldrich GmbH                      H4881 
Hoechst 33342                                                  Life Technologies, Invitrogen          H3570 
Illustra MicroSpin G-25 Column                        GE Healthcare GmbH                     27532501 
Insulin                                                                Sigma-Aldrich GmbH                      91077C-1G 
Interferon-a-2b (Intron A, injection use)            Schering-Plough 
Isopropanol (Ph. Eur.,>99.8%)                         Sigma-Aldrich GmbH                      33539-2.5L-M 
Laemmli sample buffer (4×)                              Bio-rad Laboratories                       #161-0747 
Lamivudine (3TC) (>98%)                                 Sigma-Aldrich GmbH                     L1295-10MG 
L-Glutamine (100×)                                           Life Technologies, Invitrogen         25030-024 
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Lipofectamine 3000 transfection reagent          Life Technologies, Invitrogen        L3000-001 
Methanol (>99.9%)                                           Sigma-Aldrich GmbH                     34860-2.5L-R 
Milk powder (blocking grade)                            Carl Roth GmbH                            Nr.T145.2 
Non-essential amino acids (100×)                    Life Technologies, Invitrogen         11140-035 
(N-morpholino) propane sulfonic acid (MOPS) Serva Electrophoresis GmbH         29836.02 
NP-40 (IGEPAL CA-630)                                  Sigma-Aldrich GmbH                      I8896-50ML 
PageRuler Plus prestained protein ladder        Fermentas                                       #26620 
Paraformaldehyde (PFA)                                  Sigma-Aldrich GmbH                      P6148-1KG 
Penicillin, 10000 U/mL                                      Life Technologies, Invitrogen          15140-122 
Peptone                                                             Life Technologies, Invitrogen         211677 
Polyethyleneimine (PEI), branched                   Sigma-Aldrich GmbH                     408727-100ML 
Polyethylene glycol (PEG 8000) (ultrapure)      Sigma-Aldrich GmbH                     89510-1KG-F 
Potassium chloride                                            Sigma-Aldrich GmbH                     31248-1KG 
Protease inhibitor cocktail solution                    Sigma-Aldrich GmbH                     P8340-5ML 
Protease/Phosphatase inhibitor cocktail(100×) Cell Signaling Technology             #5872S 
Puromycin                                                          InvivoGen                                      ant-pr-1 
RiboRuler High Range RNA Ladder                  Fermentas                                     #SM1821 
RNase Away reagent                                         Life Technologies, Invitrogen       10328-011 
Sodium dodecyl sulfate (SDS)                           Serva Electrophoresis GmbH       20765.03 
Streptomycin, 10000 µg/mL                               Life Technologies, Invitrogen       15140-122 
Sodium bicarbonate                                           AppliChem GmbH                        A3590,1000 
Sodium citrate dihydrate (>99%)                       AppliChem GmbH                         A2403,1000 
Sodium chloride (>99.5%)                                 Sigma-Aldrich GmbH                    S7653-1KG 
Sodium hydroxide                                              Sigma-Aldrich GmbH                   30620-1KG-R 
Tenofovir (TDF)                                                 Sigma-Aldrich GmbH                    SML1794-10MG 
Tetramethylethylene-diamine (TEMED)            Carl Roth GmbH                           Nr.2367.3 
TransIT-LT1 transfection reagent                      Mirus Bio GmbH                           MIR2300 
Tris (>99.9%)                                                    Carl Roth GmbH                            Nr.4855.2 
Triton X-100                                                      Merck                                            1.08603.1000 
Trypan blue solution (0.4%)                              Sigma-Aldrich GmbH                    93595-50ML 
Tween-20                                                          Carl Roth GmbH                           Nr.9127.1 
William’s Medium E                                           Life Technologies, Invitrogen       22551-022 
 
2.1.2.2. Buffers and solutions (solvent is sterilized water if not specified) 
For agarose gel electrophoresis: 
TAE buffer (50×): 2 M Tris, 1 M glacial acetic acid, 0.05 M EDTA (pH = 8.0) 
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TE buffer (1×): 10 mM Tris, 1 mM EDTA (pH = 8.0) 
 
For CsCl gradient ultracentrifugation and DNA dot-blot: 
Caesium chloride gradients: 1.2 g/mL (28.9 g CsCl and 100 g H2O); 1.3 g/mL (40.3 g CsCl 
and 100 g H2O); 1.4 g/mL (54.5 g CsCl and 100 g H2O), freshly prepared 20% sucrose in water 
(w/w). 
Soak I buffer: 1.5 M NaCl, 0.5 M NaOH 
Soak II buffer: 3 M NaCl, 0.5 M Tris (pH = 7.4) 
SSC buffer (20×): 3 M NaCl, 0.3 M sodium citrate (pH = 7.0) 
Denhardt’s buffer (50×): 1 % BSA, 1 % Ficoll PM70, 1 % Polyvinvlpyrrolidone 
Hybridization buffer: 10 µg/mL calf thymus DNA, 5× Denhardt’s, 6× SSC, 0.5 % SDS 
Dot-blot wash buffer: 1× SSC, 0.5 % SDS 
 
For Northern blotting: 
MOPS buffer (10×): 0.2 M MOPS free acid, 0.05 M sodium acetate anhydrous, 0.01 M 
Na2EDTA (pH = 7.5), adjust pH value to 7.0 by adding NaOH. Avoid light at room temperature. 
Northern blotting running buffer: 1× MOPS, 0.2 M formaldehyde in DEPC-treated H2O. 
1.2 % formaldehyde gel: 116 mL water, 16 mL 10× MOPS buffer, 1.92 gram agarose. 
Melting up this mixture and cooling it down to 60 degree, adding 28 mL 37% formaldehyde 
solution in a hood with gentle shaking. Casting the gel. 
In-gel denature buffer: 0.05 M NaOH, 1.5 M NaCl 
Hybridization buffer: QuikHyb Hybridization solution (Agilent), ready-to-use. 
Low-stringency wash buffer: 2× SSC, 0.1 % SDS 
High-stringency wash buffer: 0.1× SSC, 0.1 % SDS 
 
For Southern blotting: 
Southern blotting running buffer: 1× TAE buffer (see above) 
Depurination buffer: 0.2 M HCl 
Denaturing buffer: 0.5 M NaOH, 1.5 M NaCl 
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Neutralization buffer: 1.5 M NaCl, 1 M Tris-HCl (pH = 7.4) 
Hybridization buffer: QuikHyb Hybridization solution (Agilent), ready-to-use. 
Wash buffer: 1× SSC, 0.1 % SDS 
 
For SDS-PAGE: 
Resolving gel buffer (4×): 1.5 M Tris, 0.4 % SDS, 0.01 % NaN3 (pH = 8.8) 
Stacking gel buffer (4×): 0.5 M Tris, 0.4 % SDS, 0.01 % NaN3 (pH = 6.8) 
SDS running buffer (10×): 0.25 M Tris, 1.92 M glycine, 1 % SDS (pH = 8.3) 
 
For Western blot: 
    RIPA lysis buffer: 25 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1 % NP-40, 1× 
protease/phosphatase inhibitor cocktail (pH = 7.4) 
Blotting buffer: 48 mM Tris, 39 mM glycine, 0.04 % SDS, 10 % methanol 
TBS buffer (10×): 0.2 M Tris, 1.37 M NaCl (pH = 8.0) 
TBS-T wash buffer: 1× TBS, 0.05 % Tween-20 
Blocking buffer: 5 % blocking-grade milk powder in 1× TBS-T buffer 
Antibody dilution buffer: blocking buffer or 5 % BSA in 1× TBS-T buffer 
 
For immunofluorescence and confocal microscopy: 
Fixation buffer: 4 % paraformaldehyde in 1× PBS or ice-cold methanol 
Permeabilization buffer: 0.25 % Triton X-100 in 1× PBS 
Blocking buffer: 5 % blocking-grade milk powder in 1× PBS 
Antibody dilution buffer: blocking buffer or 3 % goat serum in 1× PBS 
Mounting buffer: Fluoromount G (Life Technologies) 
 
For dual-luciferase assay: 
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Passive lysis buffer (5×): 125 mM glycyl glycine, 75 mM MgSO4, 20 mM EGTA, 5 mM 
DTT, 0.5 % Triton X-100 (pH = 7.8) 
Assay buffer: 25 mM glycyl glycine, 15 mM MgSO4, 4 mM EGTA, 15 mM K2PO4 (pH = 
7.8) in order to dilute coelenterazine (the substrate of renilla luciferase). For firefly luciferase, 
add 1 mM DTT and 1 mM ATP to the assay buffer prior to D-luciferin dilution. 
 
2.1.2.3. Kits 
Kit                                                                             Provider 
GeneJET PCR purification kit                                  Fermentas, Thermo Fisher Scientific 
GeneJET Gel extraction kit                                      Fermentas, Thermo Fisher Scientific 
GeneJET plasmid mini-prep kit                                Fermentas, Thermo Fisher Scientific 
Plasmid plus midi kit                                                Qiagen 
Plasmid maxi kit                                                       Qiagen 
Megaprime DNA Labeling System                           Amersham, GE Healthcare GmbH 
NucleoSpin RNA kit                                                  Macherey-Nagel 
NucleoSpin Tissue kit                                               Macherey-Nagel 
NucleoSpin Blood kit                                                Macherey-Nagel 
High Pure Viral Nucleic Acid Kit                                Roche Life Science 
CytoTox 96 NonRadioactive Cytotoxicity Assay       Promega 
cDNA reverse transcription kit                                  ABI 
NucBuster Protein Extraction kit                               Merck Millipore 
NE-PER Nuclear and Cytoplasmic Extraction Kit     Thermo Fisher Scientific 
 
2.1.3. Biochemical consumables 
2.1.3.1. Culture medium 
Bacteria culture: 
LB medium: 10 g/L trypton, 5 g/L yeast extract, and 10 g/L NaCl 
TB medium: 12 g/L trypton, 24 g/L yeast extract, 0.35 % glycerol in 17 mM KH2PO4 and 72    
                      mM K2HPO4 
 
Cell culture: 
Cell                                                       Medium 
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Huh7, HepG2, HepG2hNTCP,                 DMEM, 10 % FCS (heat-inactivated), 2 mM L- 
HEK293T, PLC/PRF5,                           glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
HBx(WT&R96E)-HepG2hNTCP(*)            1 mM non-essential amino acids. 
HepG2-H1.3 (WT&DX)                          *: 500 µg/mL G418 added 
HepaRG, HepaRGhNTCP, PHH              William’s E, 10 % FCS (heat-inactivated), 2 mM L- 
HBx(WT&R96E)-HepaRGhNTCP(*)        glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,  
1 mM non-essential amino acids, 5 μg/mL insulin, 
50 μM hydrocortisone. During differentiation and  
                                                             HBV/HDV infection: 1.5 % DMSO added.  
                                                             *: 250 µg/mL G418 added 
HepAD38                                             DMEM/F-12, 10 % FCS (non-heat inactivated), 2 mM  
                                                             L-glutamine, 100 U/ml penicillin, 100 μg/ml  
                                                             streptomycin, 400 μg/ml G418, 5 μg/ml insulin, 50  
                                                             μg/ml hydrocortisone, 1 μg/ml doxycycline. For HBV  
                                                             production: doxycycline was removed. 
 
2.1.3.2. Enzymes 
Enzyme                                                 Provider 
Deep Vent DNA polymerase                New England Biolabs 
Q5 Hot Start DNA polymerase             New England Biolabs 
Restriction endonucleases                   New England Biolabs 
Calf Intestinal Alkaline Phosphatase    New England Biolabs 
T4 DNA ligase                                      Fermentas, Thermo Fisher Scientific 
T5 exonuclease                                    New England Biolabs 
Plasmid-safe DNase                             Epicentre, Lucigen 
iTaq Universal SYBR Green Mix          Bio-rad 
qScript XLT RT-qPCR Toughmix         Quanta Biosciences 
PerfeCTa qPCR Toughmix                  Quanta Biosciences 
Trypsin                                                 Life Technologies, Invitrogen 
 
2.1.3.3. Antibodies 
Primary antibody: 
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Antibody/Antisera       Species                            Application                Provider 
Anti-HBcAg                   Rabbit polyclonal             IF: 1:3000                   Dako 
Anti-HBcAg (M312)       Mouse monoclonal          IF: 1:2000                  Christa Kuhn 
Anti-HBxAg (#641)        Rabbit polyclonal            WB/IF: 1:500              Christa Kuhn 
Anti-HBxAg (#644)        Rabbit polyclonal            WB/IF: 1:500              Christa Kuhn 
Anti-HDAg (GEAO)       Serum of an HBV/HDV   IF: 1:3000                   Heiner Wedemeyer 
                                      co-infected patient 
Anti-HDAg (VUDA)        Serum of an HBV/HDV  IF: 1:3000                   Heiner Wedemeyer 
                                      co-infected patient 
Anti-HBsAg (HBC34)    Human monoclonal         IF: 1:3000                   Davide Corti 
Anti-b-actin                    Mouse monoclonal         WB: 1:2000                 Sigma-Aldrich 
Anti-HA tag                    Rabbit monoclonal         WB: 1:1000                 Cell Signaling Tech. 
Anti-Flag tag (M2)         Mouse monoclonal         IP: 1:100; WB: 1:1000 Sigma-Aldrich 
Anti-SMC6                     Rabbit polyclonal            IF: 1:100                     Sigma-Aldrich 
Anti-SMC6 (M01)          Mouse monoclonal         WB: 1:500                    Abgent 
Anti-hnRNP K               Rabbit polyclonal            WB: 1:500                    Proteintech 
 
Secondary antibody: 
Antibody                                Species                   Application               Provider 
Alexa Fluor anti-rabbit 488     goat                        IF: 1:500                    Invitrogen 
Alexa Fluor anti-rabbit 546     goat                        IF: 1:500                    Invitrogen 
Alexa Fluor anti-mouse 488   goat                        IF: 1:500                    Invitrogen 
Alexa Fluor anti-mouse 546   goat                        IF: 1:500                    Invitrogen 
Alexa Fluor anti-human 488   goat                        IF: 1:500                    Invitrogen 
Alexa Fluor anti-human 555   goat                        IF: 1:500                    Invitrogen 
HRP anti-rabbit IgG                goat                        WB: 1:10,000            Sigma-Aldrich 
HRP anti-mouse IgG              goat                        WB: 1:10,000            Sigma-Aldrich 
 
2.1.3.4. Peptides 
Myrcludex B (myr-preS1 2~48 amino acids) 
myr-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG 
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2.1.3.5. Plasmids 
Plasmid                             Description                                                         Provider 
pCHT-9/3091(WT)            Plasmid encoding overlength 1.1-mer HBV 
                                         (genotype D, ayw) under CMV-IE promoter        (Nassal, 1992) 
pCHT-9/3091(Xd)             Plasmid pCHT-9/3091(WT) with two stop 
                                         mutations at Q8 (C22T) and Q87 (C259T)  
                                         without alteration of polymerase                         Jessica Sonnabend 
pcDNA3.1-Zeo(-)-HBx     Plasmid pcDNA3.1 encoding full-length HBx 
                                        under CMV-IE promoter                                      Jessica Sonnabend 
pWPI-HBx-IRES-GFP     Bicistronic expression vector encoding HBx- 
                                        IRES-GFP cassette under EF1a promoter          Jessica Sonnabend 
psPAX2                           Lentiviral packaging plasmid expressing HIV 
                                        gag, pol, tat and rev proteins                                Didier Trono 
pMD2.G                           VSV-G expressing plasmid for pseudo  
                                        lentivirus packaging                                              Didier Trono 
pWPI-HBx(WT)               Bicistronic lentiviral vector encoding HBx(1-154) 
                                        and puromycin resistance gene                          Jessica Sonnabend 
pWPI-HBx(1-50)              Bicistronic lentiviral vector encoding HBx(1-50) 
                                        and puromycin resistance gene                          Bingqian Qu 
pWPI-HBx(51-154)          Bicistronic lentiviral vector encoding 
                                        HBx(51-154) and puromycin resistance gene     Bingqian Qu 
pWPI-HBx(D51-142)        Bicistronic lentiviral vector encoding HBx(1-50 
                                        fused with 143-154) and puromycin resistance   Bingqian Qu 
pWPI-HBx(51-142)          Bicistronic lentiviral vector encoding HBx 
                                        (51-142) and puromycin resistance gene           Bingqian Qu 
pWPI-HBx(58-142)          Bicistronic lentiviral vector encoding HBx 
                                        (58-142) and puromycin resistance gene           Bingqian Qu 
pWPI-HBx(R96E)            Bicistronic lentiviral vector encoding  
                                        HBx(R96E) and puromycin resistance gene       Bingqian Qu 
pWPI-HBx(R96A)            Bicistronic lentiviral vector encoding 
                                        HBx(R96A) and puromycin resistance gene       Bingqian Qu 
pWPI-GFP-puro              Bicistronic lentiviral vector encoding GFP 
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                                        and puromycin resistance gene                         Jessica Sonnabend 
pInducer20-HBx(WT)      Lentiviral vector encoding HA-tagged HBx(WT)  
                                        under TRE2 promoter and neomycin  
                                        resistance gene after IRES                                 Emanuela Milani 
pInducer20-HBx(R96E)  Lentiviral vector encoding HA-tagged  
                                        HBx(R96E) under TRE2 promoter and  
                                        neomycin resistance gene after IRES                 Emanuela Milani 
pUC18-HBx(WT)            Plasmid pUC18 encoding full-length HBx            Jessica Sonnabend 
pSHH2.1                         Plasmid pSV08 encoding a head-to-tail HBV 
                                       dimer under SV40 promoter                           (Cattaneo et al., 1983a) 
pSVLD3                          Plasmid containing a head-to-tail trimer of  
                                       full-length HDV cDNA under SV40 promoter       Camille Sureau 
pT7HB2.7                       Plasmid encoding a 2700-bp HBV subgenomic 
                                       fragment expressing envelopes and HBx under 
                                       respective authentic promoters                            Camille Sureau 
pGL3-C-Fluc                 Plasmid pGL3-Basic containing core promoter 
                                      (1403-1817) to express firefly luciferase              (Tang et al., 2014) 
pGL3-preS1-Fluc          Plasmid pGL3-Basic containing preS1 
                                      promoter (2710-2834) to express luciferase        (Tang et al., 2014) 
pGL3-preS2-Fluc         Plasmid pGL3-Basic containing preS2 
                                      promoter (2966-152) to express luciferase          (Tang et al., 2014) 
pGL3-X-Fluc                Plasmid pGL3-Basic containing X promoter 
                                     (950-1310) to express firefly luciferase                 (Tang et al., 2014) 
pRL-SV40-Rluc            Plasmid pRL encoding renilla luciferase under 
                                     SV40 promoter                                                       Promega 
 
2.1.3.6. Oligonucleotides 
Name                                 Sequence (5’ to 3’)                                              Reference 
cccDNA-F (p1040)            GTGGTTATCCTGCGTTGAT 
cccDNA-R (p1996)            GAGCTGAGGCGGTATCT 
cccDNA-probe (p1085)     FAM-AGTTGGCGAGAAAGTGAAAGCCTGC 
                                          -TAMRA                                                               This thesis 
Total DNA-F (p466)          GTTGCCCGTTTGTCCTCTAATTC 
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Total DNA-R (p541)         GGAGGGATACATAGAGGTTCCTTGA          (Lucifora et al., 2014) 
Human b-globin-F            CAGGTACGGCTGTCATCACTTAGA 
Human b-globin-R            CATGGTGTCTGTTTGAGGTTGCTA              (Steinau et al., 2006) 
pgRNA specific-F             CTCCTCCAGCTTATAGACC 
pgRNA specific-R             GTGAGTGGGCCTACAAA                             (Lucifora et al., 2014) 
HBs RNA specific-F         TGTACCAAACCTTCGGACGG 
HBs RNA specific-R         ATGCTGTACAGACTTGGCCC                           This thesis 
HBV total RNA-F              TCAGCAATGTCAACGACCGA 
HBV total RNA-R              TGCGCAGACCAATTTATGCC                           This thesis 
HDV RNA-F                      GCGCCGGCYGGGCAAC 
HDV RNA-R                      TTCCTCTTCGGGTCGGCATG 
HDV RNA-probe               FAM-CGCGGTCCGACCTGGGCATCCG 
                                          -TAMRA                                                              (Ferns et al., 2012) 
SmaI-HBx-1-F                  TCCCCCGGGATGGCTGCTAGGCTGTGCTG            This thesis 
MluI-HBx-50-R                 GCCGACGCGTTTACCCGTGGTCGGTCGGAA          This thesis 
SmaI-HBx-51-F                CGCCCGGGATGGCGCACCTCTCTTTACGCG          This thesis 
SmaI-HBx-58-F                CGCCCGGGATGCTCCCCGTCTGTGCCTTCTC        This thesis 
MluI-HBx-142-R               CGACGCGTTTAGACCAATTTATGCCTACAGC          This thesis 
MluI-HBx-154-R               GCCGACGCGTTTAGGCAGAGGTGAAAAAGTT 
                                         GCA                                                                               This thesis 
HBx-D51-142-R               TGCTGGTGCGCACCCGTGGTCGGTCGGAACG 
                                        GCA (Bold: overlapped with HBx-D51-142-long-F)        This thesis 
HBx-D51-142-long-F        ACCGACCACGGGTGCGCACCAGCACCATGCA 
                                         ACTTTTTCACCTCTGCCTAAACGCGTCGGC            This thesis 
HBx-D51-142-long-R       GCCGACGCGTTTAGGCAGAGGTGAAAAAGTTG 
                                         CATGGTGCTGGTGCGCACCCGTGGTCGGT 
                                        (Italic: annealed with HBx-D51-142-long-R)                    This thesis 
Internal-R96E-F               TCTTACATAAGGAGACTCTTGGAC                            This thesis 
Internal-R96E-R               GTCCAAGAGTCTCCTTATGTAAGA                             This thesis 
Internal-R96A-F               TCTTACATAAGGCGACTCTTGGAC                             This thesis 
Internal-R96A-R               GTCCAAGAGTCGCCTTATGTAAGA                             This thesis 
(underlined: SmaI or MluI cutting site; double underlined: the mutated 96th residue) 
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shRNA-DDB1-2C             
TGCTGTTGACAGTGAGCGCAAACACGAGATTAGAGATCTATAGTGAAGCCACAGATGTA
TAGATCTCTAATCTCGTGTTTTTGCCTACTGCCTCGGA 
mature sense: AACACGAGAUUAGAGAUCU 
mature antisense: AGAUCUCUAAUCUCGUGUU                                                   This thesis 
shRNA-DDB1-3C 
TGCTGTTGACAGTGAGCGAAACGTTGACAGTAATGAACAATAGTGAAGCCACAGATGTA
TTGTTCATTACTGTCAACGTTGTGCCTACTGCCTCGGA 
mature sense: ACGUUGACAGUAAUGAACA 
mature antisense: UGUUCAUUACUGUCAACGU                                                   This thesis 
 
2.1.4. Software 
Name                                               Application                                       Provider 
Adobe Illustrator 6.0                        Vector-based graphic editing            Adobe Systems  
Adobe Photoshop 6.0                     Graphic editing                                  Adobe Systems 
Ascent 2.4                                       Luminescence reading                     Thermo Scientific 
CFX Manager                                 Real-time qPCR signal collection      Bio-rad 
CorelDRAW Graphics Suite X3      Vector-based graphic editing            Corel Cooperations 
CorelDRAW Graphics Suite X5      Graphic export to images                  Corel Cooperations 
Endnote X7                                     Reference management                   Clarivate Analytics  
Fiji (ImageJ updated)                      Image processing                             Open source 
FlowJo V10                                    FACS raw-data analyses                  Becton-Dickinson 
GraphPad PRISM 5                       Graphic and statistic raw-data          Graphpad, Inc 
Leica Application Suite                   Confocal microscopy                        Leica Inc. 
Microsoft Excel                               Statistic software                              Microsoft 
Microsoft Word/Powerpoint            Thesis writing and presentation        Microsoft 
Nanodrop 2000 1.6                         Nucleic acid contents                       Thermo Scientific 
Odyssey Software                          Western blot analyses                      Li-COR Biosciences 
Quantity One 1-D analysis             Northern/southern blot analyses       Bio-Rad 
Vector NTI Software 11                  Sequence bioinformatics                  Life Technologies 
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2.2. Methods 
2.2.1. Molecular cloning 
2.2.1.1. Overlapping PCR and mutagenesis 
Mutagenesis is based on two rounds of PCR amplification. The first PCR amplifies two 
fragments with overlapping part carrying the mutation introduced by primers. Products of the 
first PCR are annealed and become the template of a second PCR reaction. In this thesis, the 
eventual PCR product carrying each mutation was inserted back to the original construct to 
replace WT HBx. For pWPI-HBx(R96E) generation shown as an example, HBx-1-F and 
internal HBx-R96E-R primers amplified N-terminal fragment containing R96E mutation, and 
internal HBx-R96E-F and HBx-154-R primers amplified C-terminal fragment with the same 
mutation. Two products were purified, mixed in a molar ratio 1:1 and subjected to the template 
of a second PCR using HBx-1-F and HBx-154-R primers to generate a full-length HBx(R96E) 
insert for ligation. For truncation, one direct PCR reaction was sufficient. For pWPI-HBx(1-50) 
shown as an example, HBx-1-F and HBx-50-R amplified a 150 bp product directly used as the 
insert. Specifically, the insert of pWPI-HBx(D51-142) was the product of one PCR reaction 
using HBx-1-F and a long primer HBx-D51-142 with a 36 bp tail encoding the 143~154 residues 
of HBx. 
Every 50 µL of PCR reaction using Q5 Hot Start High-Fidelity DNA polymerase included 
10 µL of 5× Q5 reaction buffer, 1 µL of 10 mM dNTPs, 2.5 µL of forward primer (10 µM), 2.5 
µL of reverse primer (10 µM), 10 ng of pWPI-HBx(WT) plasmid or 100 ng of a mixture of two 
fragments (molar ratio 1:1), 10 µL of 5× Q5 High GC Enhancer, 0.5 µL of Q5 DNA polymerase, 
and water to 50 µL. PCR program was set up as follows: 98℃ 3 min, [98℃ 10 sec, 54℃ 30 
sec, 72℃ 60 sec] for 36 cycles, 72℃ 5 min, 4℃ hold. All PCR products were subjected to 
agarose gel electrophoresis. 
 
2.2.1.2. Restriction digestion 
After gel electrophoresis, all size-characterized PCR products (c.a. 5 µg) were purified and 
subjected to a 50 µL reaction containing 20 U of each restrictive endonucleases; On the other 
hand, 5 µg of pWPI-HBx(WT) was incubated with 20 U of each endonuclease in a 50 µL 
reaction. All digestions were performed at 37℃ for 1 h and endonuclease activity was heat-
inactivated at 70~80℃ for 15-20 min. Insert DNA was silica-column purified and backbone 
DNA was purified by agarose gel electrophoresis. 
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2.2.1.3. Dephosphorylation of vector DNA 
Self-ligation of the partially linearized vector is highly reduced by dephosphorylation of 5’ ends 
of the vector. Linearized products of vector by restriction digestion were incubated with 10 U 
of calf intestinal alkaline phosphatase in CutSmart buffer at 37℃ for 1 h. Phosphatase activity 
was heat-inactivated at 65℃ for 20 min and column-purified before ligation. 
 
2.2.1.4. Agarose and formaldehyde gel electrophoresis 
For molecular cloning, PCR products of HBx (c.a.500 bp) were mixed with DNA loading dye 
and separated in a 2 % agarose gel (0.01% ethidium bromide, v/v) soaked in 1× TAE buffer. 
Likewise, pWPI plasmid backbone was separated in a 1 % agarose gel. For 28S/18S ribosomal 
RNA visualization, 2 µg of total RNA samples were mixed with RNA loading dye and separated 
in a 1 % native agarose gel. Electrophoresis was performed at 140 V for 20~30 min and signals 
inside gels were visualized under UV light. 
For Southern blotting, DNA samples were separated in a 1.2 % agarose gel without 
ethidium bromide. Electrophoresis was performed at 125 V (5 V per centimeter between anode 
and cathode electrodes) for approximate 3 h until indicating blue dye went to the edge of the 
gel. 
For northern blotting, RNA samples were separated in a 1.2% formaldehyde gel (shown 
in session 2.1.2.2) without ethidium bromide in pre-cooled 1× MOPS buffer. The formaldehyde 
gel was pre-run at 70 V for 30 min and later on RNA samples were loaded and run. 
Electrophoresis was performed at 125 V for approximate 3~4 h.  
 
2.2.1.5. Ligation and transformation 
Backbone and insert (HBx fragments, amount calculated) were mixed at a molar ratio of 1:5 
and incubated with 2 U (sticky end) or 10 U (blunt end) of T4 ligase in 1× T4 ligase buffer at 
room temperature for 1 h. Specifically, 10% of PEG4000 was added to blunt-end reactions to 
enhance ligation efficiency. One reaction with backbone alone was set up as control. 
Competent E.coli DH5a or Top10 cells were ice-thawed. 5 µL of ligation product was 
mixed with 50 µL of competent cells. The mixture pipetted up and down and incubated on ice 
for 30 min. Afterward, it was heat-shocked at 42℃ for 90 sec and immediately chilled on ice 
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for 3 min. 500 µL of antibiotic-free pre-warmed LB or TB medium was added and the recovery 
of transformed bacteria was at 37℃ for 50 min on a heater with gentle shaking. Bacteria were 
dispersed on LB-agar plates containing 100 µg/mL Ampicillin and incubated at 37℃ overnight. 
 
2.2.1.6. Colony characterization 
The next day after transformation, three colonies on each plate with the recombinant product 
and one colony on the control plate were picked up and propagated in Ampicillin-containing 
LB medium overnight at 37℃. Recombinant plasmids were extracted using a mini preparation 
kit. These plasmids were either characterized by restriction digestion (choose one endonuclease 
on the insert and the other on the backbone) or by PCR amplification using Deep Vent DNA 
polymerase. Validated recombinant plasmids were further expanded by midi plus or maxi prep. 
 
2.2.1.7. Sanger sequencing 
5 µL of mini-prep recombinant plasmid (80-100 ng/µL) were mixed with 5 µL of pWPI-seq-F 
sequencing primer (5 µM). Sequencing reactions were sent to GATC Company. Two days later, 
results of Sanger sequencing were aligned with expected correct sequences and read sequence 
by sequence using Vector NTI software. Successful plasmids were used for cell culture 
experiments. 
 
2.2.2. Cell culture 
2.2.2.1. Maintenance, thawing and freezing of cells 
All eukaryotic cells used in this thesis were cultivated in 37℃ incubator with 5% CO2 supply 
and 95% humidity. During maintenance, cells were split twice or three times per week, except 
HBx(WT)-HepaRGhNTCP cells once every two weeks. In detail, cells were rinsed once with 1× 
PBS and incubated with trypsin (e.g. 700 µL/T75 flask) at 37℃ for 3~10 min. When detached, 
the cells were resuspended in complete culture medium by pipetting up and down to obtain 
single cell suspension. The splitting factor for one passage was 1:5 ~ 1:20. Mycoplasma tests 
were randomly performed using PCR Mycoplasma Test Kit (Promokine) according to the 
instructions.  
HepaRG and HepaRGhNTCP cells were seeded (2×105 cells/12-well format or 1×105 
cells/24-well format) in the absence of DMSO. After two-week maintenance, they were 
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cultivated with differentiation medium containing 1.5 % DMSO for another two weeks to 
become susceptible for HBV and HDV infection. For MLN4924 experiments, HepAD38 cells 
were seeded as a monolayer and maintained for 7 d in the presence of 1 µg/mL of doxycycline. 
Later on, cells were washed with PBS for three times and cultivated with the same medium 
depleting doxycycline, which allows robust pgRNA transcription and virus assembly. 
To thaw cells, frozen aliquots in -80℃ or liquid nitrogen were immediately thrown in 37℃ 
water bath with shaking. As soon as they were thawed, the cells were suspended with complete 
medium and centrifuged at 500 rpm for 5 min. Pellets were resuspended in medium and cells 
were seeded in a culture flask. One day later, the medium was changed in order to remove the 
remaining DMSO. 
To freeze cells, cells in the proliferating phase were trypsinized and suspended in complete 
medium. Survival rate was determined by trypan blue staining and cells more than 95% survival 
were considered to be frozen. The cells were centrifuged at 500 rpm for 5 min and pellets were 
resuspended in 90 % FCS and 10 % DMSO and aliquoted in cryotubes. Aliquots were kept in 
freezing box containing isopropanol at -80℃ overnight before further transferred in liquid 
nitrogen. 
 
2.2.2.2. Production and enrichment of HBV mutants 
As shown in session 2.1.1.1, HepAD38 cells were cultivated as a monolayer in a multi-layer 
flask for two weeks in the presence of tetracycline. After removal of tetracycline, the 
supernatant was collected twice every week from week 2 to 8. Every 400 mL of supernatant 
was filtered and subjected to heparin affinity chromatography. The heparin-sepharose binding 
virus was eluted in 15.5 mL of Tris-NaCl buffer and immediately supplemented with 1.8 mL 
of pure FCS. This WT HBV virus was aliquoted and kept at -80℃. 
For WT and Xd virus production, HepG2-H1.3 (WT) and HepG2-H1.3 (Xd) cells were 
seeded in 15-cm petridish as a monolayer. The supernatant was collected twice every week 
from week 1 to 5. Alternately, these viruses were produced by transfection of Huh7 cells in 15-
cm petridish with pCHT-9/3091(WT) or pCHT-9/3091(Xd) using the PEI reagent (see 2.2.2.7 
transfection). Two days post transfection, cells were washed with PBS for three times and 
supernatant from d 2~7, d 7~12, and d 12~17 was collected. Supernatant from each preparation 
was centrifuged at 4000 rpm for 15 min and filtered sterile. The supernatant was mixed with 
PEG8000 at a final concentration of 6% and incubated at 4℃ overnight. The next day, the 
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supernatant was centrifuged at 10,000 rpm at 4℃ for 1 h and the pellet was resuspended in 1% 
of the original volume with PBS supplemented with 10% FCS. The resuspension was rotated 
at 4℃  overnight and centrifuged at 8000 rpm for 10 min. Clear supernatant containing 
concentrated WT or Xd virions was kept at -80℃. 
 
2.2.2.3. HBV and HDV infection 
Before infection, produced HBV virus from stable cells was titrated using HBV real-time PCR, 
whereas virus from plasmid-transfected Huh7 cells was titrated by CsCl gradient 
ultracentrifugation and DNA dot-blot. PHH, HepaRG, HepaRGhNTCP, HepG2hNTCP cells were 
seeded in 24-well plates at a density of 2×105 PHH, HepaRG, HepaRGhNTCP/well or 4×105 
HepG2hNTCP/well. For infection, 540 µL of medium (PHH, HepaRG, differentiated 
HepaRGhNTCP supplemented with 1.5% DMSO; HepG2hNTCP without DMSO) was mixed with 
60 µL of 40% PEG8000 and then HBV virus (mge/cell ranging from 100 to 3000). The infection 
inoculate was added onto the cells and cells were incubated at 37℃ overnight. The next day, 
cells were washed twice with PBS and complete medium (PHH, HepaRG, differentiated 
HepaRGhNTCP with 1.5% DMSO; HepG2hNTCP with 2% DMSO) was added. The medium was 
changed every 2~3 days until the end of experiments. For entry inhibition, the cells were pre-
treated with 1 µM of MyrB for 15 min at 37℃ and MyrB was included in inoculates during the 
infection. 
Before HDV infection, the virus was titrated using HDV-specific real-time PCR. 
Differentiated HepaRGhNTCP cells were inoculated with 540 µL of medium supplemented with 
1.5% DMSO, 60 µL of 40% PEG8000 and HDV virus (mge/cell = 100) at 37℃ overnight. 
Later on, cells were washed and medium with 1.5% DMSO was changed every 2~3 days. 
 
2.2.2.4. Production and concentration of lentivirus 
Pseudo-lentivirus were produced in HEK293T cells by triple-transfection of the plasmids: (i) 
HBx-encoding pWPI-HBx or pIncuder20-HBx or shRNA-expressing pAPM, all of which were 
compatible with packaging helpers (ii) and (iii); (ii) psPAX2 encoding HIV genes (gag, pol, tat 
and rev) that support lentivirus replication; (iii) pMD2.G encoding VSV-G glycoproteins for 
lentivirus entry. 
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Six million HEK293T cells were seeded in a 15-cm petridish on one day before co-
transfection. 27 µg of HBx-expressing plasmid, 27 µg of psPAX2 and 9 µg of pMD2.G were 
co-transfected (as shown in session 2.2.2.7). 24 h post transfection, the medium was gently 
changed. Supernatant from 24~48 h and 48~72 h post transfection was collected, pooled, 
centrifuged at 4000 rpm for 15 min at 4 ℃ and filtered sterile. The clear supernatant was 
ultracentrifuged at 20,000 rpm for 2 h at 4℃. After this centrifugation, the supernatant was 
discarded and the pellet was resuspended in 500 µL of William's E medium supplemented with 
10 % FCS and rotated for 2 h at 4℃. After final centrifugation at 8000 rpm for 10 min, the 
supernatant was kept at -80℃. 
 
2.2.2.5. Lentivirus transduction 
Before transduction, lentivirus was titrated by real-time PCR using primers that bind to the 
woodchuck Hepatitis Virus posttranscriptional regulatory element (WPRE) within packaging 
plasmids. For transient lentiviral trans-complementation assay, HepG2hNTCP and HepaRGhNTCP 
cells in 24-well plates were transduced with 25 µL of concentrated lentivirus per well (mge/cell 
= 50) in the medium supplemented with 8 µg/mL of polybrene, which enhances transduction 
efficiency in retroviral infection. The next day, inoculates were discarded and fresh medium 
was added. 
 
2.2.2.6. Generation of HBx-HepaRGhNTCP and HBx-HepG2hNTCP cells 
HepG2hNTCP and undifferentiated HepaRGhNTCP cells were seeded at 50% density in 6-well 
plates and transduced with 100 µL of concentrated lentivirus that either encodes WT or HBx 
R96E mutant. On d 1 post transduction, inoculates were discarded and fresh medium was added. 
On d 3 post transduction, the cells were split and cultivated in complete medium supplemented 
with 1 mg/mL of G418. Untransduced cells were treated similarly as antibiotics selection 
control. Between 7 and 10 days post transduction, when all untransduced cells were killed and 
detached, transduced cells were trypsinized and transferred in a T75 flask with 1 mg/mL of 
G418 until d 14. The cells were maintained with 0.5 mg/mL of G418 from d 14 to 28. Most 
cells were frozen in liquid nitrogen for long-term storage and the rest was maintained. To 
characterize, 1 µg/ml of doxycycline was added in the medium for 72 h and inducible HBx 
expression was confirmed by western blot and immunofluorescence. 
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2.2.2.7. Transfection 
Cells were seeded one day ago to achieve 60-70% density at the moment of transfection. For 
plasmid transfection, TransIT-LT1 and lipofectamine 3000 reagents were used. Specifically, 
one transfection mixture was prepared (0.5 µg of plasmid, 1.5 µL of TransIT-LT1, 50 µL of 
antibiotic-free serum-reduced Opti-MEM, 24-well format), while lipofectamine 3000 
preparation required two mixtures (mixture A: 0.5 µg of plasmid, 1 µL of P3000, 50 µL of Opti-
MEM; mixture B: 1 µL of lipofectamine 3000 in 50µL of Opti-MEM), which were mixed later. 
Each transfection mixtures was incubated at room temperature for 15~30 min and dropwise 
added onto the cells.  
For HBV and lentivirus production, affordable PEI reagent was used as similar as 
lipofectamine but with different amount rates of plasmid and PEI (w/w = 1:1 in Huh7 cells; 
w/w = 1:3 in HEK293T cells) 
For siRNA, a reverse transfection protocol was adapted according to manufacturer’s 
instructions. Firstly, siRNA was diluted to 50 nM concentration in 100 µL of Opti-MEM 
medium and then 1 µL of lipofectamine RNAiMAX was added in this one transfectant. The 
transfection mixture was directly added into the plate for 20 min at room temperature prior to 
cell seeding. Secondly, during this 20 min, HepG2 cells were trypsinated, counted and adjusted 
to 1×105 per well. Finally, the cell suspension was added on the top of the transfection mixture. 
3 d post transfection, knockdown efficiency of target genes was analyzed by real-time PCR or 
western blot. 
 
2.2.3. Assays 
2.2.3.1. DNA and RNA extraction 
HBV virion DNA was extracted from heparin-purified virus stocks or unpurified supernatant 
of HepAD38 cells using the High Pure Viral Nucleic Acid Kit according to the manufacturer’s 
instructions. 200 µL of virus or supernatant, 200 µL of freshly prepared working solution 
supplemented with carrier RNA and 50 µL of proteinase K solution was mixed and incubated 
for 10 min at 72℃. 100 µL of binding buffer afterward was added and thoroughly mixed. This 
mixture was transferred to a High Pure Filter tube and centrifuged at 8000 g for 1 min. Binding 
to the column, DNA was washed by 500 µL of inhibitor removal buffer once and 450 µL of 
wash buffer twice. DNA was eluted in 50 µL of pre-warmed water.  
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HBV DNA from infected hepatocytes was extracted using the NucleoSpin Tissue Kit 
according to the manufacturer’s manuals. Briefly, cells were washed with PBS for three times 
and immediately lysed in 200 µL of buffer T1 to obtain total lysates. The lysates were mixed 
with 25 µL of proteinase K and 200 µL of buffer B3 and incubated at 70℃ for 1 h. The product 
was mixed with 210 µL of ethanol and loaded to silica columns, washed by 500 µL of buffer 
BW once and 600 µL of buffer B5 twice. Eventually, DNA was eluted in 50~100 µL of pre-
warmed water. DNA content and A260/A280 absorbance values were measured using 
NanoDrop 2000 spectrophotometer. 
HBV virion RNA was extracted from the supernatant of HepAD38 cells using the High 
Pure Viral Nucleic Acid Kit. Viral RNA extraction was performed similarly as described above 
and eluted in 50 µL of RNase-free water. The eluate was digested by RNase-free DNase at 37℃ 
for 30 min.  
HBV total RNA from infected hepatocytes was extracted using the NucleoSpin RNA kit. 
Infected cells were lysed in 350 µL of buffer RA1 containing 3.5 µL of b-mercaptoethanol at 
room temperature for 5 min with gentle shaking. Viscose lysates were applied through the 
NucleoSpin Filter and centrifuged at 11,000 g for 1 min. The flow-through was mixed with the 
same volume of 70% ethanol by pipetting up and down. Then samples were loaded onto the 
silica columns and desalted by one wash of 350 µL of MDB. To remove cellular DNA, bound 
RNA was in-column incubated with 100 µL of reconstituted RNase-free rDNase for 15 min at 
room temperature. Columns were washed by adding 200 µL of RAW2 buffer once and 600 µL 
of RA3 buffer twice. Finally, RNA was eluted in 30 µL of RNase-free water. RNA content and 
A260/280 absorbance values were measured using a spectrophotometer. For northern blotting 
use, the concentration of RNA samples must be more than 1 µg/µL. 
 
2.2.3.2. T5 exonuclease hydrolysis 
Prior to cccDNA quantification, total DNA extracted from in vitro infected hepatocytes was 
incubated with T5 exonuclease, in this step, rcDNA, dslDNA as well as genomic DNA were 
hydrolyzed to dNTPs and cccDNA was intact, since total lysates containing high copy numbers 
of rcDNA provided false positive signals in cccDNA quantification. Among a panel of 
exonucleases, T5 exonuclease but not plasmid-safe DNase was identified to be the most 
efficient one that removes rcDNA in the presence of genomic DNA (Figure 2.1.A). The 
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combination of T5 exonuclease treatment and cccDNA-selective primers allowed specific 
quantification of cccDNA in in vitro infected hepatocytes (Figure 2.1.B).  
To be specific, 5 µL of DNA eluate was incubated with 3.5 µL of water, 1 µL of 10× 
reaction buffer #4 and 0.5 µL of T5 exonuclease (5 U) at 37℃ for 1 h and 70℃ for 20 min. 
Digestion products were frozen at -20℃  or directly subjected to cccDNA-specific qPCR 
quantification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. T5 exonuclease preserves cccDNA and efficiently removes rcDNA and 
genomic DNA. (A) Virion DNA or pUC18-HBx plasmid (3.2 kb) was digested with T5 
exonuclease (T5 Exo, 5 U) or plasmid-safe DNase (PSD, 5 U) in the absence or presence (2 
µg) of genomic DNA (top panel) at 37°C for 1 h and the products were loaded to Southern 
blotting (lower panel). (B) Virion DNA (rcV) or pSHH2.1 plasmid was incubated with T5 Exo (5 
U) or PSD (10 U) at 37°C for 1 hour, and the products were further analyzed by total DNA 
primers (pp466-541, left) or cccDNA primers (pp1040-1996, right), respectively. ns: no 
significance. 
 
2.2.3.3. cccDNA Taqman quantitative PCR (qPCR) 
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After comparison of a series of master mixes provided from several companies (Bio-rad, Qiagen, 
and Quanta Biosciences), one of them, the PerfeCTa qPCR Toughmix (95112-012), was chosen 
and used in the Bio-rad CFX96 TouchTM Real-time PCR thermocycler (data not shown). 
Real-time quantitative PCR reaction was set up by mixing 2 µL of T5 exonuclease-
digested DNA sample, 0.6 µL of p1040, 0.6 µL of p1996, 0.6 µL of probe p1085, 7.5 µL of 
PerfeCTa qPCR Toughmix and 3.7 µL of water (total volume 15 µL). Optimized two-step 
qPCR program was established:  95℃ for 15 min, followed by 95℃ for 5 seconds (denaturation) 
and 63℃ for 70 seconds (annealing, elongation) for 50 cycles. Relative fluorescence unit was 
read after each of the cycles. pSHH2.1 plasmid carrying a head-to-tail HBV dimer was 1:10 
serial diluted to generate a standard curve. For low-copy standards (103, 102, 101 copies), 10-
fold serial dilutions were specifically performed using a solvent (Tris 10 mM, EDTA 0.1 mM, 
yeast tRNA 10 ng/ml, and Tween-20 0.01%) instead of water (Quanta Biosciences, personal 
communication). Samples that were not digested by T5 exonuclease were used for human b-
globin quantifications. Levels of b-globin, a single-copy gene, were used to normalize the input 
signals. For data analysis, “cccDNA copies/well” was primarily determined by measuring total 
cccDNA copies in all eluates and it was further calculated to “cccDNA copies/cell” by dividing 
cell numbers in one well. Finally, the number of “cccDNA copies/infected cell” was determined 
by using “cccDNA copies/cell” to infectivity rate. Besides, HBV total DNA numbers were 
quantified in undigested samples using p466 and p541 primers by SYBR-green based real-time 
PCR described in session 2.2.3.5. Scheme of 2.2.3.2 and 2.2.3.3 is shown (Figure 2.2). 
 
2.2.3.4. Reverse transcription of total RNA 
Total RNA samples with HBV transcripts in HBV infection or HDV genomes in HDV infection 
were extracted as described above. Reverse transcription was performed using the High-
capacity cDNA Reverse Transcription Kit and reaction was prepared by mixing 3 µL of RNA 
(< 1 µg), 2 µL of 10× buffer, 2  µL of random primer, 0.8 µL of dNTP (100 mM), 1  µL of 
RNase inhibitor, 1 µL of RTase, and 10.2 µL of RNase-free water (total volume 20 µL). The 
mixture afterwards was subjected to RT-PCR using the program: 25℃ for 10 min (annealing 
of random primer and RNA template), 37℃ for 2 h (reverse transcription), and 85℃ for 5 min 
(RTase heat inactivation), 4℃ hold. Complementary DNA products were 1:10 diluted. 
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Figure 2.2. Working flowchart of cccDNA quantification. Susceptible cells (PHH, 
HepaRGNTCP, HepG2NTCP) infected with high mges (> 300) of HBV are lysed. (A) Lysates are 
incubated at 70 °C in the presence of proteinase K and later loaded on a silica column and 
eluted. (B) T5 exonuclease (5 U/1 h) removes host genomic DNA (black) and HBV replicative 
intermediates (rcDNA, dslDNA, etc.) (green) and preserves cccDNA intact (red). (C) cccDNA 
is amplified by p1040/p1996 primers and detected by probe p1085. 
 
2.2.3.5. Quantitative PCR of HBV transcripts and HDV RNA 
Expression levels of pgRNA, HBs and total transcripts were quantified using specific primers 
shown in session 2.1.3.6. PCR reaction contained 2 µL of diluted complementary DNA, 7.5 µL 
of 2× SYBR green mix, 0.6 µL of forward primer, 0.6 µL of reverse primer and 4.3 µL of water 
(total volume 15 µL). The qPCR was performed as follows: 95℃ × 5 min, [95℃ × 10 sec, 60℃ 
×30 sec, plate read] × 40 cycles. As standard, pSHH2.1 plasmid was 1:10 serial diluted to obtain 
standard samples with 109, 108, 107, 106, 105, 104, 103 copies/µL and loaded aside in the same 
plate. 
Reverse-transcribed HDV complementary DNA was quantified using the “Ferns” primers 
in a reaction including 2 µL of diluted DNA, 7.5 µL of 2× SYBR green mix, 0.6 µL of forward 
primer, 0.6 µL of reverse primer and 4.3 µL of water (total volume 15 µL) using the above 
program. Besides, copies of HDV RNA could be directly quantified using one-step qScript 
XLT RT-qPCR Toughmix in a reaction with 2 µL of the RNA template, 7.5 µL of 2× qScript 
XLT Toughmix, 0.6 µL of forward primer, 0.6 µL of reverse primer, 0.3 µL of probe and 4 µL 
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of water. RT-qPCR program was 50℃ × 10 min (reverse transcription), 95℃ × 3 min, [95℃ × 
10 sec, 60℃ × 30 sec, plate read] × 40 cycles. For both HDV qPCR, overlength HDV pJC126 
plasmid was 1:10 serial diluted to 108, 107, 106, 105, 104, 103, 102 copies/µL and loaded as 
standard aside. 
 
2.2.3.6. CsCl gradient ultracentrifugation 
CsCl density gradients were prepared by slowly one-by-one loading 500 µL of 1.4 g/mL CsCl 
at the bottom of ultracentrifugation tube, 500 µL of 1.3 g/mL CsCl, 500 µL of 1.2 g/mL CsCl 
and freshly prepared 500 µL of 20 % sucrose. Finally, 2.3 mL of virus supernatant or 2.3 mL 
of medium containing 50 µL of the concentrated virus was carefully loaded on the top without 
interference of CsCl layers. Ultracentrifugation tubes were accurately balanced (weight 
difference < 0.01 g). Ultracentrifugation was performed at 58,000 rpm for 3.5 h at 20℃. Later 
on, fractions were collected using Beckman Fraction Recovery System in a 96-well plate (7~8 
drops of the first fraction, 6 drops of the second to the twelfth fractions). The fractions were 
immediately subjected to DNA dot blot or frozen at -20℃ overnight. 
 
2.2.3.7. DNA dot blot 
For quantification of HBV DNA amounts in the fractions collected from CsCl density 
ultracentrifugation, PBS pre-wet positive-charged nylon membrane on the top of two pieces of 
Whatman papers were assembled on the vacuum-based 96-well dot-blot system. Standard DNA 
samples were prepared by 1:20 diluting the H0 stock (1×1011 copies/50 µL of pCHT-9/3091 
plasmid) to obtain H1 (5×109 copies/50 µL), which was further 1:5 serial diluted to H2 (1×109 
copies/50 µL), H3 (2×108 copies/50 µL), H4 (4×107 copies/50 µL), H5 (8×106 copies/50 µL) 
and H6 (1.6×106 copies/50 µL). Standards and fractions were loaded onto the nylon membrane 
and washed twice with PBS. The membrane was air-dried, rapidly incubated with Soak I buffer 
(1.5 min, twice) and afterward Soak II buffer (1 min, four times). It was air-dried again and 
DNA was crosslinked twice under UV crosslinker. 
To develop DNA signal on the membrane, radioactive HBV-specific DNA probe was 
produced using the Megaprime DNA labeling kit. In detail, 5 µL of template (SacI-linearized 
pCHT-9/3091 plasmid, 5 ng/µL) was mixed with 5 µL of random 9-mer oligonucleotide and 
16 µL of water. This mixture was denatured at 95℃ for 10 min and immediately chilled on ice 
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for 3 min. Pre-cooled 4 µL of dATP, 4 µL of dGTP, 4 µL of dTTP and 5 µL of reaction buffer 
were added to the mixture. Bringing this mixture to the iso-lab, 2 µL of Klenow fragment (1 
U/µL) and 5 µL of [a-32P]-dCTP were added. The mixture was incubated at 37℃ for 15 min 
with gentle shaking. The product was purified using a MicroSpin G25 column to remove free 
radioactive labeled nucleotides and thereby the flow-through contained 15~30 bp radioactive 
incorporated double-strand oligos, which were denatured at 95℃ for 10 min and immediately 
chilled on ice again and ready for hybridization use. 
The membrane with crosslinked DNA was pre-hybridized with home-made hybridization 
buffer at 68℃ for 1 h. The denatured probe was then dropwise added into the buffer and 
hybridization was performed by rotating the membrane and incubating with the probe at 68℃ 
overnight. The next day, the membrane was washed twice with prewarmed wash buffer for 30 
min each, air-dried. After washes, radioactivity value on the membrane was measured by a 
counter (usually the value is 100~500). The membrane was incubated with a b-radiation 32P-
sensitive film (Fuji) in a locked cassette overnight. The third day, the signal on the film was 
read by a phosphorimager (Fuji Typhoon FLA-7000). 
Using Quantify One software, a standard curve was created based on the signals from 
standards. Accordingly, signals of other dots were calculated into absolute HBV DNA copies. 
Specifically for the virus produced in transfected Huh7 cells, virus titer was the sum of DNA 
copies in three consensus dots representing only enveloped virions but not naked nucleocapsids. 
 
2.2.3.8. Southern blotting 
Southern blotting allows the detection of DNA samples with different sizes and structures. DNA 
samples extracted using the High Pure Viral Nucleic Acid Kit or the Hirt method were loaded 
on a 1.2% agarose gel. Gel electrophoresis was at 125 V for approximate 3 h until the 
bromophenol blue dye went to the boundary of the gel. 
After running, the gel was soaked with 0.2 M HCl and gently agitated for 10 min at room 
temperature to depurinate DNA. The gel was shortly rinsed in water for three times, soaked in 
denaturing buffer with gentle agitation for 1 h at room temperature. Rinsed for three times in 
water, the gel was soaked in neutralizing buffer for 1 h at room temperature. Shortly rinsed in 
water, the gel was agitated and balanced for 15 min in 20× SSC buffer. To blot DNA onto nylon 
membrane, the transfer apparatus was assembled as follows: 
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Lay two pieces of Whatman 3MM paper on a scaffold chamber higher than the surface of 
20× SSC buffer. Soak tails of Whatman papers in the buffer and completely wet the papers, get 
rid of the bubbles between papers using a plastic roller. 
Lay the gel on the top of Whatman papers, remove bubbles. 
Place pre-soaked positive-charged nylon membrane on the top of the gel, remove bubbles 
between the gel and the membrane. 
Lay two pieces of Whatman papers on the top of the membrane, remove bubbles. Seal the 
boundaries of the gel with parafilm. 
Put a stack of dry paper towels on the top of Whatman papers, avoid connection to the 
buffer. 
Add some ballast (1000 gram) on top of the whole apparatus and let the capillary transfer 
running overnight. 
The next day, disassemble the blotting apparatus, air dry the membrane, and crosslink it 
twice under UV crosslinker or bake it up to 80℃ for 1 h (both steps stabilize DNA onto the 
membrane). Probe production, (pre-)hybridization and signal development are the same as 
those described in DNA dot blot. 
 
2.2.3.9. Northern blotting 
Owing to RNA instability and its self-complementary, RNA samples were pre-denatured before 
gel electrophoresis and kept denature conditions relying on formaldehyde in the gel. 1.2 % 
formaldehyde gel was pre-run in 1× MOPS buffer supplemented with 0.2 M formaldehyde at 
70 V for at least 15 min. During the pre-run process, 10 µL of total RNA (1 µg/µL) was mixed 
with 30 µL of Formaldehyde Loading Dye (Ambion) by pipetting up and down. This mixture 
was heated up to 65℃ for 15 min to denature RNA secondary structures and chilled on ice for 
5 min. In the cool room, denatured RNA samples were loaded into the formaldehyde gel and 
electrophoresis was performed at 120 V for about 3.5 h until the dyes went to the edge of the 
gel. After running, the gel was rapidly rinsed with water twice and soaked in denaturing buffer 
(0.05 M NaOH) for 20 min at room temperature. The gel was rinsed with water for three times, 
further soaked in DEPC-treated 20× SSC buffer for 15 min before blotted using the facility as 
described above (Figure 2.3.) and transferred to nylon membrane overnight. After blotting, the 
membrane was crosslinked and hybridized as described above in session 2.2.3.7. 
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2.2.3.10. LDH cytotoxicity assay 
Released lactate dehydrogenase (LDH) was measured using a CytoTox 96 Non-Radioactive 
Cytotoxicity kit (G1780, Promega) according to the protocol. Briefly, collected supernatant was 
centrifuged at 400 g for 5 minutes to remove cell debris. 50 µl of the supernatant was incubated 
with 50 µl of CytoTox96 reagent for 30 min with protection from light. Then, 50 µl of stop 
solution was added, and the colorimetric absorbance at 490 nm was measured. The untreated 
group was set up as 100% and viability for all the groups was normalized. 
 
2.2.3.11. WST-1 cytotoxicity assay 
PHH, HepG2hNTCP and HepaRGhNTCP cells treated with MLN4924 were washed twice with PBS 
and incubated with medium freshly supplemented with 1:15 diluted WST-1 stock (Roche 
11644807001) at 37℃ for 15 min. The absorbance at 450 nm was measured using an EnVision 
multilabel reader (Perkin-Elmer). The untreated group was set up as 100% and the relative 
survival rate was calculated. 
 
2.2.3.12. HBsAg and HBeAg measurement 
The culture medium of HBV infected cells was collected and centrifuged at 4000 rpm for 5 min. 
Depending on distinct cell types, the supernatant was undiluted or 1:2 ~1:20 diluted with PBS. 
Absolute HBsAg and/or HBeAg levels were detected by commercial assays, HBsAg was 
measured by an Architect assay (Abbott), while HBeAg was quantified by an ADVIA Centaur 
XP Immunoassay System (Siemens Diagnostic). Values more than 0.05 IU/mL for HBsAg or 
1.0 index for HBeAg were regarded as positive. 
 
2.2.3.13. Immunofluorescence 
Infected cells were washed twice with PBS, fixed with 4% paraformaldehyde for 30 min at 
room temperature. After PBS washes, cells were permeabilized with 0.25% Triton X-100 for 
30 min at room temperature. Afterward, the cells were blocked with 5% milk in PBS for 1 h at 
room temperature and incubated with primary antibody at 4℃  overnight (dilution factor 
summarized in session 2.1.3.3). The next day, after three five-minute washes, the cells were 
incubated with 1:500 diluted Alexa Fluor 488/546/555-conjugated goat anti-
rabbit/mouse/human IgG (H+L) antibody and 1 µg/mL of Hoechst 33342 dye at room 
temperature for 1 h. After three washes, images were taken under a DFC350 FX microscope 
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(Leica) and analyzed using the Fiji software. Moreover, in order to calculate the infectivity rate, 
both HBcAg-positive and Hoechst-positive cell numbers were counted by eyes in twenty 
random views under a microscope, and HBcAg-positive cell number in every 100 Hoechst-
positive cells was shown. 
 
2.2.3.14. Confocal microscopy 
Confocal microscopy for SMC6 and HBcAg co-staining according to a Gilead’s protocol with 
minor modifications. HBV infected cells grew on coverslips were fixed with 4 % PFA 
supplemented with 1 % sucrose for 10 minutes at room temperature. The cells were washed by 
PBS for three times and permeabilized with 1% Triton X-100 for 30 minutes at room 
temperature. Because of the instability of SMC6 epitope, fixed cells were immediately stained 
on the same day. The cells were blocked with 3% goat serum in PBS at 4℃ for 1 h and then 
co-stained with rabbit anti-SMC6 antibody (Sigma-Aldrich HPA042733, 1:100 diluted) and 
mouse anti-HBcAg antibody (homemade M312, 1:1000 diluted) for 1 h at room temperature. 
As shown in Figure 2.4., the anti-SMC6 antibody was validated and very specific. After washes 
with PBS for eight times, the cells were co-incubated with Alexa Fluor 488 anti-rabbit IgG and 
546 anti-mouse antibody and 5 µM of DRAQ5 nuclear dye for 1 h at room temperature. After 
eight washes with PBS, coverslips were rinsed by pure water and air-dried for 30 min at room 
temperature protected from light. Finally, the mounting reagent was dropped on the slides and 
coverslips were faced down and attached on the slides. The next day, high-resolution images 
were taken under Leica confocal microscope (excitation wavelength: 488 nM SMC6, 546 nM 
HBcAg, 647 nM nucleus. All images were colorized, analyzed and merged by the Fiji software. 
Figure 2.3. Validation of the anti-SMC6 antibody by siRNA transfection and intracellular 
staining. HepG2hNTCP cells were mock-transfected or reverse-transfected with siRNA against 
EGFP (red) and SMC6 (blue). 48 h post transfection, the cells were fixed, permeabilized, and 
subjected to intracellular SMC6 staining using the Sigma-Aldrich antibody (1:200 diluted). 
SMC6 expression levels were analyzed by flow cytometry and shown in this histogram. Black 
curve: unspecific background staining; yellow curve: endogenous SMC6 level; red curve: 
EGFP negative control; blue curve: SMC6 knockdown by specific siRNA. Flow cytometry 
analysis was assisted by Pascal Mutz. 
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2.2.3.15. Western blotting 
HBx(WT)- and HBx(R96E)-HepG2hNTCP cells were lysed with 1× Laemmli buffer (Bio-rad 
#161-0747) supplemented with 1% protease/phosphatase inhibitors (Cell Signalling 
Technology #5872S) on ice for 20 min. Total cell lysates were denatured at 98℃ for 10 min 
and chilled on ice for 3 min. After short-time centrifugation, the lysates were loaded into a 4-
20 % SDS gel for protein separation at 80 V in the stacking part and 120 V in resolving part. 
Proteins were blotted onto methanol-activated PVDF membrane, which was further blocked 
with 5% milk in TBS buffer and incubated with anti-HA antibody (1:1000) (Cell Signalling 
Technology #3724S) or anti-b-actin antibody (1:2000) (Sigma-Aldrich A1978) at 4 ℃ 
overnight. Membranes were washed by TBS-T buffer for 10 min for three times and incubated 
with HRP-conjugated secondary antibody (1:10,000) (Sigma-Aldrich A0545 and A9044) at 
room temperature for 1.5 h. After washes for three times, membranes were incubated with 
enhanced ECL substrate (Perkin-Elmer NEL104001EA) and the chemical signal was developed 
by an ECL chemocam imager (Intas).  
Especially for SMC6 detection, nuclei of infected cells were isolated, washed and lysed to 
obtain nuclear lysates using the NucBuster Protein Extraction kit according to the 
manufacturer’s instructions. The nuclear lysates were loaded into an SDS gel, wet blotted at 30 
V overnight. Following steps were the same as described above. 
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2.2.3.16. Co-immunoprecipitation (co-IP) 
To perform the co-IP assay, HBx(WT)- and HBx(R96E)-HepG2hNTCP cells were transiently 
transfected with pcDNA3-Flag-DDB1 plasmid. 24 h post transfection, the cells were washed 
with PBS twice and MLN4924 was added for 48 h in the medium in the presence or absence of 
1 µg/mL of doxycycline. The cells were lysed in modified RIPA buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.1 % NP-40) with 1 % protease/phosphatase inhibitors and 1 mM of PMSF on ice 
for 30 min. The lysates were centrifuged at 12,000 rpm for 10 min at 4℃ and the clear 
supernatant was transferred to new tubes, where proteins were incubated with mouse anti-Flag 
M2 antibody (Sigma-Aldrich F1804, 2 µL of antibody per 200 µL of supernatant) at 4℃ on a 
rotator overnight. The next day, protein G sepharose beads (GE Healthcare 10164015) were 
added at 4℃ for 2 h to capture Flag-DDB1 and HA-HBx(WT or R96E) complex. The beads 
were centrifuged down, washed with ice-cold lysis buffer for 5 cycles and finally resuspended 
with 1× Laemmli buffer. After 98℃ denaturation, samples were subjected to western blot. 
 
2.2.3.17. Dual luciferase assay 
Huh7 cells seeded in 24-well plates were co-transfected with 50 ng of pRL-SV40-Rluc plasmid 
as well as 450 ng of pGL3-HBV-promoter-Fluc plasmid overnight. The cells were treated with 
5 µM of MLN4924 or 5 µM of Lamivudine for another 48 h. Later on, cells were washed with 
PBS for three times and lysed with 100 µL of 1× passive lysis buffer for 20 min at room 
temperature. 20 µL of the lysates were transferred into a white-wall 96-well plate. Using 
luminometer, 100 µL of coelenterazine substrate in assay buffer was automatically added to the 
lysate and 5 seconds later renilla luciferase unit was read. Furthermore, 100 µL of luciferin 
substrate in assay buffer supplemented with DTT and ATP was added and firefly luciferase unit 
was measured in the luminometer. Relative luciferase unit was calculated as the rate of firefly 
unit and renilla unit.
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3. RESULTS 
3.1. Kinetics of cccDNA establishment and evaluation of inhibitors on cccDNA stability 
3.1.1. Raising the mge results in an increase of infected cells and cccDNA copies 
Using the method of T5 exonuclease digestion of total 
DNA samples followed by cccDNA-specific qPCR, the 
kinetics of cccDNA formation was firstly analyzed in 
the HepG2hNTCP cells infected at different mge’s. By 
rising the mge of HBV in inoculates, the accumulation 
of cccDNA in the HepG2hNTCP cells was measured. 
Using mge’s of 30, 100, 300, 1000 and 3000 per cell as 
shown in Figure 3.1., expression levels of intracellular 
HBcAg confirmed productive infection. At mge from 
30 to 1000, evidently more HBcAg positive cells were 
observed, however the infection at the highest mge 
3000 did not lead to a further increase of HBcAg+ cells. 
On the other hand, at mge >1000 the entry inhibitor 
MyrB profoundly reduced HBcAg expression, 
suggesting that HBV replication under those conditions 
is exclusively initiated by the receptor-mediated entry 
of virions and therefore HBcAg expression is cccDNA-
dependent. 
Figure 3.1. HBcAg expression levels in infections 
with increasing mge. HepG2hNTCP cells were infected 
with different amounts of virus inoculates (mge/cell = 
30, 100, 300, 1000, 3000). As control MyrB (1 µM) was 
co-administered during the infection to verify NTCP-
mediated entry of the virus. On d 10 p.i., intracellular 
HBcAg expression levels (red) were visualized. Nuclei 
were indicated by Hoechst staining (blue). 
The rise of mge per cell from 30 to 1000 led to not only 
an increase of infected cells but a correlative increase of total cccDNA copies per well. 
Similarly, the level of total DNA was also increased in a linear manner. However, at an mge 
of 3000 no proportional increase of cccDNA and total DNA numbers was observed (Figure 
3.2.A). Therefore, cccDNA copy numbers show saturated when very high mge of the virus is 
used under conditions when the majority of cells have been infected, although the mechanism 
how the host controls cccDNA copy number is still unknown. Consistently, the correlation of 
mge with HBeAg and HBsAg secretion and an increased number of infected cells was 
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observed previously in HepaRG cells and PHH (Schulze et al., 2012). Indeed, at mge’s from 
30 to 1000, both HBeAg and HBsAg levels were accordingly increased. From mge’s 1000 to 
3000, the increase of HBsAg level was not proportional but HBeAg level was greatly inclined, 
probably due to the cross-detection of nucleocapsids at such a high mge (Figure 3.2.B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. cccDNA and secreted antigen levels in infections with increasing mge. (A) 
HepG2hNTCP cells were infected with different amounts of virus inoculates (mge/cell = 30, 100, 
300, 1000, 3000) in parallel and total DNA samples were prepared on d 10 p.i.. Samples were 
hydrolyzed by T5 Exo (5 U/60 min) at 37°C for 1 h, and cccDNA level was determined using 
pp1040-1996 primers. Total DNA copy numbers were determined in undigested samples using 
pp466-541 primers. (B) Within the same infections, extracellular replicative markers, secreted 
HBsAg (grey) and HBeAg (white) values from d 7 to 10 p.i., were measured. 
 
3.1.2. Comprehensive kinetics of cccDNA establishment in infected hepatocytes 
To achieve moderate infection rates, an mge of 300 was used for infection. The cccDNA 
formation over time p.i. in PHH, HepaRG, HepaRGhNTCP, and HepG2hNTCP cells was analyzed. 
Under the same infection conditions, infection rates of HepG2hNTCP, HepaRGhNTCP, HepaRG 
cells and PHH were 24%, 8.6%, 5.3% and 16.7%, respectively, which were determined by 
counting HBcAg+ cells at d 7 p.i. as shown in Figure 3.3.. 
It was observed that 24.0 % of HepG2hNTCP cells were infected, which provides the 
maximal infectivity among all models. To my surprise, the infectivity rate in HepG2hNTCP cells 
was even higher than PHH with physiological hNTCP expression. However, differentiated 
HepaRGhNTCP (8.6%) and HepaRG cells (5.3%) at the same mge value were less infected, 
suggesting that HBV has a strict hepatocyte-specific tropism and in these models co-existing 
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biliary cells can not be infected. This was confirmed by the observation that cytokeratin 18 
protein, a hepatocyte-specific marker (Wells et al., 1997), was expressed in 7.8% of total 
differentiated HepaRGhNTCP cells, which was very close to the infectivity rate 8.6%. 
 
 
 
 
 
 
 
Figure 3.3. Infectivity of infected hepatocytes at an mge value of 300. Infectivity rates (d 7 
p.i., mge/cell = 300) in indicated cultures were determined by counting HBcAg-positive and 
Hoechst-positive cell numbers from twenty random views under a microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. cccDNA formation and accumulation in infected PHH. PHH were infected at 
an mge of 300. MyrB (1 µM) and Tenofovir (15 µM) were used as controls shown in the timeline. 
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(A) Total DNA was extracted on d 1, 3, 7, 10 p.i.. T5 exonuclease treatment (37°C, 5 U/60 min) 
was performed prior to cccDNA quantification (left). cccDNA copy number was normalized by 
a factor derived from b-globin level to eliminate variation from inputs and further calculated to 
“cccDNA copies/cell”. Finally, the value of “cccDNA copies/infected cell” was determined by 
using “cccDNA copies/cell” to divide the elution rate and infectivity rate (Figure 3.3.). (B) 
Undigested DNA samples were used for quantification of total HBV DNA (right). (C) Productive 
infection in this infection was validated by measuring secreted HBeAg (white) and HBsAg (grey) 
values during d 7 to 10 p.i.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. cccDNA formation and accumulation in differentiated HepaRG cells. 
Differentiated HepaRG cells were infected at an mge of 300, MyrB (1 µM) and Tenofovir (15 
µM) were used as controls shown in the timeline. (A) Total DNA was extracted on d 1, 3, 7, 10, 
14 p.i.. T5 exonuclease treatment (37°C, 5 U/60 min) was performed prior to cccDNA 
quantification (left). (B) Undigested DNA samples were used for quantification of total HBV 
DNA (right). (C) Productive infection in this infection was validated by measuring secreted 
HBeAg (white) and HBsAg (grey) values during d 7 to 10 p.i.. 
Next, the kinetics of cccDNA formation was comprehensively analyzed in all infection 
models. In PHH, cccDNA was hardly detectable on d 1 p.i. but accumulated swiftly to an 
average of 5.8 copies per infected cell at d 10 p.i. (Figure 3.4.A). Mean copy numbers of 
cccDNA in PHH from three donors ranged from 2.5 to 10.5 (data not shown). As expected, 
cccDNA formation was blocked by MyrB but not Tenofovir treatment. Input virion DNA was 
detected on d 1 p.i. and total HBV DNA (rcDNA and cccDNA) produced from viral replication 
rapidly increased at later time courses (> d 3), suggesting pgRNA synthesis and its reverse 
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transcription. Total DNA synthesis was sensitive to Tenofovir treatment (Fig. 3.4.B). In 
differentiated HepaRGhNTCP and HepaRG cells, cccDNA was detectable on d 1 p.i. A unique 
feature was that cccDNA copy numbers increased rapidly until d 3 and remained at a stable 
level of 1~4 copies per infected cell until d 14, which suggests that most of the cccDNA 
molecules are formed simultaneously and do not undergo amplification after d 3 p.i. (Figure 
3.5. and 3.6.). CccDNA formation in infected HepG2hNTCP cells was similar to that in PHH with 
a linear increase from 0.5 copy per cell at d 3 p.i to approximate 1 copy per cell at d 14 (Figure 
3.7.). Furthermore, although the kinetics of cccDNA formation differs in PHH and other cell 
lines, the mean values of cccDNA numbers in all the models are generally low (< 6 copies per 
infected cell). The cccDNA pool does not undergo intracellular amplification during two weeks 
after infection, which implies that significant amplification of cccDNA after the first-round 
establishment does not occur in all those models (Qu et al., 2018) 
Regarding total HBV DNA, hundreds of copy numbers representing input virions were 
detected in all the systems on d 1 p.i.. Later on, a steady increase of total DNA levels 
representing the majority of rcDNA inside progeny nucleocapsids could be observed in all the 
models. However, even after two weeks p.i., there were merely 3-fold more progeny DNA than 
the inoculated DNA in PHH. Likewise, replicative HBV DNA produced in HepaRGhNTCP and 
HepG2hNTCP cell models was never more than the inoculates (Figure 3.4.~3.7.B). This in vitro 
data contrast the concept that HBV successful infection in chimpanzees requires inoculated 
dosage as low as 10 mge per animal. 
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Figure 3.6. cccDNA formation and accumulation in differentiated HepaRGhNTCP cells. 
Differentiated HepaRGhNTCP cells were infected at an mge of 300 as shown in the timeline. (A) 
Total DNA was extracted on d 1, 3, 7, 10, 14 p.i. and cccDNA levels were quantified (left). (B) 
Level of total HBV DNA (right) was measured similarly as shown in Figure 3.5.. (C) Productive 
infection was validated by measuring secreted HBeAg (white) and HBsAg (grey) values during 
d 7 to 10 p.i..  
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Figure 3.7. cccDNA formation and accumulation in infected HepG2hNTCP cells. 
HepG2hNTCP cells were infected at an mge of 300 as shown in the timeline. (A) Total DNA was 
extracted on d 1, 3, 7, 10, 14 p.i. and cccDNA levels were quantified (left). (B) Level of total 
HBV DNA (right) was measured similarly as shown in Figure 3.5..(C) Productive infection was 
validated by measuring secreted HBeAg (white) and HBsAg (grey) values during d 7 to 10 p.i.. 
MyrB (1 µM) and Tenofovir (15 µM) were used as controls. 
 
3.1.3. Effects of different drugs on cccDNA formation 
As shown above, the kinetics of cccDNA accumulation in HepG2hNTCP cells is very close to 
that in PHH. Hence HepG2hNTCP cells were further used for evaluation of the effect of 
representative drugs on cccDNA formation, which act at different steps of the HBV life cycle. 
The inhibitors tested were interferon-a-2b (Intron-A, Schering-Plough), two nucleos(t)ide 
analogues Lamivudine and Tenofovir, two entry inhibitors Myrcludex B (MyrB) and 
cyclosporine, and two capsid inhibitors GLS4 and BAY41-4109. 
First, IFN-a, MyrB and cyclosporine were co-administered with the virus whereas 
nucleos(t)ide analogues and capsid inhibitors were treated p.i.. Compared to the untreated group, 
IFN-a did not lead to a considerable reduction of HBcAg at 100 IU/mL however moderately 
reduced its level at 1000 IU/mL. MyrB blocked viral entry and subsequent HBcAg expression, 
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whereas cyclosporine as a weaker entry inhibitor slightly reduced it. Lamivudine and Tenofovir 
failed to reduce HBcAg level. In contrast as capsid inhibitors, both BAY41-4109 and GLS4 
profoundly reduced HBcAg at 1 µM (Figure 3.8.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Effect of antiviral drugs on HBcAg expression. Infected HepG2hNTCP cells 
(mge/cell = 300) were treated with interferon-a-2b (100 and 1000 IU/mL), Lamivudine (1 and 
10 µM), Tenofovir (1 and 10 µM), MyrB (0.5 and 5 µM), and Cyclosporine A (1 and 10 µM) for 
six days or one week as shown. On d 7 p.i., cells were fixed and HBcAg staining was performed 
by an immunofluorescence assay (red). Hoechst staining indicates nuclei (blue). 
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Figure 3.9. Effect of antiviral drugs on cccDNA establishment and maintenance. IFN-a-
2b, entry inhibitor MyrB and cyclosporine (entry inhibition activity via NTCP binding), were co-
administered with HBV inoculates during infection in HepG2hNTCP cells. The drugs were 
maintained in cell culture medium for one week. Lamivudine, Tenofovir, BAY41-4109, and 
GLS4 were added from d 1 to 7 p.i. (A) Cell viability was determined by an LDH release assay. 
Survival rate: % to untreated set as 100 %. Dashline: 80 %. (B) Secreted HBeAg values, (C) 
calculated cccDNA (left) and (D) total DNA copies (right) per infected HepG2hNTCP cell were 
shown. 
Except 10 µM of BAY41-4109 and cyclosporine A, all treatments did not induce more 
than 20% cell death as shown in Figure 3.9.A. IFN-a inhibited cccDNA formation and HBeAg 
secretion in a dose-dependent manner when it was administered up to 1000 IU/mL, which is 
consistent with a recent report (Shen et al., 2018). MyrB completely blocked viral entry, 
cccDNA formation and subsequent HBeAg secretion, when it was co-administered with the 
virus. A similar but weaker effect was observed for cyclosporine that also prevents HBV entry 
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by interacting NTCP (EC50 = 8 µM). Nucleos(t)ide analogues hardly affected cccDNA levels 
when they were applied at d 1 p.i.. At 1 µM, neither GLS4 nor BAY41-4109 affected cccDNA 
copy numbers when they were administered at d 1 p.i.. However, a 30% reduction of cccDNA 
copy numbers was observed at 10 µM (Figure 3.9.C). 
 
Figure 3.10. Co-treatment of MyrB or 
GLS4 with virus blocks cccDNA 
formation. MyrB (0.1 and 1 µM), GLS4 
(0.2 and 2 µM), and Tenofovir (1 and 10 
µM) were co-administered with HBV 
(mge/cell = 300) during infection (co-
treatment) or p.i. from d 1 to 7. (post-
treatment). CccDNA expression levels 
were measured on d 7 p.i.. 
 
 
 
The second experiment was set up to compare MyrB, capsid inhibitor GLS4 and nucleotide 
analogue Tenofovir. This data revealed that MyrB as entry inhibitor was functional in blocking 
cccDNA formation when it was co-administered with the virus, but not post treated. Indeed, 
MyrB profoundly reduced cccDNA levels at an EC50 value of 10 nM and an EC90 value of 100 
nM (Qu et al., 2018). To less extent, co-administration of GLS4 at a high dose of 2 µM with 
virus, affected early cccDNA formation, however post treatment of GLS4 seldom reduced 
cccDNA level, which is consistent with the observation that such capsid inhibitors can directly 
act on already assembled capsids and functionally alter their structures (Guo et al., 2017, 
Schlicksup et al., 2018). However, the concentrations required for this activity are far exceeding 
the EC50 values for interference with virus assembly (Figure 3.10.). This data shed light on dual 
functions of capsid inhibitors, including the destruction of nucleocapsids during infection and 
interference of virus assembly p.i. (Berke et al., 2017). 
Taken together, the results in this session demonstrate that (I) not only HepaRG but the 
recently developed NTCP-transduced cell lines, are suitable systems to study cccDNA early 
formation and medium-term accumulation, (II) absolute cccDNA copy numbers are extremely 
low (less than 6 copies per infected cell) in all in vitro infection models, (III) entry inhibitor 
MyrB blocks cccDNA formation and to less extent GLS4 interferes with cccDNA formation. 
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3.2. Nuclear HBx promotes transcription from cccDNA 
3.2.1. HBx expressed by its authentic promoter is located in the nucleus 
As depicted in the introduction, HBx is 
regarded as a multi-functional non-structural 
protein involved in many nuclear and 
cytoplasmic cellular processes. The first 
scientific question I thought was whether HBx 
is expressed in the nucleus, cytoplasm, or both. 
In terms of reliable detection of HBx protein in 
authentic HBV infection, there are two major 
problems: low expression level of HBx protein 
and long-term restriction of an antibody with 
the maximal sensitivity. All commercial anti-
HBx antibodies and homemade anti-HBx sera 
were tested in order to visualize HBx 
expression in real HBV infection in various 
models (PHH, HepG2hNTCP and Huh7hNTCP 
cells) and at multiple mge’s (mge/cell = 300, 
1000, 3000). However, over years none of 
these attempts gave rise to one reliable 
visualization of HBx protein measured by 
either western blot or immunofluorescence 
(data were not shown). In order to study HBx 
localization, I stepped backward to perform 
transient transfection using conditions that are 
closer to virus infection. Therefore, Huh7 
hepatoma cells were transfected with several 
formats of plasmid encoding HBx by different 
promoters (pcDNA3.1-HBx; pWPI-HBx; 
pCH-9/3091-HBV-1.1mer) and in each case 
HBx subcellular localization was monitored. 
To my surprise, HBx localizations 
diversified. As shown in Figure 3.11.A, HBx 
protein was mostly located within cytoplasm 
when it was expressed by the CMV promoter 
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(pcDNA3.1-HBx). It was observed that HBx aggregated and formed speckles in the cytoplasm 
when its expression level was extremely high by a strong promoter like CMV. Only a small 
proportion of HBx appeared in the nucleus. Besides, loss of cells that was shown by reduced 
nuclear staining was correlated with HBx expression at such high level, suggesting that cell 
death might be induced in the presence of aberrantly high expression of HBx.  
In contrast, when HBx was expressed by the EF1a promoter (pWPI-HBx) that is weaker 
than CMV promoter, HBx became mostly nuclear while a minor proportion was located in the 
cytoplasm. Unlike cytosolic HBx, nuclear HBx proteins were all diffused in the whole nucleus 
without forming any visible aggregates (Figure 3.11.B). Remarkably, when Huh7 cells were 
transfected with overlength HBV genome (pCH-9/3091-WT) in which HBx was expressed by 
its authentic X promoter, only background unspecific signals were found in cytoplasm due to 
the least expression of HBx protein leading to less antibody binding specificity, again, HBx 
protein was exclusively located and diffused expressed in the nucleus, which was very similar 
to what was shown in the panel B (Figure 3.11.C). 
Furthermore, the amounts of HBx expression correlate with HBx subcellular localization. 
Driven by the strong CMV promoter, HBx is cytosolic however this situation is artificial and 
not physiological. By weaker EF1a or X promoter, HBx becomes nuclear but seems not co-
localized with nucleolus and any nuclear bodies (Figure 3.11.). Assuming that HBx protein 
expressed from cccDNA in the authentic infection is less transcriptional efficient but similar to 
the case of transfection with overlength HBV plasmid containing the same X promoter, it is 
speculated that therefore HBx expression level is pretty low and HBx is also localized in 
nucleus of infected cells, although it remains not traceable by current methods. Additionally, it 
is further expected that the majority of HBx proteins arise in the nucleus and thus regulate 
nuclear events during HBV replication. These findings are consistent with insights presented 
by experienced HBx researchers (Slagle et al., 2015). 
With this, for the first time, this observation suggested that at least HBx protein could be 
involved in the nuclear games of HBV replication, mostly meaning cccDNA formation and its 
transcription. Therefore, two following scientific questions were raised up: (I) whether HBx 
protein is indispensable in cccDNA formation and maintenance of cccDNA stability and (II) 
whether HBx modulates cccDNA transcription. 
Figure 3.11. HBx is a nuclear protein when it is expressed by the authentic promoter. 
Huh7 cells were transiently transfected with plasmids (A) pcDNA3.1-HBx; (B) pWPI-HBx-
IRES-GFP and (C) pCH-9/3091-HBV-1.1mer (WT) (0.5 µg plasmid per well in 24-well plate). 
48 hours post transfection, the cells were fixed and stained with anti-HBx rabbit serum (#644, 
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1:500 diluted) (red). Hoechst staining indicates nuclei (blue). Magnification factor = 200; For 
zoom-in images, magnification factor = 400. 
 
3.2.2. HBx transactivates cccDNA transcription but not affects its formation 
To investigate exact roles of HBx in formation and transcription of cccDNA, WT virions 
together with HBx-minus (Xd) virions (HBx expression is null by introducing two stop codons 
within X ORF without altering polymerase and core ORFs) were generated. Since HBx is not 
detectable in infection, virion DNA of Xd stock was amplified by PCR and the PCR product 
was Sanger sequenced to confirm stop mutations on HBx (data not shown). As shown in Figure 
3.12.A, when HepG2hNTCP cells were infected with the same mge of WT and Xd virions 
produced in two independent preparations, comparable cccDNA kinetics over time was 
observed, suggesting that HBx is dispensable for the formation of cccDNA and maintenance of 
cccDNA stability. Moreover, during d 1 to 3 p.i., levels of pregenomic RNA and total transcripts 
were hardly affected. In contrast, compared to Xd, transcription of WT virus was significantly 
enhanced in the presence of HBx and this difference started from d 3 to 7 and sustained from d 
7 to 10, when transcription is initiated by newly synthesized cccDNA, implying that maximal 
HBV transcription of cccDNA requires HBx and HBx also maintains transcription (Figure 
3.12.B and C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. HBx is not essential in cccDNA formation but required in cccDNA 
transcription in HepG2hNTCP cells. WT and Xd virions were generated by transfection of Huh7 
cells and enriched by PEG precipitation. Prior to infection, virus titers were determined by CsCl 
gradient ultracentrifugation and DNA dot-blot. HepG2hNTCP cells were infected with the same 
mge of WT and Xd virions (mge/cell = 100). (A) At d 1, 3, 7, 10, 14 p.i., total DNA was extracted 
and cccDNA expression levels were measured. prep.: independent preparations of each virus. 
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(B) At d 1, 3, 7, 10 p.i., total RNA was extracted and pgRNA genome copies were measured. 
(C) At d 1, 3, 7, 10 p.i., copies of total HBV transcripts were determined. As a control, MyrB (1 
µM) was co-treated during each infection. 
A previous study has demonstrated that HBx is a key regulator to initiate and maintain 
HBV replication in differentiated HepaRG cells (Lucifora et al., 2011). To confirm it, this 
function of HBx protein on cccDNA was further studies in differentiated HepaRGhNTCP cells. 
When infected with WT and Xd virions, both viruses replicated similarly during d 1 and 3 p.i., 
except some more pgRNA signals from Xd virion on d 1 was detected. However again WT 
virion showed enhanced transcriptional activity over time until d 21. The transcription of the 
WT virus was declined after d 14, probably due to loss of differentiation status in HepaRGhNTCP 
cells (Figure 3.13.). Moreover, these data implied that functional HBx protein might be 
translated very early, as transcription of WT virus started exceeding that of Xd virus at d 3 p.i., 
and the expression of HBx protein could be sustained at least during the first two weeks p.i.. 
 
Figure 3.13. HBx enhances cccDNA transcription in differentiated HepaRGhNTCP cells. 
Differentiated HepaRGhNTCP cells were infected with the same mge of WT and Xd. virions side 
by side (mge/cell = 100). (A) At d 1, 3, 7, 14, 21 p.i., total RNA was extracted and genome 
copies of pgRNA were determined. (B) Total HBV transcripts in the same RNA samples were 
shown. MyrB (1 µM) was co-treated during infection. 
 
3.2.3. C-terminal mini-HBx is sufficient and indispensable in transactivation 
Next, the molecular determinants within HBx protein that mediate regulation of cccDNA 
transcription were characterized. Overlapping with ORFs of polymerase and core, HBx is not 
suitable for engineering within its genome for virus production, however, the combination of 
Xd infection and lentiviral trans-complementation encoding HBx mutants allows genetic 
modification of HBx protein.  
Firstly, lentiviruses encoding truncation and deletion forms of HBx protein were generated 
and validated. When HepG2hNTCP cells were infected with WT virus and superinfected with 
lentivirus expressing either GFP or full-length HBx (1-154), cccDNA transcription was not 
affected further inclined, indicating that basal level of HBx expressed from the WT virus is 
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sufficient to maintain its transcription and redundant ectopic HBx could not further elevate 
transcription of cccDNA. Nevertheless, when Xd virus-infected HepG2hNTCP cells were 
subsequently transduced with lentivirus expressing full-length HBx (1-154), the transcription 
level was fully enhanced to the exact level of WT virus, illustrating that the cccDNA templates 
of Xd virus stay transcriptional inactive as long as they encounter HBx (1-154) and immediately 
become active, even though the HBx proteins are ectopic and late expressed. Most importantly, 
when Xd virus-infected cells were transduced with lentivirus expressing HBx truncations, 
entire C-terminal HBx (51-154) showed the same enhancing activity of cccDNA transcription 
as full-length HBx, the N-terminal HBx (1-50) and a deletion mutant (D51-142), however, 
showed no activity anymore on the cccDNA of Xd virus. In addition, two shorter truncations 
(HBx 51-142 and 58-142) were partially functional and rescued transcriptional degree of Xd 
virus to 50~70 % of the level of WT virus (Figure 3.14.A). Taken together, these data suggested 
that C-terminal HBx is sufficient and indispensable to rescue cccDNA transcription of Xd virus. 
In the experiments, patterns of secreted HBeAg were very consistent with corresponding 
transcription (Figure 3.14. B). Similar to Figure 3.12., no significant alteration of cccDNA 
during transduction and expression of these HBx mutants was observed, except that HBx (58-
142) showed a two-fold decrease at the cccDNA level compared to the untransduced group 
(Figure 3.14.C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. C-terminal HBx is sufficient and indispensable in cccDNA transactivation. 
HepG2hNTCP cells were infected with WT and Xd virions (mge/cell = 100). On d 2 p.i., infected 
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cells were transduced with lentiviruses expressing GFP, HBx (1-154), HBx (1-50), HBx (51-
154), HBx (D51-142), HBx (51-142) and HBx (58-142) (mge/cell = 50) overnight and afterward 
medium was changed every 2~3 days. On d 8 p.i., (A) pgRNA and (C) cccDNA expression 
levels were determined. (B) Supernatant from d 5 to 8 p.i. was collected and HBeAg values 
were measured. 
Secondly, attentions were paid on the DDB1-binding deficient mutant, HBx (R96E). Xd 
virus-infected HepG2hNTCP cells were transduced with lentiviruses expressing HBx (WT), HBx 
(R96E) and HBx (R96A). Two types of lentivirus vectors, constitute expression vector pWPI-
HBx, and inducible expression vector pInducer20-HBx (kind gift provided by Bernd 
Wollscheid, ETH Zürich), were devised. As a positive control, transduction of HBx (WT) 
rescued transcription of Xd virus to the level of WT virus. For both transductions, HBx (R96E) 
was not able to enhance the transcription. However, HBx (R96A) still showed 80% rescue 
activity as shown (Figure 3.15.).  
Since the arginine 96 residue is crucial to HBx-DDB1 binding, it was thereby confirmed 
that DDB1-binding function of HBx, or in another word, the HBx-DDB1 complex is 
responsible for HBx’s transactivation in authentic infection setting, which provides a forward 
step consistent with previous study using plasmid system (Leupin et al., 2003). The R96E 
mutation that alters a basic residue to an acidic residue, may inactivate HBx-DDB1 binding 
activity. Unlike R96E, R96A mutation itself may cause a mild biochemical change and not 
affect the binding activity (Li et al., 2010c). 
Figure 3.15. R96E single-point mutation on HBx abolishes its transactivation activity. 
HepG2hNTCP cells were infected with WT or Xd viruses (mge/cell = 100). For Xd infection, 
infected cells were transduced with lentivirus (pWPI-HBx and pInducer20-HBx formats, 
mge/cell = 50) on d 2 p.i.. After pInducer20-HBx transduction, doxycycline (1 µg/mL) was 
added on d 5 p.i. to induce HBx expression. (A) On d 8 p.i., total RNA was extracted and 
pgRNA expression levels were examined. (B) For both transductions, supernatant from d 5 to 
8 was collected and HBeAg values were measured. 
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To sum up this chapter, HBx is a nuclear protein when it is expressed by authentic X 
promoter and nuclear HBx functions as a modulator at the cccDNA level. Experiments with 
comparison of WT and Xd infections demonstrated that HBx protein is a transcriptional 
enhancer in trans but not essential in cccDNA formation. These data suggest the nature of HBx 
as a nuclear transactivator in trans. Furthermore, relying on the lentivirus-based trans-
complementation assay, I confirmed that entire C-terminal HBx is sufficient but indispensable 
to enhance cccDNA transcription, presumably because generalized DDB1-binding region 
covers the whole C-terminus (61-154) but not the minimal binding motif (88-101) in the middle 
of the C-terminus, although the minimal motif is core component responsible for HBx-DDB1 
binding. This has been proved by the fact that HBx (R96E) could not rescue the transcription 
of Xd virus, indicating that one of the functions of HBx, DDB1 binding, is the major mechanism 
for enhancing cccDNA transcription. Entire C-terminal HBx (51-154), termed “mini-HBx”, 
plays the same role as WT HBx in modulating HBV replication at the cccDNA level. However, 
what is the exact role of its N-terminus (1-50) is still largely unknown. 
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3.3. Neddylation blockage inhibits transcription from persistent cccDNA 
Recently, two independent groups identified SMC5 and SMC6 as major restriction factors that 
are ubiquitinated and degraded during HBV replication (Decorsiere et al., 2016, Murphy et al., 
2016), which provides a new direction that the prevention of this degradation may become a 
drug target. From HBV side, HBx protein binds DDB1 and recruits host E3 ubiquitin ligase 
Cullin 4A and this complex mediates SMC5/6 degradation. So far, no regimen is available to 
interfere with HBx-DDB1 interaction or HBx itself. Given that neddylation is required for the 
activation of Cullin 4A, subsequent degradation of SMC5/6 and initiation of cccDNA 
transcription, neddylation inhibitor may break down the HBx-DDB1-Cullin 4A complex at the 
Cullin 4A level. 
 
3.3.1. MLN4924 selectively inhibits HBV but not HDV replication 
Figure 3.16. MLN4924 inhibits HBV replication and does not affect HDV RNA replication. 
Differentiated HepaRGhNTCP cells were infected with HBV and treated with two-fold serial 
diluted MLN4924 (15.6, 31.2, 62.5, 125, 250, 500 nM) from d 1 to 7. (A) Secreted HBsAg and 
(B) HBeAg levels from d 5 to 7 were measured. On d 7 p.i., total RNA was extracted and (C) 
pgRNA and (D) total RNA genome copies were determined. (E) The same batch of 
differentiated HepaRGhNTCP cells was infected with HDV and treated with the same indicated 
doses of MLN4924 from d 1 to 7. On d 7 p.i., total RNA was extracted and copies of HDV RNA 
genome were measured. MyrB (1 µM) was co-treated during infection. 
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As shown in Figure 3.16., six-day MLN4924 treatment reduced all HBV transcripts 
(pgRNA and total RNA) and secreted viral proteins (HBeAg, HBsAg) in a dose-dependent 
manner starting from a very low dose of 30 nM. At higher doses (> 250 nM), the inhibitory 
effects were comparable to the levels by MyrB treatment. In contrast, HDV replication at RNA 
genome level was not altered up to 250 nM. Since HBV and HDV shared the same envelopes 
and strategies of virus entry via NTCP receptor, this data suggested that MLN4924 does not 
interfere with attachment and entry steps. It also implied that neddylation is of importance 
specific in HBV but not HDV replication. 
 
Figure 3.17. MLN4924 reduces intracellular HBcAg level but not HDAg expression. (A) 
Differentiated HepaRGhNTCP cells were infected with HBV and administered with MLN4924 from 
d 1 to 7 p.i.. On d 7, cells were fixed, stained and HBcAg expression levels were visualized. 
(B) Differentiated HepaRGhNTCP cells were infected with HDV and treated with MLN4924 from 
d 1 to 7 p.i.. On d 7, infected cells were fixed and HDAg levels were determined. For both 
infections, MyrB (1 µM) was co-treated during infection. 
The other piece of evidence proving that selective effect upon MLN4924 treatment was 
the expression levels of HBV and HDV intracellular viral antigens. For HBV infection, HBcAg 
was present in all infected hepatocytes in the untreated group and its expression was diminished 
at 125 nM and 500 nM of MLN4924. Combining with the data in Figure 3.16, MLN4924 led 
to the reduction of all RNA and protein markers during HBV replication. In contrast, HDAg 
levels were not affected up to 500 nM in HDV infection. Besides, although cell death occurred 
in a small proportion of cells, either the HDAg expression in alive cells or total rate of HDAg 
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positive cells was not changed (Figure 3.17.). Hence, in HBV replication MLN4924 at least 
targets exactly on the step of RNA production or at the upstream of transcription. 
 
3.3.2. MLN4924 reduces the production of HBV DNA- and RNA-containing virions 
In recent three years, an emerging concept is the identification of pgRNA-containing particles 
that are enriched during nucleos(t)ide treatment. RNA-containing virions are infectious and 
become a new clinical marker in antiviral therapy (Wang et al., 2016, Wang et al., 2017, Wang 
et al., 2018). As shown in Figure 3.17., MLN4924 potentiated inhibition of intracellular pgRNA 
expression, one of the follow-up questions was whether MLN4924 also inhibits the production 
of RNA-containing virions. To test this possibility, HepAD38, the virus-producing cell that 
generates pgRNA and secrets a great number of virions, was incubated with MLN4924 during 
virus production and the amounts of RNA- as well as DNA-containing virions were measured. 
Figure 3.18. MLN4924 prevents the secretion of DNA- and RNA-containing virions. 
HepAD38 cells were seeded at a confluent density and maintained with supplemented 
doxycycline (1 µg/mL) as shown in the timeline (tet-on phase). On d 7 post seeding, 
doxycycline was removed and Lamivudine (5 µM), Tenofovir (5 µM), MLN4924 (1 µM or 5 µM), 
GLS4 (0.2 µM) and DMSO (0.5%) were added. The supernatant (SN) was collected every 3 
days until d 19. Before nucleic acid extraction, the supernatant was centrifuged at 4000 rpm 
for 10 min to remove any cellular components. (A) Total DNA was extracted and eluates were 
digested with RNase (10 U/60 min) and DNA copies in the product were measured. (B) Total 
RNA was extracted and eluates were digested with RNase-free DNase (10 U/60 min) then 
RNA copies in the product were determined. 
As expected, Lamivudine as well as Tenofovir, resulted in 300-fold (approximate 2.5 log-
scale) less encapsidated DNA in the supernatant during d 16 to 19. Interestingly, Lamivudine 
showed unexpected better inhibitory effect on DNA secretion than Tenofovir, which is more 
potent in patients. As a positive control, the capsid inhibitor GLS4 led to a reduction of virus 
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production to the same extent as that induced by nucleos(t)ide inhibitors. Upon MLN4924 
treatment, 30-fold (1.5 log-scale) less DNA-containing viruses in the supernatant were detected 
(Figure 3.18.A). On the other hand, GLS4 showed a similar 300-fold reduction of RNA-
containing particles as DNA-containing particles at the late time course, demonstrating that 
GLS4 decreases production of RNA- and DNA-containing viruses in common probably due to 
the inhibition of capsid assembly independent on pgRNA conversion to rcDNA. However, 
Lamivudine and Tenofovir treatments failed to decline RNA amounts, compared to the 
untreated group, which is consistent with their modes of action that block reverse transcription 
of pgRNA but do not affect pgRNA itself. Remarkedly, MLN4924 treatment resulted in 10-
fold less production of RNA-containing particles (Figure 3.18.B). Unlike nucleos(t)ides 
selective to DNA inhibition, MLN4924 showed no selectivity on the RNA- and DNA-
containing viruses, although both inhibitory effects were less efficient than GLS4. These data 
implied that the mechanism of MLN4924 might be (I) prevention of pgRNA production as 
shown in Figure 3.16. and/or (II) blockage of capsid assembly similar but less efficient to GLS4. 
Nevertheless, the mechanism (I) is distinct from modes of action of nucleos(t)ide inhibitors and 
capsid modulators. 
Figure 3.19. CC50 values of MLN4924 in HepaRGhNTCP, HepG2hNTCP cells and PHH. (A) 
Differentiated HepaRGhNTCP and (B) HepG2hNTCP cells were treated with 1:3 serial doses of 
MLN4924 (HepaRGhNTCP: 6.7 nM, 20 nM, 67 nM, 200 nM, 667 nM, 2 µM, 6.67 µM, 20 µM; 
HepG2hNTCP: 67 nM, 200 nM, 667 nM, 2 µM, 6.67 µM, 20 µM, 66.7 µM, 200 µM) from d 1 to 8 
post seeding. On d 8, WST-1 assay was performed and survival rates were calculated 
(untreated: 100%). (C) PHH were treated with different doses of MLN4924 (6.7 nM, 20 nM, 67 
nM, 200 nM, 667 nM, 2 µM, 6.67 µM) from d 1 to 7 post seeding. On d 7, WST-1 assay was 
performed and survival rates were calculated (untreated: 100%). 
 
3.3.3. Transcripts of all HBV promoters on cccDNA are declined upon treatment 
Furthermore, pharmacologic index values of MLN4924 in all models were measured. CC50 
values in PHH and HepaRGhNTCP cells were comparable, however, HepG2hNTCP cells were 
much more tolerant with a CC50 value of 70 µM (Figure 3.19.). Next, EC50 values of MLN4924 
were measured in those infection systems. HBV infected HepaRGhNTCP and HepG2hNTCP cells 
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were treated with MLN4924 for 7 days and infected PHH for 6 days. Comprehensive 
documentation at secreted HBsAg/HBeAg, total transcripts as well as cccDNA was made. In 
HepaRGhNTCP cells, the EC50 value of HBsAg was 26.9 nM and the value of HBeAg was 15 
nM, while the EC50 value of transcription was 30.2 nM. Except for 2 µM leading to cytotoxicity 
and loss of cccDNA numbers, MLN4924 never induced more than 30% reduction on the 
cccDNA numbers, suggesting that MLN4924 is a transcriptional inhibitor (Figure 3.20. A~D). 
Figure 3.20. EC50 values of MLN4924 in HepaRGhNTCP, HepG2hNTCP cells and PHH. 
Differentiated HepaRGhNTCP cells were HBV infected and treated with MLN4924 (6.7 nM, 20 
nM, 67 nM, 200 nM, 667 nM, 2 µM) from d 1 to 8 p.i.. (A) HBsAg and (B) HBeAg levels in the 
supernatant from d 5 to 8 were determined. (C) On d 8, total RNA was extracted and total 
transcripts were measured and (D) cccDNA level in total lysates was determined. *: cytotoxicity 
at 2 µM. HepG2hNTCP cells were infected and treated with MLN4924 (6.7 nM, 20 nM, 67 nM, 
200 nM, 667 nM, 2 µM) from d 1 to 8 p.i.. (E) HBsAg and (F) HBeAg levels in the supernatant 
from d 5 to 8 were determined. (G) On d 8, total transcripts were measured and (H) cccDNA 
level was examined. PHH were infected and treated with MLN4924 (6.7 nM, 20 nM, 67 nM, 
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200 nM, 667 nM, 2 µM, 6.67 µM) from d 1 to 7 p.i.. (I) HBsAg and (J) HBeAg levels in the 
supernatant from d 5 to 7 were determined. (K) On d 7, total transcripts were measured and 
(L) cccDNA level was examined. 
In HepG2hNTCP cells, the EC50 value of HBsAg was 175 nM and the value of HBeAg was 
30.2 nM, but the EC50 value of transcription was much higher at 484.7 nM. cccDNA level, 
however, was quite stable upon MLN4924 treatment (Figure 3.20. E~H). In PHH, the EC50 
value of HBsAg was 293.4 nM, the value of HBeAg was 143.7 nM and the value of 
transcription was 292.4 nM (Figure 3.20. I~L). Overall, all EC50 values in all three models were 
in the nanomolar range (< 1 µM). Besides, HBV replication in HepaRGhNTCP and HepG2hNTCP 
cells, compared to PHH, was more sensitive in responding to MLN4924 treatment according to 
the EC50 values. 
Figure 3.21. MLN4924 mediates irreversible transcriptional inhibition from persistent 
cccDNA in HepaRGhNTCP cells. Differentiated HepaRGhNTCP cells were infected with HBV and 
maintained until d 14, when cells were pulse-treated with MLN4924 (200 nM and 600 nM) or 
GLS4 (200 nM) from d 14 to 17 and d 23 to 26. During d 17 to 23, MLN4924 was removed. 
Starting from d 11 p.i., the supernatant was collected every 3 days and (A) HBsAg and (B) 
HBeAg values were determined. On d 14, 17, 20, 23, and 26, (C) total RNA was extracted and 
total transcripts were examined. (D) cccDNA levels were also measured. 
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As shown in Figure 3.20., MLN4924 is a transcriptional inhibitor without interference 
with cccDNA. Since cccDNA reservoir has been established in chronic HBV patients, it is 
meant to address whether transcription remains hampered upon MLN4924 treatment when the 
cccDNA pool has been fully formed. I therefore conducted long-term infection in differentiated 
HepaRGhNTCP cells and maintained them for 14 d which was followed by a pulse treatment (3-
day on, 6-day off and 3-day on of MLN4924). Transcription from persistent cccDNA was 
rapidly inhibited upon the first round 3-day treatment and sustained inhibition of transcription 
was observed during withdrawal of MLN4924. In addition, the second round of 3-day treatment 
achieved a 41-fold reduction of transcription. As a result, 27-fold reduced HBsAg and 9-fold 
reduced HBeAg levels were observed by the end of the second round treatment. In contrast, 
capsid inhibitor GLS4, neither affected transcripts nor HBsAg secretion. Loss of cccDNA 
numbers occurred spontaneously in the untreated HepaRGhNTCP cells after 20 d p.i. (7 weeks 
post cultivation) and in this case, MLN4924 speeded up cccDNA decay but this acceleration 
effect was minimal (approximate 2 fold) (Figure 3.21.). Besides not only cccDNA numbers, 
after 14 d long-term infection, levels of transcripts and secreted HBsAg/HBeAg were also 
declined without any treatments in differentiated HepaRGhNTCP cells, meaning that the cellular 
environment of HepaRGhNTCP cells becomes worse and worse to support stable HBV replication 
over time. 
Since differentiated HepaRGhNTCP cells are not the best model supporting stable HBV 
replication for more than three weeks, the HepG2hNTCP cells, which allow long-term infection 
were infected (Yi Ni & Bingqian Qu, 2016 international HBV meeting) and pulse-treated with 
MLN4924 from 14 d p.i. on. During initial 3-day treatment, MLN4924 inhibited cccDNA 
transcription as well as antigen secretion. To my surprise, a rebound of transcription occurred 
during the removal of MLN4924. Especially during d 3 to 6 post withdrawal (d 20 to 23 p.i.), 
the number of transcripts came back to the same level of untreated group, meaning that cccDNA 
transcription is completely recovered. Interestingly, the rebound transcription was immediately 
inhibited again compared to the untreated by the second round of MLN4924 treatment, 
suggesting that MLN4924 can inhibit reactivated transcription from cccDNA being activated 
after transcriptional silence (Figure 3.22.A~C). In this model, the cccDNA pool was much more 
stable. Except for one outlier (MLN4924, 3 µM, d 20), MLN4924 did not affect cccDNA 
stability and thereby this “switch on-and-off” of cccDNA transcription was independent on 
cccDNA destruction but relying on its transcriptional manipulation (Figure 3.22.D). The 
findings clearly demonstrated that MLN4924 blockage of transcription is reversible in 
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HepG2hNTCP cells and suggested that modes of the exact action of cccDNA transcription in 
HepG2hNTCP and HepaRGhNTCP cells might be distinct. 
 
Figure 3.22. Rebound of cccDNA transcription after MLN4924 withdrawal is prompt in 
HepG2hNTCP cells. HepG2hNTCP cells were infected with HBV and maintained until d 14 when 
cells were pulse-treated with MLN4924 (1 µM and 3 µM) or GLS4 (200 nM) from d 14 to 17 
and d 23 to 26 (3-day on, 6-day off and 3-day on of MLN4924). From d 11 p.i., the supernatant 
was collected every 3 days and (A) HBsAg and (B) HBeAg values were determined. On d 14, 
17, 20, 23, and 26, (C) total RNA was extracted and total transcripts were examined. (D) 
cccDNA level was also quantified. 
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Figure 3.23. Transcription from all HBV 
promoters is inhibited upon MLN4924 
treatment. HBV-infected HepG2hNTCP cells 
(mge/cell = 500) were treated with MLN4924 from 
d 2 to 7 or Lamivudine from d 3 to 7 p.i.. On d 7, 
cellular total RNA was extracted.  
10 µg of each RNA samples were analyzed by 
northern blotting (upper) and 2 µg of the same 
samples were shown on a native 1 % agarose gel 
(lower). 
 
 
 
 
 
 
As previously shown, MLN4924 is a potent transcriptional inhibitor  (Figure 3.20., 3.21. 
and 3.22), however it is unclear whether MLN4924 can solely reduce the level of one 
subgenomic RNA, or whether it inhibits general transcription of all HBV promoters, including 
core, preS1, preS2 and X promoters. The northern blotting analysis showed that MyrB blocked 
virus entry and profoundly reduced all transcriptions due to less formed cccDNA. In contrast, 
Lamivudine targeting at the reverse transcription of pgRNA, had no effect on transcription. 
MLN4924 induced decrease of all the transcripts in a dose-dependent manner, which showed 
pronounced effects on pgRNA and X RNA levels at 1 µM and further strongly reduced preS/S 
RNA levels at 5 µM. Although the reduction of preS/S RNA requires a higher concentration, 
overall MLN4924 did not show any selectivity on transcription from a specific promoter. 
Therefore, this data suggested that MLN4924 is a pan-transcriptional inhibitor targeting at all 
HBV promoters (Figure 3.23.). 
In chronic HBV infection, HBsAg generation is not only relying on transcription from 
episomal cccDNA but also from integration into the host genome (Wooddell et al., 2017). Since 
MLN4924 inhibits transcription from all promoters located on cccDNA, I further evaluated 
whether MLN4924 also affected transcription of HBV integrants HBV by studying PLC/PRF5 
the “Alexander” cell, which carries 7~8 natural HBs integrants (without full-length pgRNA 
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sequence). When PLC/PRF5 cells were treated with MLN4924 for 6 days, no significant 
reduction of HBs transcription was observed at increasing concentrations up to 3 µM (higher 
concentrations e.g. 10 µM, induced cytotoxicity, not shown) (Figure 3.24.). Besides, the same 
test was performed using another hepatoma cell, Hep3B, with fewer copies of integrants per 
cell. MLN4924 also did not show any alterations at HBs transcripts in the Hep3B cells (data 
not shown). 
Figure 3.24. MLN4924 does not reduce HBs transcription in PLC/PRF5 cells. PLC/PRF5 
cells were seeded and maintained until they formed a monolayer (d 4~6 post seeding) when 
MLN4924 (0.3 µM, 1 µM, 3 µM) was treated onto the cells for 6 days. On d 6, total RNA was 
extracted and HBs transcripts were measured. Lamivudine (5 µM) was added as a negative 
control. 
Unlike that HBsAg present in the supernatant of Hep3B cells is unmeasurable, PLC/PRF5 
cells produce and secret considerable amounts of HBsAg. The HBsAg levels of PLC/PRF5 
cells upon MLN4924 treatment were measured. As shown in Figure 3.25.A, over time post 
seeding intracellular HBsAg was accumulated. Compared to the untreated, 0.3 µM of 
MLN4924 showed no reduction on HBsAg, however 1 µM and 3 µM of MLN4924 led to a 
slight reduction. For extracellular HBsAg, at d 0~2 post treatment, MLN4924 induced a 35% 
decrease and later on d 2~4 and d 4~6, the reduction degree was enlarged up to 70%, indicating 
that continuous MLN4924 treatment results in translational inhibition, although transcription 
level as previously shown in this model was not changed at all (Figure 3.25.B). 
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Figure 3.25. MLN4924 inhibits HBsAg production in PLC/PRF5 cells. (A) PLC/PRF5 cells 
were seeded and secreted HBsAg level was measured every two days before treatment and 
when MLN4924 (0.3 µM, 1 µM, 3 µM) was treated onto the cells for 6 days. On d 6 post 
treatment, intracellular HBsAg was visualized by IF staining (HBC34 anti-HBsAg, 1: 3000 
diluted). (B) On d (-6)~(-4), d 0~2, d 2~4 and d 4~6, the supernatant was collected and HBsAg 
level was measured, respectively. Lamivudine (5 µM) was used as a negative control. 
To summarize this session, MLN4924 was characterized as a transcriptional inhibitor with 
determined EC50 and CC50 values in PHH, HepG2hNTCP and differentiated HepaRGhNTCP cells. 
As a consequence of transcriptional inhibition, MLN4924 reduced amounts of both DNA- and 
RNA-containing particles in the supernatant of virus-producing HepAD38 cells. By pulse-
treatment experiment, a discrepancy that MLN4924 showed the irreversible effect on 
HepaRGhNTCP cells and reversible effect on HepG2hNTCP cells was shown. MLN4924 did not 
show any promoter specificity but minimized transcription from all four HBV promoters 
located at cccDNA. Furthermore, MLN4924 did not inhibit transcription from the same preS1 
and preS2 promoters when they are integrated, however MLN4924 showed a moderate 
inhibition on HBsAg production probably by targeting at its translation and post-translational 
modification. 
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3.4. MLN4924 inhibits cccDNA transcription in an HBx-dependent manner 
3.4.1. MLN4924 does not decrease HBx expression or interfere with HBx-DDB1 binding 
To investigate whether MLN4924 effect is dependent on HBx, this hypothesis was firstly tested 
in an HBx-null system by performing HBV reporter assay. As shown in Figure 3.26., when 
pGL3-HBVpromoter-Fluc (a kind gift from Dongyan Jin, University of Hong Kong) and pGL3-
SV40-Rluc plasmids were co-transfected in normal Huh7 cells, Lamivudine treatment showed 
no difference in expression levels of firefly and renilla luciferases. MLN4924 treatment in the 
transfected cells also did not change in relative firefly luciferase levels expressed by preS1 and 
X promoters. However, MLN4924 even induced 3-fold and 4-fold more luciferase levels 
expressed by core and preS2 promoters, respectively, compared to the mock-treated. 
Nevertheless, MLN4924 did not inhibit luciferase transcription driven by any of the four HBV 
promoters in the absence of HBx protein. 
Figure 3.26. MLN4924 does not inhibit 
transcription in the absence of HBx. Huh7 cells 
were co-transfected with 450 ng of pGL3-core 
promoter-Fluc, pGL3-preS1 promoter-Fluc, pGL3-
preS2 promoter-Fluc, pGL3-X promoter-Fluc and 
50 ng of pRL-SV40-Rluc (w/w = 9: 1). 24 hours post 
transfection, the cells were treated with MLN4924 
(5 µM) and Lamivudine (5 µM) for another 48 hours. 
Cells were lysed and total lysates were used for 
two-step dual-luciferase measurements by 
determining firefly and renilla readouts. Relative 
luciferase unit was calculated as firefly/renilla rate 
and further normalized as fold change to the mock-
treated (set up as 1). 
To elucidate the accurate role of HBx upon MLN4924 treatment requires more authentic 
systems, two stable cell lines expressing HA-tagged HBx fusion protein under inducible tet-
mini-CMV promoter were generated. As shown in the scheme, integration of the HBx(WT) 
cassette was introduced by lentiviral transduction and stabilized by G418 selection in 
HepG2hNTCP and HepaRGhNTCP cells. In parallel, HepG2hNTCP and HepaRGhNTCP cells with 
stable expression of HBx (R96E) mutant (indicated by red asterisks) that has almost no 
transactivation function and impaired DDB1-binding activity were also generated (Figure 
3.27.). Unexpectedly, the proliferation of the HBx(WT)-HepaRGhNTCP cells was extremely slow 
compared to parental HepaRGhNTCP cells, and it took more than two weeks for one splitting. 
Therefore, it was not comparable at all since HBx(R96E)-HepaRGhNTCP cells proliferated as 
normal as parental cells (data not shown). The HBx(WT)-HepG2hNTCP and HBx(R96E)-
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HepG2hNTCP cells, however, grew at the same speed. For this reason, the HepG2hNTCP cells were 
selected for further experiments. 
 
 
 
 
 
 
 
 
 
Figure 3.27. Generation of stable HBx(WT)- and HBx(R96E)-HepG2hNTCP cells. (Left) 
HepG2hNTCP cell line with endogenous expression of DDB1 was transduced with lentivirus 
generated from pInducer20-HA-HBx(WT) plasmid that expresses WT HBx in a tetracycline-
/doxycycline-dependent manner. Lentiviral integration was stabilized by G418 (1 mg/mL) 
selection for two weeks and reinforced by adding G418 (0.5 mg/mL) for another two weeks. 
(Right) The same parental HepG2hNTCP cell was transduced with lentivirus expressing R96E 
HBx mutant (red asterisks) with impaired binding activity to DDB1. After transduction, the 
HBx(R96E)-HepG2hNTCP cell was G418 selected and maintained similarly. 
Figure 3.28. MLN4924 does not reduce HBx expression. HBx(WT)-HepG2hNTCP cell (WT 
cell) and HBx(R96E)-HepG2hNTCP cell (R96E cell) were seeded at the same numbers in parallel, 
doxycycline (1 µg/mL) and MLN4924 (mock, 1 µM, 5 µM) were co-treated for 3 d. Total lysates 
of these cells were analyzed by western blot to show HBx expression. 
The HBx(WT)-HepG2hNTCP (WT cell) and HBx(R96E)-HepG2hNTCP cells (R96E cell) 
allowed investigation of HBx functions upon MLN4924 treatment in authentic infection. HBx 
expression was measured in both cells. When MLN4924 was not treated, both cells showed 
doxycycline-inducible expression levels of HBx proteins, compared to the background 
expression in the absence of doxycycline, and the final levels of WT and R96E proteins were 
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almost the same. HBx expression was very stable in the presence of MLN4924 in the WT cell. 
To my surprise, MLN4924 treatment split HBx(R96E) protein to two bands, including one with 
the same size as HBx(WT) and the other larger. Since MLN4924 is a neddylation inhibitor, the 
larger band was definitely not the neddylated HBx(R96E) but a possible phosphorylation form 
of HBx(R96E), when dephosphorylation of the glutamic acid was somehow blocked upon 
MLN4924 treatment. Nevertheless, total amounts of the two bands remained equal to the 
original amount when MLN4924 was not added. At least, MLN4924 treatment did not alter 
HBx expression in the WT cell (Figure 3.28.). 
Next, a Flag-tagged DDB1 fusion protein was transiently overexpressed in those cells, the 
Flag-DDB1 protein was pulled-down and HBx that binds DDB1 was detected. Ectopic DDB1 
fusion bound to HBx protein in the WT cell and MLN4924 treatment could not reduce DDB1-
HBx interaction (rates of [IP: DDB1; IB: HBx]/[IP: DDB1; IB: DDB1] were unchanged). The 
detection of HBx protein in pulled-down DDB1 complex represented authentic HBx-DDB1 
binding, since (i) without doxycycline induction this interaction was hardly visualized and (ii) 
in the control R96E cell this interaction was profoundly impaired (Figure 3.29.). Consistent 
with a previous report (Leupin et al., 2003), the arginine residue was regarded as the major 
determinant responsible for HBx-DDB1 interaction, HBx(R96E) protein had a weak binding 
activity to DDB1 and the R96 cell represented a situation where HBx was present but not 
functional in transactivation (Figure 3.15.). More importantly, I confirmed that MLN4924 
neither reduced HBx(WT) expression nor interfered with HBx-DDB1 association in WT and 
R96E cells, which are reliable models allowing an authentic infection to further explore HBx 
functions. 
Figure 3.29. MLN4924 does not interfere with HBx-DDB1 interaction. WT and R96E cells 
were transiently transfected with a pcDNA3 plasmid expressing Flag-DDB1 fusion protein. 24 
h post transfection, transfectants were removed, cells were washed by PBS twice and treated 
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with MLN4924 (mock, 1 µM, 5 µM) for another 48 h in medium without or with doxycycline (1 
µg/mL). In the end, cells were lysed in modified RIPA buffer (50 mM Tris-HCI, 150 mM NaCl, 
0.1% NP-40) and lysates were centrifuged at 12,000 rpm for 10 minutes, the supernatant was 
collected and used for the co-IP assay. IP: immunoprecipitation, IB: western blotting, WCL: 
whole cell lysates. 
 
3.4.2. MLN4924 restricts cccDNA transcription in an HBx-dependent manner 
Since full-length HBx has been integrated into the host genome of WT and R96E cells, one 
drawback is that when the cells are infected total transcripts from cccDNA can not be reliably 
detected by PCR because of a great amount of HBx transcripts generated from integrates. 
However, pgRNA expressed only from cccDNA but not from integrated HBx is a decent marker 
to reflect the real transcriptional activity from cccDNA. Therefore, WT and R96E cells were 
infected with Xd virions, HBx expression was induced by adding doxycycline and pgRNA 
levels, as well as HBeAg, were evaluated. PgRNA expression levels were 10-fold enhanced in 
WT cell when HBx(WT) was present and MLN4924 treatment could cut off this HBx-
dependent enhancement to the background level. In contrast, HBx(R96E) protein induced a less 
than 2-fold increase of pgRNA expression and even this slight enhancement was reduced by 
MLN4924 to the basal level (Figure 3.30.A). Similarly, HBeAg value was 4-fold inclined in 
the presence of HBx(WT) and MLN4924 completely eliminated enhanced its value to the 
baseline level of Xd virus, whereas HBeAg value was not enhanced by HBx(R96E) yet 
MLN4924 further declined it by 50% (Figure 3.30.B). As expected, cccDNA was not reduced 
in both WT and R96E cells (Figure 3.30.C). 
To further illustrate this HBx dependency, in addition to the stable HBx-expressing cells, 
Xd infection was combined with lentiviral transcomplementation to study whether MLN4924 
showed similar phenotype when HBx was transiently provided in trans. HepaRGhNTCP and 
HepG2hNTCP cells were infected with Xd virus, transduced with lentivirus expressing GFP, 
HBx(WT) and HBx(R96E) proteins on d 2 p.i., and further treated with MLN4924 on d 5. 
Similar to Figure 3.15., HBx(WT), but not GFP or HBx(R96E) fully enhanced pgRNA levels 
in both cells. In HepaRGhNTCP cells, MLN4924 but not Lamivudine, completely repressed 
transcription from cccDNA back to the level of Xd infection. MLN4924 performance in 
HepG2hNTCP cells was not as potent as that in HepaRGhNTCP cells but remained functional. Again 
HBx(R96E) protein could not enhance transcription of Xd virus but MLN4924 displayed a 2-
fold reduction of transcription in both cells (Figure 3.31.). Using two different models as shown 
in Figure 3.30 and 3.31, mode of MLN4924 action was confirmed in an HBx-dependent manner. 
MLN4924 selectivity on HBx(WT) but not HBx(R96E) also suggested that the mechanism of 
MLN4924 was highly relying on the HBx-DDB1 complex. 
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Figure 3.30. MLN4924 inhibits transcription from cccDNA in an HBx-dependent manner 
in two stable cells. WT cell and R96E cell were infected with Xd virions (mge/cell = 100). Two 
days p.i., doxycycline (1 µg/mL) was administered on d 2~5 and later MLN4924 (5 µM) was 
added during d 5~8 p.i.. (A) Viral pgRNA and (B) HBeAg secretion were examined, and (C) 
cccDNA levels were measured. MyrB (1 µM) was used to show NTCP-mediated virus entry. 
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Figure 3.31. MLN4924 inhibits transcription from cccDNA in an HBx-dependent manner 
when HBx is expressed in trans. (A) Differentiated HepaRGhNTCP and (B) HepG2hNTCP cells 
were infected with Xd virions and transiently transduced with indicating lentiviruses encoding 
GFP, HBx(WT) and HBx(R96E) proteins as shown on d 2 p.i.. Transduced cells were further 
treated with MLN4924 (5 µM in HepG2hNTCP cells/0.5 µM in HepaRGhNTCP cells) or Lamivudine 
(5 µM in both cells). On d 8 p.i., pgRNA levels were determined by qPCR. 
 
3.4.3. MLN4924 restores HBx-mediated SMC6 degradation 
Recently, SMC5 and SMC6 proteins were identified as major restriction factors that prevent 
maximal transcription from cccDNA. HBx protein binds DDB1 and bridges E3 ubiquitin ligase 
Cullin 4A and this functional complex induces SMC5/6 degradation. If MLN4924 indeed 
serves as a transcriptional inhibitor in an HBx-DDB1-dependent manner but does not reduce 
HBx amounts or interfere with HBx-DDB1 association, it makes sense to speculate that 
MLN4924 deactivates the function of HBx-DDB1 complex, which mediates SMC5/6 
degradation. 
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Two-color confocal microscopy allowed visualization of SMC6 and HBcAg at the single 
infected HepaRGhNTCP cells. SMC6 proteins showed exclusive nuclear expression and very 
specific nuclear localization as bright dots in the uninfected hepatocytes, which was consistent 
with the recent finding showing co-localization of SMC6 protein and PML nuclear bodies (Niu 
et al., 2017). During infection, HBV replication diminished SMC6 signals in HBcAg high-
expressing hepatocytes (Figure 3.32.A). Since long-term MLN4924 treatment resulted in loss 
of HBcAg as shown in Figure 3.17., I had to shorten MLN4924 treatment time, focus on cells 
with accumulated lower HBcAg level (meaning that the cells have been infected) and seek for 
moderate SMC6 expression, which was expected as newly synthesized SMC6 protein upon 
MLN4924 treatment, after all old SMC6 proteins were eliminated during the former 6-day HBV 
replication. The re-emergence of SMC6 signals evidenced that MLN4924 deactivated HBx-
DDB1 machinery and as a consequence, newly synthesized SMC6 proteins were restored. 
However, Lamivudine was not able to restore SMC6 expression in HBcAg-positive cells 
(Figure 3.32.B and C). 
Figure 3.32. MLN4924 prevents HBx-mediated SMC5/6 degradation in infected 
HepaRGhNTCP cells. Differentiated HepaRGhNTCP cells were infected with HBV virions (mge/cell 
= 500) and (A) mock-treated, or (B) treated with MLN4924 (1 µM) from d 6~7 p.i., or (C) 
Lamivudine (5 µM) from d 4~7 p.i.. The cells were fixed and freshly fixed SMC6 epitopes were 
detected by immunofluorescence on the same day of fixation using a validated antibody (green: 
anti-SMC6). HBcAg (red: anti-HBcAg) was co-stained. Representative images were taken 
under confocal microscopy. Bar: 10 µM. 
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Figure 3.33. MLN4924 prevents HBx-mediated SMC5/6 degradation in infected PHH. PHH 
were infected with HBV virions (mge/cell = 500) and (A) mock-treated, or (B) treated with 
MLN4924 (1 µM) from d 4~5, or (C) Lamivudine (5 µM) from d 2~5 p.i.. The cells were fixed 
and fresh SMC6 epitopes (green: anti-SMC6) were detected by immunofluorescence on the 
same day of fixation. HBcAg (red: anti-HBcAg) was co-stained. Images were taken under 
confocal microscopy. Bar: 10µM. 
Moreover, more physiological PHH were infected. In HBV infection, most cells were 
HBcAg positive that was correlated with complete loss of SMC6 signals. Upon MLN4924 
treatment, cells with robust HBcAg and detectable SMC6 expression were found, although the 
restoration of SMC6 signals was not as nice as that in infected HepaRGhNTCP cells (Figure 3.33.). 
 
 
 
 
 
 
 
 
Figure 3.34. HBV replication induces SMC6 degradation. HepG2hNTCP cells were infected 
with HBV (mge/cell = 600). On d 4 p.i., MLN4924 (5 µM) and Lamivudine (5 µM) treatments 
were initiated. On d 7, nuclei of infected cells were isolated, washed and lysed. Nuclear lysates 
were subjected to western blotting. levels of SMC6 and hnRNPk were determined. 
Detection of SMC6 protein level by western blotting provided an overview beyond single-
cell confocal analysis. When HepG2hNTCP cells were infected with HBV at a moderate mge 
(mge/cell = 600) and SMC6 levels in nuclear fraction were measured, HBV replication induced 
3-fold reduction of SMC6 protein level compared to the uninfected, indicating that SMC6 
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proteins were largely degraded during infection (considering that at such mge, not all cells were 
infected and SMC6 proteins were not eliminated in the uninfected cells). Distinct from 
Lamivudine, MLN4924 treatment led to enhanced SMC6 expression level during infection. 
However, it seems that the level of another HBx-binding protein hnRNP K was also elevated. 
(Figure 3.34.). This issue is still under investigation. 
To summarize, endogenous SMC6 is not a specific target of host ubiquitination machinery 
in natural condition. In HBV infection, HBx protein at very low expression level hijacks host 
ubiquitin ligase via direct DDB1 binding and potential SMC6 association. The complex induces 
SMC5/6 degradation. SMC5/6 degradation enables the maximal transcriptional activity of 
cccDNA and facilitates robust HBV replication. On the other hand, the neddylation inhibitor 
MLN4924 neither reduces the amounts of HBx protein nor disturbs HBx-DDB1 association. 
Instead, MLN4924 probably deactivates the function of this complex by blocking neddylation 
of downstream Cullin 4A. Consequently, newly synthesized SMC5/6 proteins can not be 
degraded and in turn, the presence traps cccDNA in “transcriptional silence”. 
 
Figure 3.35. HBx-mediated transcription from cccDNA and its inhibition by MLN4924. 
Left panel: In HBV infection that expresses HBx protein, it binds DDB1 and bridges host Cullin 
4A (CUL4) ligase complex with SMC5/6 proteins and thereby mediates SMC5/6 ubiquitination 
and degradation. As a result, cccDNA shifts to a “transcriptional active” status to support robust 
HBV replication. Adapted from (Decorsiere et al., 2016). 
Right panel: Neither HBx amount nor HBx-DDB1 interaction is affected by MLN4924. 
MLN4924 blocks CUL4 neddylation and full activation and thereby SMC5/6 degradation is 
prevented to some extent. In the presence of MLN4924, infected cells synthesize new batch 
of SMC5/6, which traps cccDNA in “transcriptional silence”. 
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4. DISCUSSION 
4.1. New insights of cccDNA in HBV biology 
Formation and transcription of cccDNA are two of the most mysterious topics in HBV biology. 
However, due to the scarcity of susceptible models, knowledge of cccDNA was largely adapted 
from studies of other hepadnaviruses, like DHBV and WHV. DHBV cccDNA persists within 
hepatocytes with its half-life comparable to that of the host cell, where numbers of 50 or higher 
cccDNA molecules are present, especially when L envelope protein is depleted (Summers et 
al., 1990, Wu et al., 1990, Kajino et al., 1994, Zhu et al., 2001). In contrast, the copy number 
of HBV cccDNA in human hepatocytes seems much lower, although excessive numbers of 
replicative intermediates are present, which could replenish and amplify the cccDNA pool 
(Nassal, 2015). Indeed, although in the DHBV system cccDNA is rapidly formed and the pool 
can be efficiently amplified upon nuclear re-import of newly formed rcDNA-containing 
nucleocapsids (Wu et al., 1990), there is no strong evidence whether and to what extent 
intracellular amplification of cccDNA in HBV-infected human hepatocytes occurs, especially 
in in vitro infection. 
So far, efficient in vitro infection in all susceptible cell lines requires inoculation with a 
high amount of virions for certain hours (> 4 h) in the additional presence of PEG, as shown in 
Figure 3.1 and 3.3. (e.g. 10% infected cells at an mge of 300). Unlike that many viruses require 
lower moi of 0.1~1, this unusual infection feature in HBV virology is possibly due to a slow 
transition of naive virions to a mature hNTCP-binding competent state that is required for 
infection, after sufficient cellular association with HSPG. This profound association of virions 
and subviral particles occurs even in non-susceptible cells (Qu et al., 2018). Furthermore, virus 
stocks from cell culture supernatants contain rcDNA-containing naked nucleocapsids if not 
properly purified by heparin affinity chromatography (Seitz et al., 2016). These naked capsids 
also show a strong tendency to attach to different types of cells in the absence of NTCP. 
Therefore, on early days after virus inoculation when cccDNA is being formed, the 
rcDNA/cccDNA rate is extremely high compared to the in vitro samples harvested at later time 
points p.i. or the in vivo samples of patients or humanized mouse livers. The problem of accurate 
cccDNA quantification has been solved in this thesis using T5 exonuclease that removes 
cellular DNA and all HBV intermediates via its exonuclease activity targeting free ends of 
rcDNA and dslDNA but leaves cccDNA intact (Qu et al., 2018). Applying the method to this 
study, comprehensive cccDNA kinetics in all models was determined and these findings 
answered some scientific questions related to cccDNA biology: 
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First, it compares the kinetics of cccDNA accumulation in different infection models, 
including PHH, HepaRG, HepaRGhNTCP and HepG2hNTCP cells. The results demonstrated that 
copy numbers are relatively low in all models (<6 per infected cell)(Figure 3.4.~3.7.)(Qu et al., 
2018). The numbers are consistent with previous studies depicted in PHH and HepaRG cells 
(Miller and Robinson, 1984, Laras et al., 2006) but contrast earlier studies in the liver of DHBV 
infected ducks and primary duck hepatocytes, or WHV infected woodchuck hepatocytes with 
the numbers in the range of 10~100 (Mason et al., 1982, Zhang et al., 2003). Of note, Zhang et 
al found that using single-cell analysis 90% of the nuclei in chronically DHBV infected duck 
had 1~17 cccDNA numbers and the rest of nuclei contained significantly more cccDNA (Zhang 
et al., 2003). In this thesis, it is clear that absolute cccDNA numbers in HBV infection were far 
less than average cccDNA numbers in DHBV infection as previously reported. This difference 
can be partially explained by a direct comparison of DHBV and HBV in transfected HepG2 
cells showing that DHBV rcDNA to cccDNA conversion was more efficient than HBV (Kock 
et al., 2010). This unique characteristic enables higher cccDNA numbers in DHBV replication. 
Unlike DHBV, cccDNA copy number was approximate 1.5 per cell in chronic hepatitis B 
patients. Remarkably, the cccDNA level in HBeAg-negative patients was even 10-fold lower 
than that in HBeAg-positive ones. This cccDNA level was comparable with that in in vitro 
infected HepaRG and HepG2hNTCP cells and slightly lower than the average level in PHH. 
However, so far due to detection sensitivity, HBV cccDNA copy number at the single-cell level 
is largely unknown. Recently, one report suggested that nuclear DNA level determined by 
fluorescent in situ hybridization assay in HepAD38 cells meets the Normal distribution (Li et 
al., 2018b). However, the method can not show cccDNA in a specific way in a nuclear pool 
containing protein-free rcDNA. In the future, the exact cccDNA number and its heterogeneity 
at the single-cell level need to be further investigated. 
Second, cccDNA copy numbers can not be further increased by raising the mge when all 
cells are infected (Figure 3.2.)(Qu et al., 2018). This data indicates that there is an intracellular 
restriction for the unstoppable conversion of rcDNA to cccDNA. It is consistent with our earlier 
observation that depicted a saturation of HBV antigen level at mge/cell above 8000, when 100% 
of PHH were almost infected at this mge (Schulze et al., 2012). In this study, raising mge from 
30 to 1000 associates with a linear incline of accumulated cccDNA level. At mge >1000, 
however, no further proportional increase of cccDNA and total DNA levels was observed 
(Figure 3.2.). The harsh control of cccDNA generation at high mge’s limits HBV cccDNA 
numbers lower than the DHBV cccDNA numbers. This unique feature might be explained by 
two theories. Firstly, some host factor(s) involved in the processes of cccDNA formation 
(nuclear import of capsids, removal of the covalently-bound polymerase, etc.) can be used at 
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lower mge’s but completely occupied at mge >1000, which therefore limits rcDNA to cccDNA 
conversion. These factor(s) may be HBV specific, since DHBV rcDNA converts much more 
efficiently to cccDNA than HBV in the same HepG2 cells in cross-species transfection 
experiments (Kock et al., 2010). Secondly, established cccDNA episomes may induce nuclear 
innate immune responses to shut-off the host machinery for excessive cccDNA formation. At 
lower mge’s, low numbers of cccDNA evade the defense pathway. Once accumulated cccDNA 
copies in the nucleus exceed the threshold of sensing (e.g. > 6 copies per infected cell), the host 
cell elicits feedback, in turn, locking the nucleus and avoids further cccDNA formation. 
Third, the effects of representative inhibitors on cccDNA formation and maintenance were 
analyzed. Once established, numbers of cccDNA do not further amplify during late days of 
infection, which is in line with the kinetics of cccDNA formation leading to the saturation of 
copy numbers (Figure 3.4.~3.7.)(Qu et al., 2018). Staying stable, cccDNA is difficult to be 
eliminated. In patients resolved in acute HBV infection, cccDNA is even not completely cleared 
for decades although adaptive immunity has been activated (Rehermann et al., 1996). For 
approved antivirals, Lamivudine and Tenofovir barely affected cccDNA levels, while IFN-a at 
high dose induced cccDNA reduction with low efficacy, suggesting that first-line therapies are 
poorly effective in the elimination of cccDNA pool (Figure 3.9.). The best entry inhibitor, MyrB 
(available on market in 2019~2020), has shown drastically inhibitory effect on de novo 
establishment of cccDNA when it was pre- and co-administered. In the liver, MyrB protects 
uninfected hepatocytes from being secondarily infected by the viruses released from infected 
cells (Volz et al., 2013). Post treatment of capsid modulator GLS4 at high dose also led to 
cccDNA decline, but co-treatment of GLS4 was more efficient probably due to direct action on 
nucleocapsids before rcDNA to cccDNA conversion (Figure 3.10.). This finding is in 
agreement with that other capsid assembly modulators upon co-treatment also have interference 
with capsids and effect on cccDNA (Berke et al., 2017, Lahlali et al., 2018). 
 
4.2. Transcriptional promotion is the major function of HBx 
Using the plasmid transfection system, researchers have revealed that HBx presumably interacts 
with a great number of host factors and is required for maximal HBV replication. However, the 
exact role of HBx in authentic HBV infection is obscure. All the attempts were restricted for 
over twenty years for two major reasons: (I) absence of convenient in vitro infection systems 
(Table 1.3.); (II) scarcity of HBx detection in infected cells due to the low expression level of 
HBx protein and lack of a specific antibody with sufficient detection sensitivity. In addition, 
the biology of HBx protein is partially related to cccDNA, which was also not reliably detected. 
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The first issue has been overcome in the era of the discovery of HBV receptor, human 
NTCP (Yan et al., 2012) and subsequent generation of a series of stable hepatoma cells with 
human NTCP reconstitution that allows HBV entry, cccDNA formation, and replication (Ni et 
al., 2014). Later on, reliable cccDNA detection in these cell lines was established, including 
handy qPCR assay (Figure 3.2.~3.10.). With these tools, the potential functions of HBx on 
cccDNA can be investigated. However, the second problem has not been solved. In all models, 
most of the HBV replication markers were well detected, except HBx and polymerase. 
Overexpression of tagged HBx protein was widely used in hundreds of studies, although fusing 
tags with HBx may alter its conformation (Slagle et al., 2015). In our previous studies, 
seventeen home-made anti-sera and commercial HBx antibodies were screened by 
immunofluorescence and western blot analysis using hepatoma cells with HBx overexpression. 
It was disappointed that only three out of the seventeen anti-sera/antibodies showed enough 
detection specificity. Even worse, none of them detected HBx in authentic in vitro infection 
(Sonnabend J, thesis, 2013). Detection failure may be caused by its low expression abundancy 
or short half-life (approximate 3 h) (Beran et al., the International Liver Congress, 2018). 
As shown in Figure 3.11., the expression level of HBx correlated with its subcellular 
localization. It was believed that HBx was a cytoplasmic mediator involved in many pathways 
and a nuclear transcriptional activator (Doria et al., 1995). When HBx was overexpressed by a 
CMV promoter, HBx showed rarely nuclear but exclusively cytoplasmic localization (Figure 
3.11.A). In contrast, when HBx was overexpressed by mammalian EF1a promoter or expressed 
by its own X promoter from the overlength HBV genome, HBx almost became a nuclear protein 
(Figure 3.11.B and C). The alteration of HBx distribution, which is likely of determination by 
its expression amount, is consistent with an early study showing that HBx was predominantly 
localized in the nuclei in weakly expressing cells (Henkler et al., 2001). Of note, HBx protein -
in physiological occasion- is expressed by the X promoter using either cccDNA or directly 
translated from a low amount of virion HBx transcripts (Niu et al., 2017). Therefore, it is 
concluded that HBx has an exclusive or at least predominant nuclear localization in authentic 
infection. The possibility can not be excluded that HBx protein shuttles between nucleus and 
cytoplasm since HBx has both nuclear localization signal and nuclear export signal (Cha et al., 
2009). Nevertheless, nuclear localization of HBx suggests that the biggest function of HBx, 
from HBV side of view, takes place in the nucleus and thereby narrows to formation or 
transcription of cccDNA. 
HBx protein is essential to maintain HBV replication but not for the generation of cccDNA 
in infected HepaRG cells (Lucifora et al., 2011). This finding was confirmed in HepaRGhNTCP 
and the new model HepG2hNTCP cells in which Xd virus showed reduced transcriptional activity 
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than WT virion starting from d 3 p.i.. In addition, persistent HBx expression maintained HBV 
transcription over weeks after infection (Figure 3.12~3.13.). The transcriptional enhancement 
can be explained by two DDB1-mediated mechanisms (Hodgson et al., 2012): HBx-DDB1-
cccDNA binding model that requires transcriptional factors recruited directly by HBx binding 
to the cccDNA via DDB1. This has been partially supported by an HBx chromatic IP validation 
in HBV transfected cells (Belloni et al., 2009), and HBx-DDB1 displacement model that 
requires HBx association with SMC5/6 and DDB1 recruitment of host ubiquitin machinery to 
induce degradation of these restriction factors (Decorsiere et al., 2016). 
Essential domains located on HBx are essential for this function. Since HBV genome is 
too compact to be edited and HBx is undetectable in in vitro infection, a lentiviral-based trans-
complementation assay to restore the transcription of Xd virus to the level of WT infection was 
applied. This system is feasible and flexible to introduce HBx truncations and single point 
mutations. Using this method, it was proved that the whole C-terminal HBx is sufficient and 
functional (Figure 3.14.). Compared to the full-length HBx(1-154), the N-terminal HBx(1-50) 
did not rescue transcription of Xd virus, meaning that the N-terminal has no transcriptional 
enhancing activity or it is poorly expressed due to its smaller size (6 kD). C-terminal HBx(51-
154) alone was completely functional as HBx(WT) so that the HBx(1-50) could be dispensible, 
which was consistent with two previous reports (Murakami et al., 1994, Misra et al., 2004). 
Furthermore, deletion of the residues 51-142 led to a complete loss of function, suggesting that 
this region at least is essential. Two shorter truncations HBx (51-142) and (58-142) were only 
partially functional, indicating that not only 51-142 but 143-154 residues played a role in 
transactivation. Overall, the data revealed that transcriptional activation of HBx is not relying 
on one short and continuous motif but dependent on the whole C-terminus, or at least three 
fragments 51-57, 58-142, and 143-154 at the same time. These findings fit an early study when 
separate domains of HBx (around residue 68 and residues 110-139) are both necessary for its 
function that was determined by co-transfecting HepG2 cells with an HBx-minus genome 
plasmid and the other plasmid expressing mutated HBx (Runkel et al., 1993). It is also 
consistent with another finding that residues 58-140 retain transactivation function but with less 
activity (Kumar et al., 1996). 
In the past twenty years, researchers focused on identifying HBx-interacting proteins. The 
trend was initiated when HBx was found to interfere with cellular DNA repair machinery by 
binding DDB1, which is one of the authentic binding proteins again characterized in this thesis 
(Becker et al., 1998). Of note, DDB1 is the major but not sole determinant with HBx interaction 
and the binding is responsible for transactivation properties of HBx protein (Wentz et al., 2000). 
Nevertheless, later one structural study ensured the authentic association of recombinant DDB1 
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protein and a promiscuous a-helical HBx peptide and showed that HBx residue 88-101 is the 
key motif responsible for DDB1 binding (Li et al., 2010c). The results in this thesis showed 
that the HBx(R96E) mutant completely lost its transactivation activity, meaning DDB1 
dependency in the transactivation. Interestingly, the HBx(R96A) mutant was still functional 
(Figure 3.15.). One of the explanations is that R96E mutation results in a major charge turnover 
and conformational change of HBx protein that is fierce enough to break up the HBx-DDB1 
interaction, whereas R96A mutation alters the protein to a weaker extent -in this case- allowing 
the partial association of HBx and DDB1. As a promising binding partner, DDB1 is absolutely 
involved in the process of HBx-mediated transactivation. Since DDB1 has two major functions 
including DNA repair via formation of DDB1-DDB2 complex (Nag et al., 2001, Leupin et al., 
2005) and recruitment of host ubiquitin-proteasome system (Minor and Slagle, 2014). 
Regarding that no evidence has shown that DNA repair is required in cccDNA maintenance 
and HBx is not required in cccDNA formation (Figure 3.12.), it is concluded that HBx-DDB1 
complex hijacks ubiquitin-proteasome machinery and unlocks SMC5/6 restriction on the 
transcription of cccDNA. Overall, transcriptional promotion is the major function of HBx after 
HBV infection. 
 
4.3. Co-evolutionary strategies of HBx, cccDNA and its transcriptional capacity 
Except one report insisted that a regulatory protein, allegedly termed DHBx, exists and is 
expressed by a hidden reading frame in DHBV genomes (Chang et al., 2001), most researchers 
have believed that DHBV lacks a homologue of the X protein. On the other hand, cccDNA 
copy number per infected cell in HBV infection is far less than the DHBV cccDNA number. If 
the major function of HBx acts only on transactivation of cccDNA, from DHBV to HBV, a 
hypothesis comes out that specific evolutionary emergence of HBx in WHV and HBV infection 
largely enhances the transcriptional capacity of cccDNA. Compared to DHBV, HBV has more 
transcriptional active cccDNA and therefore the cccDNA numbers evolve to fewer copies to 
hide in the nucleus and better fits the host. 
The SMC5/6 complex serves as a host restriction factor and HBx-induced degradation of 
SMC5/6 enhances HBV transcription (Decorsiere et al., 2016, Murphy et al., 2016). In HBV 
infection, the internal connection of HBx protein and cccDNA is exclusively dependent on the 
SMC5/6 complex. During HBV human adaptation, it is likely that the driven force of HBx 
emergence was to degrade SMC5/6 complex, enhance cccDNA transcription. At the very 
beginning of HBV replication in human hepatocytes, the first virion evolved HBx protein and 
showed significantly enhanced replication efficiency. Over time, the virus encoding HBx 
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protein became evolutionarily dominant. Later on, the virus lowered cccDNA copy number. 
This hypothesis was supported by a recent study showing that highly divergent GSHBx, WHx, 
bat X and HBx were able to degrade mammalian SMC6 protein. Importantly, the HBx-induced 
degradation among all X proteins was the most efficient. Vice versa, SMC6 protein is the least 
conserved component of the SMC5/6 complex (Abdul et al., 2018). This virus-host “arms race” 
suggests that HBx has evolved in several species and eventually becomes completely functional 
in transactivation. In addition, whether avian (duck, chicken, etc.) SMC5/6 complex prevents 
DHBV cccDNA transcription, becomes a very interesting topic. If duck complex has no or low 
restrictive activity on the transcription of DHBV cccDNA, correspondingly, the “DHBx” is not 
required. 
Colocalization of SMC6 protein and PML nuclear bodies may hint the specific residence 
of cccDNA and explain why cccDNA maintains at low copy numbers. Two recent publications 
and our data of SMC6 staining pattern showed that SMC6 was mostly colocalized in the nuclear 
bodies (Figure 3.32~3.33) (Niu et al., 2017, Livingston et al., 2017). Niu et al showed that 
knockdown of SMC6 fully restored transcription of Xd virus to the level of WT virus, implying 
that a majority of active cccDNA transcription (> 95%) is restricted by SMC6 or depends on 
HBx-mediated counteraction of this restriction. Therefore, SMC6 protein has to capture the few 
copy cccDNA and silence its transcription inside or close to the nuclear bodies where SMC6 is 
located. It is further expected that formation and /or transcription of cccDNA prefer to occur in 
the nuclear bodies for genomic loci. The interplay among HBx, cccDNA and SMC6 in PML 
nuclear bodies will be investigated in future studies. Table 4.1. summarizes properties of HBx, 
SMC6 and cccDNA. 
Table 4.1. Properties of X proteins, SMC6 and cccDNA among viruses.  
Virus cccDNA copy 
per infected cell 
X protein SMC6 
restriction 
X-induced 
SMC6 degradation 
HBV + (1~6) HBx Yes Yes 
WHV ND WHx ND Yes 
DHBV ++ (50~100) NA ND No 
NA: not available; ND: not determined; +: low copy; ++: high copy. 
 
4.4. MLN4924 is a new-class antiviral with dual targets 
MLN4924 is a new-class antiviral. As shown in Figure 1.10., most steps in the HBV life cycle 
have been considered as drug targets except HBx. In drug discovery, viral proteins with 
enzymatic activity or known crystal structure are prone to be developed as targets of small 
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molecules. For instance, HCV that encodes a batch of viral enzymes (NS3, NS5A and NS5B) 
served as candidates of direct-acting antivirals (Sofosbuvir, etc.) (Gotte and Feld, 2016). HBV 
encodes only one polymerase with RTase and RNase H activities. However, NUCs have a major 
limitation since they selectively block one of the branches in HBV replication, reverse 
transcription of pgRNA. Upon NUC treatment, HBeAg translated by precore mRNA derived 
from cccDNA and HBsAg translated by preS/S integrates are actively expressed (Wooddell et 
al., 2017), although prolonged treatment (median 126 months) may lead to cccDNA decline 
(Lai et al., 2017). In this thesis, MLN4924 was identified as a transcriptional inhibitor that 
decreases transcription (pgRNA, preS/S RNA and X RNA) from all four HBV promoters 
(Figure 3.23.), which further leads to a reduction on HBsAg and HBeAg. Transcription 
inhibition of cccDNA is the most promising target of MLN4924. 
MLN4924 not only acts as a new antiviral but becomes a tool in modulating HBx-mediated 
transcription in in vitro experiments. Six-day removal of MLN4924 led to HBV rebound in 
long-term infected HepG2hNTCP cells but not in HepaRGhNTCP cells (Figure 3.21.~3.22.). Since 
it was also reported that MLN4924-mediated inhibition of Cullin 4A neddylation and Vpx-
induced degradation of SAMHD1 in HIV infection is reversible (Hofmann et al., 2013), it is 
consistent that MLN4924 acts as a reversible transcriptional inhibitor in HepG2hNTCP cells and 
serves as a modulator at the transcriptional level upon pulse treatment, which provides a simple 
way to switch on and off transcription and will facilitate future studies on transcription of 
cccDNA. However, what causes the discrepancy between HepG2hNTCP and HepaRGhNTCP cells 
is still unclear. One possible explanation is due to the different metabolic kinetics in these cells. 
As shown in Table 4.2., differentiated HepaRGhNTCP cells have the lowest EC50 values and the 
most sensitive upon MLN4924 treatment. Regarding their non-proliferating status, 
HepaRGhNTCP cells may not completely decay MLN4924 after six-day removal (Gripon et al., 
2002). Remaining intracellular MLN4924 inhibits the rebound of HBV replication. In contrast, 
HepG2hNTCP cells with proliferation may be able to dilute out MLN4924 to a concentration that 
is much lower than its respective EC50 values and in this occasion, HBV replication is 
reactivated after six days. 
Table 4.2. Summary of MLN4924 EC50 and CC50 values in three models. 
EC50/CC50 (nM) PHH HepaRGhNTCP HepG2hNTCP 
EC50 of HBsAg 293.4 [102~860]* 26.9 [9~66] 175.1 [40~910] 
EC50 of HBeAg 143.7 [68~298] 15.0 [5~33] 30.2 [0~235] 
EC50 of transcription 292.4 [18~11596] 30.2 [5~113] 484.7 [>80] 
CC50 857.0 [245~3607] 2442 [1025~6545] >50000 
*Best-fit values [95% Cl (profile likelihood) calculated based on independent experiments]; 
EC50: half maximum of effective dose; CC50: half maximum of cytotoxicity 
Discussion 
 
 
114 
MLN4924’s second target is blockage of HBsAg translation and secretion. In chronic 
infection, integrated HBV DNA is another source of HBsAg production (Wooddell et al., 2017, 
Tu et al., 2017). My work also revealed the inhibition of HBsAg secretion upon MLN4924 
treatment in PLC/PRF5 cells with natural HBs integration. The mechanism for the inhibition of 
HBsAg secretion is probably distinct from that for the inhibition of transcription. Targeting 
neddylation inhibits transcription from cccDNA in de novo infection but not from integrated 
DNA in the PLC/PRF5 cells (Figure 3.24.). This phenotype is consistent with the fact that HBx 
protein enhances gene transcription selectively from extrachromosomal DNA templates but 
shows no effect lentiviral mediated insertion DNA in the host genome (van Breugel et al., 2012). 
Indeed, MLN4924 treatment seems no inhibitory effect on the transcription from natural 
integrates. Remarkably, MLN4924 treatment induced a 3-fold reduction on HBsAg secretion, 
although HBs transcription was not affected (Figure 3.25.). Given that the first mode of 
MLN4924 action is selective transcriptional inhibition from cccDNA, in addition to that 
MLN4924 reduces HBsAg expression or interferes with HBsAg stability at the translational 
level. It is totally unknown whether HBsAg can be a direct neddylation target, but HBx protein 
itself may require HDM2-mediated neddylation to maintain its function and stability. Mass 
spectrometry analysis in HEK293T cells transfected with HBx identified that lysine 91 and 95 
are two major neddylation sites (Liu et al., 2017). In conclusion, MLN4924 has dual targets: (1) 
prevention of HBx-mediated degradation of SMC5/6 complex components, as a result, 
inhibition of transcription from cccDNA; (2) reduction of HBsAg at the translational or post-
translational level. So far, point (1) was proved in this thesis and (2) requires further 
experiments. 
As shown in Figure 3.27~3.31., it is confirmed that the mode of MLN4924 action at the 
transcriptional level is dependent on HBx-DDB1 complex, using stable cell lines and lentiviral 
transcomplementation assay. These findings not only support the authentic availability of HBx-
DDB1-Cullin 4A interaction in HBV replication but suggest this complex as a novel drug target. 
MLN4924 is not a direct-acting antiviral yet since it mainly targets the NAE1-mediated 
neddylation that is downstream of HBx-DDB1 complex but not HBx-DDB1 interaction, 
although HBx neddylation might be a direct target. Targeting HBx or HBx-DDB1 complex 
must be much more specific and lead to better efficiency and less toxicity on host cells. A major 
bottleneck is the lack of structures of HBx protein or HBx-DDB1 complex. At this stage, an 
alternative is an efficient and rapid system for assaying HBx-mediated transactivation (Zhou et 
al., 2017), which is the only available model to initiate drug screening and investigate small 
molecules interfering with HBx-DDB1 complex. 
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All the attempts in this thesis shed light on the topic that targeting the HBx-DDB1-Cullin 
complex inhibits transcription from HBV cccDNA in susceptible hepatoma cells and the 
complex is absolutely druggable (Qu et al., the International Liver Congress 2019). To achieve 
this aim, either depleting HBx as shown in Figure 3.13., knocking down DDB1 (data not shown), 
interfering with HBx-DDB1 association, or blocking Cullin 4 neddylation result in remarkable 
inhibition at the transcriptional level. Figures 3.32~3.34 showed that HBV replication almost 
diminished SMC6 signals in infected PHH and HepaRGhNTCP cells and MLN4924 treatment 
restored the expression of SMC6 probably by switching off HBx function. The SMC6 mediated 
transcriptional silence of cccDNA seems HBV specific and not universal to foreign episomal 
genomes of other DNA viruses, since a recent study has shown that SMC6 protein is not 
required at all for the E2-mediated transcriptional activation or E1/E2-mediated transient 
replication in human papillomavirus infection, despite its binding activity to viral E2 protein 
(Bentley et al., 2018). Perhaps, SMC6 binds cccDNA and this binding recruits other 
transcriptional repressors to control the epigenetic status of cccDNA, which would be further 
characterized (Belloni et al., 2009). 
Figure 4.1. Proposed working model of MLN4924. In HBV replication, HBx protein is 
expressed and located in the nucleus. HBx binds DDB1 and recruits Cullin 4A E3 ubiquitin 
ligase, in order to counteract host restrictions on cccDNA and then transactivates cccDNA 
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transcription. HBx-mediated cccDNA transcription is the major target of a neddylation inhibitor, 
MLN4924, which inhibits Cullin 4A activation and probable neddylation of HBx protein. 
Consequently, MLN4924 mediates transcriptional inhibition in an HBx-dependent manner. In 
addition, MLN4924 reduces HBsAg production directly at the translational or post-translational 
level. 
 
4.5. Comparison of MLN4924 and other transcriptional inhibitors 
Given that MLN4924 is not the only HBV transcriptional inhibitors, other prodrugs are under 
development and investigation. For instance, 640 FDA-approved drugs were screened for the 
ability to inhibit HBV transcription from a reporter plasmid cotransfected with HBx in 
HEK293T cells. Some compounds inhibited HBV transcription in the presence of HBx. These 
drugs (Terbinafine etc.) also interfered with HBx-mediated transcription in HepG2.2.15 and 
transfected HepG2 cells (van de Klundert et al., 2016b). However, using the models that do not 
form authentic cccDNA, whether the validated drugs target HBx-mediated cccDNA 
transcription is unclear. Overexpressed HBx may have artificial effects.  
Using HepG2hNTCP infection model, several HBV transcriptional inhibitors were also 
identified. 1827 FDA-approved drugs were validated by a recombinant HBV-based NanoLuc 
assay and KX2-391, an inhibitor of Src kinase and tubulin polymerization, was identified as a 
leading candidate. KX2-391 suppressed HBV replication in PHH and HepG2hNTCP cells in a 
dose-dependent manner and inhibited HBV transcription from precore promoter in an HBx-
independent manner but not other promoters (Harada et al., 2017). Distinct from MLN4924 that 
inhibits transcription from all four HBV promoters (Figure 3.23.), KX2-391 relies on a specific 
host factor, hepatocyte nuclear factor 4a (HNF4a), selective on precore promoter as proposed 
in the paper. This suggests that transcriptional factors and co-factors may act on a specific 
promoter and could be targets of transcriptional inhibitors. As an example, retinoid X receptor 
alpha (RXRa) modulates transcriptional network and controls hepatic lipid metabolism. The 
RXR-specific agonist bexarotene inhibits HBV transcription in HepaRG cells, HepG2hNTCP 
cells and primary tupaia hepatocytes (Song et al., 2018). Later on, retinoic acid receptor (RAR) 
agonists were also identified as transcriptional inhibitors. To be specific, among the agonists 
Tazarotene repressed cccDNA transcription in PHH and HepaRG cells and showed the most 
potent inhibitory effect on HBsAg secretion in PHH (EC50: ~30nM). RNA sequencing analysis 
confirmed that Tazarotene altered the expression level of genes in RAR and metabolic pathways 
and inhibited HBV in part through RARb but not RARa (Li et al., 2018a). In our group, we 
also have screened 1181 FDA-approved drugs and identified RARa-specific agonist Am80 
(tamibarotene) potent in inhibition of transcription from cccDNA. HBV genotypes B, D and E 
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were equally inhibited, showing a general role of RARa in HBV replication (Nkongolo et al., 
2019). None of the studies above evaluated HBx dependency of the drugs in infection settings. 
Although nuclear HBx targets the SMC5/6 complex, it could not be excluded that HBx also 
binds and modulates transcriptional cofactors like HNF4a, RARa/b and RXR onto the cccDNA 
and transactivates its transcription. 
Beside small molecules that can repress transcription from cccDNA, RNAi-based 
therapeutics have the potential to clear existing HBV transcripts (Wooddell et al., 2013). One 
of the siRNA regimens under development, ARC-520, has shown a dramatical reduction on 
HBsAg in treatment-näive HBeAg positive patients but much less reduction in HBeAg negative 
or NUC-treated patients (Wooddell et al., 2017). Many integrants in infected chimpanzees 
lacked targeting sites of ARC-520 and produced mRNA that was difficult to be targeted. 
MLN4924 also showed profound inhibition of transcription from cccDNA but not integrants, 
because of the HBx selectivity only on cccDNA templates (Figure 3.24.) (van Breugel et al., 
2012). The selectivity of both ARC-520 and MLN4924 on cccDNA limits their future 
applications. Different from ARC-520, MLN4924 showed an additional effect on HBsAg 
stability or assembly (Figure 3.25.). However, this effect is too weak to efficiently block a great 
amount of HBsAg produced from integrants. 
Nevertheless, MLN4924 is the first available antiviral targeting the HBx-DDB1-Cullin 4A 
complex, although at this stage it is not conclusive whether MLN4924 is also a direct-acting 
antiviral if MLN4924 inhibits neddylation of HBx protein and stability of HBsAg. At present, 
this finding ensures the HBx-DDB1 complex as a prerequisite in cccDNA transcription and a 
promising antiviral target. After two years of my finding (Qu et al., 2016 International HBV 
Meeting), one group identified MLN4924 (Pevonedistat) as a potent HBV inhibitor (Sekiba et 
al., 2019a). Very recently, the authors also proposed Nitazoxanide (NTZ), a thiazolidine anti-
infective agent, as an inhibitor of transcription from cccDNA by targeting the HBx-DDB1 
interaction (Sekiba et al., 2019b). However, the drugs in both studies showed less pronounced 
inhibitory effects on transcription (2~3 fold) compare to my study. More importantly, they lack 
key evidence showing HBx dependency in authentic infection (e.g. using Xd virus). 
Additionally, the same effects of MLN4924 and Nitazoxanide in two studies are contradictory 
to the scientific concept that the effect of Nitazoxanide targeting HBx-DDB1 association should 
be more specific and effective than that of MLN4924 targeting downstream Cullin 4A adaptor. 
Therefore, one direction in drug discovery is to seek for or re-design small molecules with better 
efficacy that directly deactivate HBx protein or disturb HBx-DDB1 binding. For this view, 
either HBx crystal structure (if it exists) or HBx-DDB1 complex structure will be helpful. The 
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second way is to further unravel the HBx protein and its new and authentic functions. For 
instance, what is the exact function of the N-terminal HBx (1~50 amino acids)? Consistent with 
my study as shown in Figure 3.14. and 3.15. (Qu et al., 2017 International HBV Meeting), 
functional analysis revealed that highly conserved residues, the CCCH motif (C61, C69, C137, 
and H139), are required for HBx function and HBx exhibits stoichiometric zinc binding in the 
presence of DDB1 (Fletcher et al., 2017 International HBV Meeting). HBx as a zinc-finger 
protein that is highly active in general transcriptional processes, are definitely worthy to be 
further studied and new functions are expected to be translated into novel antiviral targets. 
 
4.6. Final summary 
240 million people worldwide are chronically infected with HBV. Thus, the urgent need for 
curative therapies is unquestionable. To achieve a sterilizing or functional cure, eliminating 
cccDNA or silencing its transcription becomes the ultimate goal. In this thesis, a quantitative 
and comprehensive analysis of the dynamics and stability of cccDNA in in vitro infected 
hepatocytes allows more understandings of cccDNA biology. Accurate quantification of 
cccDNA is meaningful to judge clinical endpoint under conventional therapies (pegylated IFNa, 
NUCs) in patients when cccDNA level is reduced and also helpful for evaluation of the 
outcomes of novel regimens (e.g. phase III trials of Myrcludex B and capsid inhibitors). 
Additionally, cccDNA turnover determined based on current and ongoing experimental data in 
long-term infection can be translated and built up to mathematical models, which predict 
whether and how long elimination of cccDNA occurs and provide a message of the endpoint in 
future HBV therapy. 
HBx is a nuclear protein and makes use of its entire C-terminus to associate with DDB1. 
This complex recruits Cullin 4A unlocks the restriction of SMC5/6 complex on the cccDNA 
and maximize its transcription. This virus-host interaction enables and maintains cccDNA 
transcription and, as a consequence, guarantees extremely efficient transcription from a few 
copies of cccDNA template and lowers the copy number in the long-term evolution. Persistence 
of cccDNA transcription highly relies on HBx expression. Therefore, depletion of HBx or loss 
of its transactivation function traps cccDNA to a “latent” status, which is frequently occurred 
in other DNA viruses (HSV, HPV, etc.). As the sole viral protein acting on transcription from 
cccDNA, targeting HBx is much more specific, compared to epigenetic modulators (histone 
methylation, acetylation, etc.), which show no selectivity between cccDNA and genomic DNA. 
Targeting HBx-mediated transcription by a neddylation inhibitor, MLN4924, is not only 
a decent tool switching on and off transcription in basic research but a direction of new-class 
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antivirals. In this direction HBx, DDB1 and Cullin 4A can be targeted. Blockage of HBx-
mediated transcription from cccDNA may open novel translational therapeutic approaches 
allowing the functional cure of chronic hepatitis B. In future, these include: (1) evaluation of 
MLN4924 and other neddylation inhibitors towards in vivo models and (2) identification of 
other HBx inhibitors by targeting HBx zinc-binding activity and HBx-DDB1 interaction.
Publications 
 
 
120 
5. PUBLICATIONS AND PATENTS 
5.1. Peer-reviewed publications (2016~2019) 
1. A novel method to precisely quantify Hepatitis B Virus covalently closed circular (ccc)DNA 
formation, maintenance, and loss. 
Tu T, Zehnder B, Qu B, Main N, Allweiss L, Dandri M, Shackel N, Urban S. 
J Hepatol. Submitted. 
 
2. Stem cell-derived polarized hepatocytes. 
Dao Thi VL, Wu X, Belote R, Andreo U, Takacs C, Fernandez J, Vale-Silva L, Prallet S, Decker 
C, Fu RM, Qu B, Uryu K, Molina H, Saeed M, Steinmann E, Urban S, Singaraja R, Schneider 
W, Simon S, Rice C. 
Nat Commun. Minor revision. 
 
3. Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. 
Wang J, Qu B, Zhang F, Zhang C, Deng W, Dao Thi VL, Xia Y. 
Stem Cells Int. 2019 Jun 12: 9605252. DOI: 10.1155/2019/9605252. 
 
4. Quantification of Hepatitis B Virus Covalently Closed Circular DNA in Infected Cell Culture 
Models by Quantitative PCR. 
Qu B, Urban S. 
Bio-protocol. 2019 Apr; 9(7), e3202. DOI: 10.21769/BioProtoc.3202. 
 
5. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable 
Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.  
Qu B, Ni Y, Lempp FA, Vondran FWR, Urban S.  
J Virol. 2018 Nov 12; 92(23). DOI: 10.1128/JVI.01117-18. 
 
6. HBV Bypasses the Innate Immune Response and Does not Protect HCV From Antiviral 
Activity of Interferon.  
Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, 
Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, 
Baumert TF, Binder M, Urban S, Bartenschlager R. 
Gastroenterology. 2018 May; 154(6): 1791-1804.e22. DOI: 10.1053/j.gastro.2018.01.044. 
 
7. Critical Role of HAX-1 in Promoting Avian Influenza Virus Replication in Lung Epithelial 
Cells. 
Li X*, Qu B*, He G, Cardona CJ, Song Y, Xing Z. 
Publications 
 
 
121 
Mediators Inflamm. 2018 Jan; 2018: 3586132. DOI: 10.1155/2018/3586132. 
*: equally contributed 
 
8. Sodium Taurocholate Cotransporting Polypeptide Is the Limiting Host Factor of Hepatitis B 
Virus Infection in Macaque and Pig Hepatocytes.  
Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, 
Urban S.  
Hepatology. 2017 Sep; 66(3): 703-716. DOI: 10.1002/hep.29112. 
 
9. Restrictive Influence of SAMHD1 on Hepatitis B Virus Life Cycle.  
Sommer AF, Rivière L, Qu B, Schott K, Riess M, Ni Y, Shepard C, Schnellbächer E, 
Finkernagel M, Himmelsbach K, Welzel K, Kettern N, Donnerhak C, Münk C, Flory E, Liese 
J, Kim B, Urban S, König R. 
Sci Rep. 2016 May; 27; 6: 26616. DOI: 10.1038/srep26616. 
 
10. Hepatitis B Virus Infection of A Mouse Hepatic Cell Line Reconstituted with Human 
Sodium Taurocholate Cotransporting Polypeptide.  
Lempp FA, Qu B, Wang YX, Urban S. 
J Virol. 2016 Apr; 90(9): 4827-31. DOI: 10.1128/JVI.02832-15. 
 
5.2. Oral presentations at conferences (first authorship) (2016~2019) 
1. The NEDD8-activating enzyme inhibitor MLN4924 potently inhibits transcription from 
covalently closed circular DNA in a Hepatitis B Virus X protein-dependent manner.  
Qu B, Leuthold M, Mutz P, Nebioglu F, Bartenschlager R, Urban S. 
31st International Conference on Antiviral Research (ICAR). Session: Hepatitis and 
Retroviruses, number 201. Presented on June 13th 2018, Porto, Portugal. 
 
2. The NEDD8-activating enzyme (NAE) inhibitor MLN4924 potently interferes with HBV 
infection.  
Qu B, Leuthold M, Urban S.  
2016 International HBV Meeting. O-7.  Presented on September 21th 2016, Seoul, Korea. 
 
5.3. Poster presentations at conferences (2015~2019) 
1. Targeting the HBx-DDB1-Cullin complex inhibits transcription from HBV covalently closed 
circular DNA in susceptible hepatoma cells. 
Qu B, Leuthold MM, Sonnabend J, Urban S. 
The International Liver Congress 2019; 70(1), e712-e713. Presented on April 13th 2019, Vienna. 
Publications 
 
 
122 
DOI: 10.1016/S0618-8278(19)31427-6 
 
2. A comparative evaluation of antiviral inhibitors and HBc-deficient HBV on cccDNA 
formation and stability.  
Qu B, Zehnder B, Tu T, Ni Y, Urban S.  
2018 International HBV Meeting. Presented on October 5th 2018, Taormina. 
 
3. HBx:  Hepatitis B Virus Swiss Army Knife enabling successful infection.  
Milani E, Qu B, Urban S, Wollscheid B.  
17th Human Proteome Organization World Congress-HUPO 2018. Presented on October 1st 
2018, Orlando. 
 
4. Functional analysis identifies key fragments and residues to promote HBx transactivation. 
Qu B, Leuthold M, Sonnabend J, Urban S.  
2017 International HBV Meeting. P-46. Presented on September 4th 2017, Washington DC. 
 
5. Selective digestion of HBV rcDNA by T5 exonuclease allows reliable PCR-based 
quantification of cccDNA in in vitro infection systems.  
Qu B, Ni Y, Lempp FA, Urban S. 
2015 International HBV Meeting. P-35. Presented on October 6th 2015, Dolce Bad Nauheim. 
 
6. Myrcludex B and GLS4 interfere with the formation of HBV covalently closed circular DNA. 
Qu B, Zehnder B, Tu T, Ni Y, Urban S.  
28th Annual Meeting of the Society for Virology. P-295. Presented on March 15th 2018, 
Wuerzburg. 
 
7. The NEDD8-activating enzyme inhibitor MLN4924 potently inhibits HBV transcription in 
an HBx-dependent manner.  
Qu B, Leuthold M, Urban S. 
27th Annual Meeting of the Society for Virology. P-221. Presented on March 23th 2017, Marburg. 
 
8. DNA damage-binding protein 1 promotes transcription from covalently closed circular DNA 
in Hepatitis B Virus infection.  
Qu B, Sonnabend J, Hezel P, Urban S.  
26th Annual Meeting of the Society for Virology. P-328. Presented on April 8th 2016, Muenster. 
Publications 
 
 
123 
 
5.4. Patents 
1. Compounds and combinations thereof for preventing and/or treating HBV and/or HDV 
infections 
Inventors: Florian Lempp, Stephan Urban, Yi Ni, Lea Nussbaum, Bingqian Qu 
Patent number: WO2018054891A1 
Application number: PCT/EP2017/073608 
 
References 
 
 
124 
6. REFERENCES 
ABDUL, F., FILLETON, F., GEROSSIER, L., PATUREL, A., HALL, J., STRUBIN, M. & ETIENNE, L. 2018. 
Smc5/6 Antagonism by HBx Is an Evolutionarily Conserved Function of Hepatitis B Virus 
Infection in Mammals. J Virol, 92. 
 
ALLEN, M. I., DESLAURIERS, M., ANDREWS, C. W., TIPPLES, G. A., WALTERS, K. A., TYRRELL, D. 
L., BROWN, N. & CONDREAY, L. D. 1998. Identification and characterization of mutations in 
hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 
27, 1670-7. 
 
ALLWEISS, L., VOLZ, T., GIERSCH, K., KAH, J., RAFFA, G., PETERSEN, J., LOHSE, A. W., BENINATI, 
C., POLLICINO, T., URBAN, S., LUTGEHETMANN, M. & DANDRI, M. 2018. Proliferation of 
primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete 
nuclear cccDNA in vivo. Gut, 67, 542-552. 
 
ANGUS, P., VAUGHAN, R., XIONG, S., YANG, H., DELANEY, W., GIBBS, C., BROSGART, C., 
COLLEDGE, D., EDWARDS, R., AYRES, A., BARTHOLOMEUSZ, A. & LOCARNINI, S. 2003. 
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in 
the HBV polymerase. Gastroenterology, 125, 292-7. 
 
ASSELAH, T., BOYER, N., SAADOUN, D., MARTINOT-PEIGNOUX, M. & MARCELLIN, P. 2016. 
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-
free treatment and future perspectives. Liver Int, 36 Suppl 1, 47-57. 
 
BALDICK, C. J., EGGERS, B. J., FANG, J., LEVINE, S. M., POKORNOWSKI, K. A., ROSE, R. E., YU, C. 
F., TENNEY, D. J. & COLONNO, R. J. 2008a. Hepatitis B virus quasispecies susceptibility to 
entecavir confirms the relationship between genotypic resistance and patient virologic 
response. J Hepatol, 48, 895-902. 
 
BALDICK, C. J., TENNEY, D. J., MAZZUCCO, C. E., EGGERS, B. J., ROSE, R. E., POKORNOWSKI, K. 
A., YU, C. F. & COLONNO, R. J. 2008b. Comprehensive evaluation of hepatitis B virus reverse 
transcriptase substitutions associated with entecavir resistance. Hepatology, 47, 1473-82. 
 
BALSANO, C., BILLET, O., BENNOUN, M., CAVARD, C., ZIDER, A., GRIMBER, G., NATOLI, G., 
BRIAND, P. & LEVRERO, M. 1993. The hepatitis B virus X gene product transactivates the HIV-
LTR in vivo. Arch Virol Suppl, 8, 63-71. 
 
BARTENSCHLAGER, R., KUHN, C. & SCHALLER, H. 1992. Expression of the P-protein of the 
human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated 
P-gene product by radiolabelling at newly introduced phosphorylation sites. Nucleic Acids Res, 
20, 195-202. 
 
BARTENSCHLAGER, R. & SCHALLER, H. 1988. The amino-terminal domain of the hepadnaviral 
P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse 
transcription. Embo j, 7, 4185-92. 
 
BARTENSCHLAGER, R. & SCHALLER, H. 1992. Hepadnaviral assembly is initiated by polymerase 
binding to the encapsidation signal in the viral RNA genome. Embo j, 11, 3413-20. 
 
BAZINET, M., PANTEA, V., CEBOTARESCU, V., COJUHARI, L., JIMBEI, P., ALBRECHT, J., SCHMID, 
P., LE GAL, F., GORDIEN, E., KRAWCZYK, A., MIJOCEVIC, H., KARIMZADEH, H., ROGGENDORF, 
M. & VAILLANT, A. 2017. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for 
References 
 
 
125 
treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 
301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol 
Hepatol, 2, 877-889. 
 
BECKER, S. A., LEE, T. H., BUTEL, J. S. & SLAGLE, B. L. 1998. Hepatitis B virus X protein interferes 
with cellular DNA repair. J Virol, 72, 266-72. 
 
BELLONI, L., ALLWEISS, L., GUERRIERI, F., PEDICONI, N., VOLZ, T., POLLICINO, T., PETERSEN, J., 
RAIMONDO, G., DANDRI, M. & LEVRERO, M. 2012. IFN-alpha inhibits HBV transcription and 
replication in cell culture and in humanized mice by targeting the epigenetic regulation of the 
nuclear cccDNA minichromosome. J Clin Invest, 122, 529-37. 
 
BELLONI, L., POLLICINO, T., DE NICOLA, F., GUERRIERI, F., RAFFA, G., FANCIULLI, M., 
RAIMONDO, G. & LEVRERO, M. 2009. Nuclear HBx binds the HBV minichromosome and 
modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A, 106, 19975-9. 
 
BENTLEY, P., TAN, M. J. A., MCBRIDE, A. A., WHITE, E. A. & HOWLEY, P. M. 2018. The SMC5/6 
complex interacts with the papillomavirus E2 protein and influences maintenance of viral 
episomal DNA. J Virol. 
 
BERGAMETTI, F., SITTERLIN, D. & TRANSY, C. 2002. Turnover of hepatitis B virus X protein is 
regulated by damaged DNA-binding complex. J Virol, 76, 6495-501. 
 
BERKE, J. M., DEHERTOGH, P., VERGAUWEN, K., VAN DAMME, E., MOSTMANS, W., VANDYCK, 
K. & PAUWELS, F. 2017. Capsid Assembly Modulators Have a Dual Mechanism of Action in 
Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother, 
61. 
 
BLANK, A., MARKERT, C., HOHMANN, N., CARLS, A., MIKUS, G., LEHR, T., ALEXANDROV, A., 
HAAG, M., SCHWAB, M., URBAN, S. & HAEFELI, W. E. 2016. First-in-human application of the 
novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol, 65, 483-9. 
 
BLOOM, K., ELY, A., MUSSOLINO, C., CATHOMEN, T. & ARBUTHNOT, P. 2013. Inactivation of 
hepatitis B virus replication in cultured cells and in vivo with engineered transcription 
activator-like effector nucleases. Mol Ther, 21, 1889-97. 
 
BLUMBERG, B. S., ALTER, H. J. & VISNICH, S. 1965. A "NEW" ANTIGEN IN LEUKEMIA SERA. Jama, 
191, 541-6. 
 
BOCK, C. T., SCHRANZ, P., SCHRODER, C. H. & ZENTGRAF, H. 1994. Hepatitis B virus genome is 
organized into nucleosomes in the nucleus of the infected cell. Virus Genes, 8, 215-29. 
 
BOCK, C. T., SCHWINN, S., LOCARNINI, S., FYFE, J., MANNS, M. P., TRAUTWEIN, C. & ZENTGRAF, 
H. 2001. Structural organization of the hepatitis B virus minichromosome. J Mol Biol, 307, 183-
96. 
 
BOGOMOLOV, P., ALEXANDROV, A., VORONKOVA, N., MACIEVICH, M., KOKINA, K., 
PETRACHENKOVA, M., LEHR, T., LEMPP, F. A., WEDEMEYER, H., HAAG, M., SCHWAB, M., 
HAEFELI, W. E., BLANK, A. & URBAN, S. 2016. Treatment of chronic hepatitis D with the entry 
inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol, 65, 490-8. 
References 
 
 
126 
BONTRON, S., LIN-MARQ, N. & STRUBIN, M. 2002. Hepatitis B virus X protein associated with 
UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. J Biol 
Chem, 277, 38847-54. 
 
BOUCHARD, M. J. & SCHNEIDER, R. J. 2004. The enigmatic X gene of hepatitis B virus. J Virol, 
78, 12725-34. 
 
BOUCHARD, M. J., WANG, L. H. & SCHNEIDER, R. J. 2001. Calcium signaling by HBx protein in 
hepatitis B virus DNA replication. Science, 294, 2376-8. 
 
BOURNE, C. R., FINN, M. G. & ZLOTNICK, A. 2006. Global structural changes in hepatitis B virus 
capsids induced by the assembly effector HAP1. J Virol, 80, 11055-61. 
 
BREZILLON, N., BRUNELLE, M. N., MASSINET, H., GIANG, E., LAMANT, C., DASILVA, L., BERISSI, 
S., BELGHITI, J., HANNOUN, L., PUERSTINGER, G., WIMMER, E., NEYTS, J., HANTZ, O., SOUSSAN, 
P., MOROSAN, S. & KREMSDORF, D. 2011. Antiviral activity of Bay 41-4109 on hepatitis B virus 
in humanized Alb-uPA/SCID mice. PLoS One, 6, e25096. 
 
BRINGAS, R. 1997. Folding and assembly of hepatitis B virus core protein: a new model 
proposal. J Struct Biol, 118, 189-96. 
 
BROWNELL, J. E., SINTCHAK, M. D., GAVIN, J. M., LIAO, H., BRUZZESE, F. J., BUMP, N. J., SOUCY, 
T. A., MILHOLLEN, M. A., YANG, X., BURKHARDT, A. L., MA, J., LOKE, H. K., LINGARAJ, T., WU, 
D., HAMMAN, K. B., SPELMAN, J. J., CULLIS, C. A., LANGSTON, S. P., VYSKOCIL, S., SELLS, T. B., 
MALLENDER, W. D., VISIERS, I., LI, P., CLAIBORNE, C. F., ROLFE, M., BOLEN, J. B. & DICK, L. R. 
2010. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 
inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell, 37, 102-11. 
 
BRUNETTO, M. R., RODRIGUEZ, U. A. & BONINO, F. 1999. Hepatitis B virus mutants. 
Intervirology, 42, 69-80. 
 
BRUSS, V. & GERLICH, W. H. 1988. Formation of transmembraneous hepatitis B e-antigen by 
cotranslational in vitro processing of the viral precore protein. Virology, 163, 268-75. 
 
CAI, C. W., LOMONOSOVA, E., MORAN, E. A., CHENG, X., PATEL, K. B., BAILLY, F., COTELLE, P., 
MEYERS, M. J. & TAVIS, J. E. 2014. Hepatitis B virus replication is blocked by a 2-
hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. 
Antiviral Res, 108, 48-55. 
 
CAI, D., MILLS, C., YU, W., YAN, R., ALDRICH, C. E., SAPUTELLI, J. R., MASON, W. S., XU, X., GUO, 
J. T., BLOCK, T. M., CUCONATI, A. & GUO, H. 2012. Identification of disubstituted sulfonamide 
compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. 
Antimicrob Agents Chemother, 56, 4277-88. 
 
CAI, D., WANG, X., YAN, R., MAO, R., LIU, Y., JI, C., CUCONATI, A. & GUO, H. 2016. Establishment 
of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg 
for screening of cccDNA modulators. Antiviral Res, 132, 26-37. 
 
CAMPAGNA, M. R., LIU, F., MAO, R., MILLS, C., CAI, D., GUO, F., ZHAO, X., YE, H., CUCONATI, 
A., GUO, H., CHANG, J., XU, X., BLOCK, T. M. & GUO, J. T. 2013. Sulfamoylbenzamide derivatives 
inhibit the assembly of hepatitis B virus nucleocapsids. J Virol, 87, 6931-42. 
References 
 
 
127 
CASCIANO, J. C. & BOUCHARD, M. J. 2018. Hepatitis B virus X protein modulates cytosolic Ca(2+) 
signaling in primary human hepatocytes. Virus Res, 246, 23-27. 
 
CATTANEO, R., WILL, H., DARAI, G., PFAFF, E. & SCHALLER, H. 1983a. Detection of an element 
of the SV40 late promoter in vectors used for expression studies in COS cells. Embo j, 2, 511-4. 
 
CATTANEO, R., WILL, H., HERNANDEZ, N. & SCHALLER, H. 1983b. Signals regulating hepatitis B 
surface antigen transcription. Nature, 305, 336-8. 
 
CATTANEO, R., WILL, H. & SCHALLER, H. 1984. Hepatitis B virus transcription in the infected 
liver. Embo j, 3, 2191-6. 
 
CHA, M. Y., RYU, D. K., JUNG, H. S., CHANG, H. E. & RYU, W. S. 2009. Stimulation of hepatitis B 
virus genome replication by HBx is linked to both nuclear and cytoplasmic HBx expression. J 
Gen Virol, 90, 978-86. 
 
CHAMI, M., FERRARI, D., NICOTERA, P., PATERLINI-BRECHOT, P. & RIZZUTO, R. 2003. Caspase-
dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X 
protein. J Biol Chem, 278, 31745-55. 
 
CHANG, L. J., HIRSCH, R. C., GANEM, D. & VARMUS, H. E. 1990. Effects of insertional and point 
mutations on the functions of the duck hepatitis B virus polymerase. J Virol, 64, 5553-8. 
 
CHANG, S. F., NETTER, H. J., HILDT, E., SCHUSTER, R., SCHAEFER, S., HSU, Y. C., RANG, A. & WILL, 
H. 2001. Duck hepatitis B virus expresses a regulatory HBx-like protein from a hidden open 
reading frame. J Virol, 75, 161-70. 
 
CHANG, T. T., LAI, C. L., KEW YOON, S., LEE, S. S., COELHO, H. S., CARRILHO, F. J., POORDAD, F., 
HALOTA, W., HORSMANS, Y., TSAI, N., ZHANG, H., TENNEY, D. J., TAMEZ, R. & ILOEJE, U. 2010. 
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic 
hepatitis B. Hepatology, 51, 422-30. 
 
CHEN, E. Q., DAI, J., BAI, L. & TANG, H. 2015. The efficacy of zinc finger antiviral protein against 
hepatitis B virus transcription and replication in tansgenic mouse model. Virol J, 12, 25. 
 
CHEN, M., HIENG, S., QIAN, X., COSTA, R. & OU, J. H. 1994. Regulation of hepatitis B virus ENI 
enhancer activity by hepatocyte-enriched transcription factor HNF3. Virology, 205, 127-32. 
 
CHEN, Y. & MARION, P. L. 1996. Amino acids essential for RNase H activity of hepadnaviruses 
are also required for efficient elongation of minus-strand viral DNA. J Virol, 70, 6151-6. 
 
CONDREAY, L. D., WU, T. T., ALDRICH, C. E., DELANEY, M. A., SUMMERS, J., SEEGER, C. & 
MASON, W. S. 1992. Replication of DHBV genomes with mutations at the sites of initiation of 
minus- and plus-strand DNA synthesis. Virology, 188, 208-16. 
 
COURTOIS, G., BAUMHUETER, S. & CRABTREE, G. R. 1988. Purified hepatocyte nuclear factor 
1 interacts with a family of hepatocyte-specific promoters. Proc Natl Acad Sci U S A, 85, 7937-
41. 
 
CUI, X., CLARK, D. N., LIU, K., XU, X. D., GUO, J. T. & HU, J. 2016. Viral DNA-Dependent Induction 
of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes. J Virol, 
90, 486-96. 
References 
 
 
128 
CUI, X., GUO, J. T. & HU, J. 2015. Hepatitis B Virus Covalently Closed Circular DNA Formation in 
Immortalized Mouse Hepatocytes Associated with Nucleocapsid Destabilization. J Virol, 89, 
9021-8. 
 
CUI, X., LUDGATE, L., NING, X. & HU, J. 2013. Maturation-associated destabilization of hepatitis 
B virus nucleocapsid. J Virol, 87, 11494-503. 
 
DAEMER, R. J., FEINSTONE, S. M., ALEXANDER, J. J., TULLY, J. G., LONDON, W. T., WONG, D. C. 
& PURCELL, R. H. 1980. PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and 
studies of infectivity. Infect Immun, 30, 607-11. 
 
DANE, D. S., CAMERON, C. H. & BRIGGS, M. 1970. Virus-like particles in serum of patients with 
Australia-antigen-associated hepatitis. Lancet, 1, 695-8. 
 
DECORSIERE, A., MUELLER, H., VAN BREUGEL, P. C., ABDUL, F., GEROSSIER, L., BERAN, R. K., 
LIVINGSTON, C. M., NIU, C., FLETCHER, S. P., HANTZ, O. & STRUBIN, M. 2016. Hepatitis B virus 
X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 531, 386-9. 
 
DELANEY, W. E. T., EDWARDS, R., COLLEDGE, D., SHAW, T., FURMAN, P., PAINTER, G. & 
LOCARNINI, S. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of 
wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents 
Chemother, 46, 3057-60. 
 
DERES, K., SCHRODER, C. H., PAESSENS, A., GOLDMANN, S., HACKER, H. J., WEBER, O., KRAMER, 
T., NIEWOHNER, U., PLEISS, U., STOLTEFUSS, J., GRAEF, E., KOLETZKI, D., MASANTSCHEK, R. N., 
REIMANN, A., JAEGER, R., GROSS, R., BECKERMANN, B., SCHLEMMER, K. H., HAEBICH, D. & 
RUBSAMEN-WAIGMANN, H. 2003. Inhibition of hepatitis B virus replication by drug-induced 
depletion of nucleocapsids. Science, 299, 893-6. 
 
DIAO, J., KHINE, A. A., SARANGI, F., HSU, E., IORIO, C., TIBBLES, L. A., WOODGETT, J. R., 
PENNINGER, J. & RICHARDSON, C. D. 2001. X protein of hepatitis B virus inhibits Fas-mediated 
apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem, 276, 
8328-40. 
 
DIENSTAG, J. L., SCHIFF, E. R., WRIGHT, T. L., PERRILLO, R. P., HANN, H. W., GOODMAN, Z., 
CROWTHER, L., CONDREAY, L. D., WOESSNER, M., RUBIN, M. & BROWN, N. A. 1999. 
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 341, 
1256-63. 
 
DORIA, M., KLEIN, N., LUCITO, R. & SCHNEIDER, R. J. 1995. The hepatitis B virus HBx protein is 
a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. 
Embo j, 14, 4747-57. 
 
DRYDEN, K. A., WIELAND, S. F., WHITTEN-BAUER, C., GERIN, J. L., CHISARI, F. V. & YEAGER, M. 
2006. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell, 
22, 843-50. 
 
DUDA, D. M., BORG, L. A., SCOTT, D. C., HUNT, H. W., HAMMEL, M. & SCHULMAN, B. A. 2008. 
Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of 
conjugation. Cell, 134, 995-1006. 
 
References 
 
 
129 
DURANTEL, D. & ZOULIM, F. 2016. New antiviral targets for innovative treatment concepts for 
hepatitis B virus and hepatitis delta virus. J Hepatol, 64, S117-S131. 
 
ECKHARDT, S. G., MILICH, D. R. & MCLACHLAN, A. 1991. Hepatitis B virus core antigen has two 
nuclear localization sequences in the arginine-rich carboxyl terminus. J Virol, 65, 575-82. 
 
ELMORE, L. W., HANCOCK, A. R., CHANG, S. F., WANG, X. W., CHANG, S., CALLAHAN, C. P., 
GELLER, D. A., WILL, H. & HARRIS, C. C. 1997. Hepatitis B virus X protein and p53 tumor 
suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A, 94, 14707-
12. 
 
EMBADE, N., FERNANDEZ-RAMOS, D., VARELA-REY, M., BERAZA, N., SINI, M., GUTIERREZ DE 
JUAN, V., WOODHOO, A., MARTINEZ-LOPEZ, N., RODRIGUEZ-IRURETAGOYENA, B., 
BUSTAMANTE, F. J., DE LA HOZ, A. B., CARRACEDO, A., XIRODIMAS, D. P., RODRIGUEZ, M. S., 
LU, S. C., MATO, J. M. & MARTINEZ-CHANTAR, M. L. 2012. Murine double minute 2 regulates 
Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 55, 
1237-48. 
 
ENCHEV, R. I., SCHULMAN, B. A. & PETER, M. 2015. Protein neddylation: beyond cullin-RING 
ligases. Nat Rev Mol Cell Biol, 16, 30-44. 
 
ENGELKE, M., MILLS, K., SEITZ, S., SIMON, P., GRIPON, P., SCHNOLZER, M. & URBAN, S. 2006. 
Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology, 43, 
750-60. 
 
ESSER, K., LUCIFORA, J., WETTENGEL, J., SINGETHAN, K., GLINZER, A., ZERNECKE, A. & PROTZER, 
U. 2018. Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step 
in the virus life cycle. Antiviral Res, 151, 4-7. 
 
FAVRE, M., BREITBURD, F., CROISSANT, O. & ORTH, G. 1977. Chromatin-like structures 
obtained after alkaline disruption of bovine and human papillomaviruses. J Virol, 21, 1205-9. 
 
FELD, J. J., COLLEDGE, D., SOZZI, V., EDWARDS, R., LITTLEJOHN, M. & LOCARNINI, S. A. 2007. 
The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA 
packaging. Antiviral Res, 76, 168-77. 
 
FERNS, R. B., NASTOULI, E. & GARSON, J. A. 2012. Quantitation of hepatitis delta virus using a 
single-step internally controlled real-time RT-qPCR and a full-length genomic RNA calibration 
standard. J Virol Methods, 179, 189-94. 
 
FLETCHER, S. P. & DELANEY, W. E. T. 2013. New therapeutic targets and drugs for the treatment 
of chronic hepatitis B. Semin Liver Dis, 33, 130-7. 
 
FORGUES, M., MARROGI, A. J., SPILLARE, E. A., WU, C. G., YANG, Q., YOSHIDA, M. & WANG, X. 
W. 2001. Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export 
pathway. J Biol Chem, 276, 22797-803. 
 
FUNG, J., LAI, C. L., SETO, W. K. & YUEN, M. F. 2011. Nucleoside/nucleotide analogues in the 
treatment of chronic hepatitis B. J Antimicrob Chemother, 66, 2715-25. 
 
References 
 
 
130 
GAO, B., DUAN, Z., XU, W. & XIONG, S. 2009. Tripartite motif-containing 22 inhibits the activity 
of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. 
Hepatology, 50, 424-33. 
 
GARCIA, P. D., OU, J. H., RUTTER, W. J. & WALTER, P. 1988. Targeting of the hepatitis B virus 
precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage 
translocation can be aborted and the product released into the cytoplasm. J Cell Biol, 106, 
1093-104. 
 
GAREAU, J. R. & LIMA, C. D. 2010. The SUMO pathway: emerging mechanisms that shape 
specificity, conjugation and recognition. Nat Rev Mol Cell Biol, 11, 861-71. 
 
GEARHART, T. L. & BOUCHARD, M. J. 2010. The hepatitis B virus X protein modulates 
hepatocyte proliferation pathways to stimulate viral replication. J Virol, 84, 2675-86. 
 
GENG, X., HARRY, B. L., ZHOU, Q., SKEEN-GAAR, R. R., GE, X., LEE, E. S., MITANI, S. & XUE, D. 
2012a. Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ 
increase and cell death in Caenorhabditis elegans. Proc Natl Acad Sci U S A, 109, 18465-70. 
 
GENG, X., HUANG, C., QIN, Y., MCCOMBS, J. E., YUAN, Q., HARRY, B. L., PALMER, A. E., XIA, N. 
S. & XUE, D. 2012b. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular 
calcium, required for virus replication and cell death induction. Proc Natl Acad Sci U S A, 109, 
18471-6. 
 
GERLICH, W. H. & ROBINSON, W. S. 1980. Hepatitis B virus contains protein attached to the 5' 
terminus of its complete DNA strand. Cell, 21, 801-9. 
 
GISH, R. G., GIVEN, B. D., LAI, C. L., LOCARNINI, S. A., LAU, J. Y., LEWIS, D. L. & SCHLUEP, T. 2015. 
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future 
opportunities. Antiviral Res, 121, 47-58. 
 
GLEBE, D., URBAN, S., KNOOP, E. V., CAG, N., KRASS, P., GRUN, S., BULAVAITE, A., SASNAUSKAS, 
K. & GERLICH, W. H. 2005. Mapping of the hepatitis B virus attachment site by use of infection-
inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology, 129, 234-45. 
 
GORDIEN, E., ROSMORDUC, O., PELTEKIAN, C., GARREAU, F., BRECHOT, C. & KREMSDORF, D. 
2001. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol, 
75, 2684-91. 
 
GOTTE, M. & FELD, J. J. 2016. Direct-acting antiviral agents for hepatitis C: structural and 
mechanistic insights. Nat Rev Gastroenterol Hepatol, 13, 338-51. 
 
GRIPON, P., CANNIE, I. & URBAN, S. 2005. Efficient inhibition of hepatitis B virus infection by 
acylated peptides derived from the large viral surface protein. J Virol, 79, 1613-22. 
 
GRIPON, P., DIOT, C. & GUGUEN-GUILLOUZO, C. 1993. Reproducible high level infection of 
cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on 
adsorption and penetration. Virology, 192, 534-40. 
 
GRIPON, P., DIOT, C., THEZE, N., FOUREL, I., LOREAL, O., BRECHOT, C. & GUGUEN-GUILLOUZO, 
C. 1988. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of 
dimethyl sulfoxide. J Virol, 62, 4136-43. 
References 
 
 
131 
GRIPON, P., RUMIN, S., URBAN, S., LE SEYEC, J., GLAISE, D., CANNIE, I., GUYOMARD, C., LUCAS, 
J., TREPO, C. & GUGUEN-GUILLOUZO, C. 2002. Infection of a human hepatoma cell line by 
hepatitis B virus. Proc Natl Acad Sci U S A, 99, 15655-60. 
 
GUO, F., ZHAO, Q., SHERAZ, M., CHENG, J., QI, Y., SU, Q., CUCONATI, A., WEI, L., DU, Y., LI, W., 
CHANG, J. & GUO, J. T. 2017. HBV core protein allosteric modulators differentially alter cccDNA 
biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog, 13, 
e1006658. 
 
GUO, L., WANG, X., REN, L., ZENG, M., WANG, S., WENG, Y., TANG, Z., WANG, X., TANG, Y., HU, 
H., LI, M., ZHANG, C. & LIU, C. 2014. HBx affects CUL4-DDB1 function in both positive and 
negative manners. Biochem Biophys Res Commun, 450, 1492-7. 
 
GUO, W., CHEN, M., YEN, T. S. & OU, J. H. 1993. Hepatocyte-specific expression of the hepatitis 
B virus core promoter depends on both positive and negative regulation. Mol Cell Biol, 13, 443-
8. 
 
HADZIYANNIS, S. J., TASSOPOULOS, N. C., HEATHCOTE, E. J., CHANG, T. T., KITIS, G., RIZZETTO, 
M., MARCELLIN, P., LIM, S. G., GOODMAN, Z., MA, J., BROSGART, C. L., BORROTO-ESODA, K., 
ARTERBURN, S. & CHUCK, S. L. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-
negative chronic hepatitis B for up to 5 years. Gastroenterology, 131, 1743-51. 
 
HAGENBUCH, B. & MEIER, P. J. 1994. Molecular cloning, chromosomal localization, and 
functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest, 93, 1326-
31. 
 
HARADA, K., NISHITSUJI, H., UJINO, S. & SHIMOTOHNO, K. 2017. Identification of KX2-391 as 
an inhibitor of HBV transcription by a recombinant HBV-based screening assay. Antiviral Res, 
144, 138-146. 
 
HARTMANN-STUHLER, C. & PRANGE, R. 2001. Hepatitis B virus large envelope protein interacts 
with gamma2-adaptin, a clathrin adaptor-related protein. J Virol, 75, 5343-51. 
 
HEATHCOTE, E. J., MARCELLIN, P., BUTI, M., GANE, E., DE MAN, R. A., KRASTEV, Z., GERMANIDIS, 
G., LEE, S. S., FLISIAK, R., KAITA, K., MANNS, M., KOTZEV, I., TCHERNEV, K., BUGGISCH, P., 
WEILERT, F., KURDAS, O. O., SHIFFMAN, M. L., TRINH, H., GUREL, S., SNOW-LAMPART, A., 
BORROTO-ESODA, K., MONDOU, E., ANDERSON, J., SORBEL, J. & ROUSSEAU, F. 2011. Three-
year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. 
Gastroenterology, 140, 132-43. 
 
HEERMANN, K. H., GOLDMANN, U., SCHWARTZ, W., SEYFFARTH, T., BAUMGARTEN, H. & 
GERLICH, W. H. 1984. Large surface proteins of hepatitis B virus containing the pre-s sequence. 
J Virol, 52, 396-402. 
 
HEERMANN, K. H., KRUSE, F., SEIFER, M. & GERLICH, W. H. 1987. Immunogenicity of the gene 
S and Pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology, 28, 14-25. 
 
HENKLER, F., HOARE, J., WASEEM, N., GOLDIN, R. D., MCGARVEY, M. J., KOSHY, R. & KING, I. A. 
2001. Intracellular localization of the hepatitis B virus HBx protein. J Gen Virol, 82, 871-82. 
 
References 
 
 
132 
HIRSCH, R. C., LAVINE, J. E., CHANG, L. J., VARMUS, H. E. & GANEM, D. 1990. Polymerase gene 
products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse 
transcription. Nature, 344, 552-5. 
 
HIRSCHMAN, S. Z., PRICE, P., GARFINKEL, E., CHRISTMAN, J. & ACS, G. 1980. Expression of 
cloned hepatitis B virus DNA in human cell cultures. Proc Natl Acad Sci U S A, 77, 5507-11. 
 
HODGSON, A. J., HYSER, J. M., KEASLER, V. V., CANG, Y. & SLAGLE, B. L. 2012. Hepatitis B virus 
regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV 
replication. Virology, 426, 73-82. 
 
HOFMANN, H., NORTON, T. D., SCHULTZ, M. L., POLSKY, S. B., SUNSERI, N. & LANDAU, N. R. 
2013. Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated 
restriction of HIV-1. J Virol, 87, 11741-50. 
 
HORI, T., OSAKA, F., CHIBA, T., MIYAMOTO, C., OKABAYASHI, K., SHIMBARA, N., KATO, S. & 
TANAKA, K. 1999. Covalent modification of all members of human cullin family proteins by 
NEDD8. Oncogene, 18, 6829-34. 
 
HU, Y., CHENG, X., CAO, F., HUANG, A. & TAVIS, J. E. 2013. beta-Thujaplicinol inhibits hepatitis 
B virus replication by blocking the viral ribonuclease H activity. Antiviral Res, 99, 221-9. 
 
HUANG, D. T., AYRAULT, O., HUNT, H. W., TAHERBHOY, A. M., DUDA, D. M., SCOTT, D. C., BORG, 
L. A., NEALE, G., MURRAY, P. J., ROUSSEL, M. F. & SCHULMAN, B. A. 2009. E2-RING expansion 
of the NEDD8 cascade confers specificity to cullin modification. Mol Cell, 33, 483-95. 
 
HUANG, D. T., HUNT, H. W., ZHUANG, M., OHI, M. D., HOLTON, J. M. & SCHULMAN, B. A. 2007. 
Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity. Nature, 445, 394-8. 
 
HUANG, D. T., PAYDAR, A., ZHUANG, M., WADDELL, M. B., HOLTON, J. M. & SCHULMAN, B. A. 
2005. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. Mol 
Cell, 17, 341-50. 
 
HUANG, M. J. & SUMMERS, J. 1991. Infection initiated by the RNA pregenome of a DNA virus. 
J Virol, 65, 5435-9. 
 
HUOVILA, A. P., EDER, A. M. & FULLER, S. D. 1992. Hepatitis B surface antigen assembles in a 
post-ER, pre-Golgi compartment. J Cell Biol, 118, 1305-20. 
 
JANSSEN, H. L., VAN ZONNEVELD, M., SENTURK, H., ZEUZEM, S., AKARCA, U. S., CAKALOGLU, 
Y., SIMON, C., SO, T. M., GERKEN, G., DE MAN, R. A., NIESTERS, H. G., ZONDERVAN, P., HANSEN, 
B. & SCHALM, S. W. 2005. Pegylated interferon alfa-2b alone or in combination with 
lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 365, 123-9. 
 
JIANG, T., LIU, M., WU, J. & SHI, Y. 2016. Structural and biochemical analysis of Bcl-2 interaction 
with the hepatitis B virus protein HBx. Proc Natl Acad Sci U S A, 113, 2074-9. 
 
JILBERT, A. R., FREIMAN, J. S., GOWANS, E. J., HOLMES, M., COSSART, Y. E. & BURRELL, C. J. 
1987. Duck hepatitis B virus DNA in liver, spleen, and pancreas: analysis by in situ and Southern 
blot hybridization. Virology, 158, 330-8. 
References 
 
 
133 
JOST, S., TURELLI, P., MANGEAT, B., PROTZER, U. & TRONO, D. 2007. Induction of antiviral 
cytidine deaminases does not explain the inhibition of hepatitis B virus replication by 
interferons. J Virol, 81, 10588-96. 
 
KAJINO, K., JILBERT, A. R., SAPUTELLI, J., ALDRICH, C. E., CULLEN, J. & MASON, W. S. 1994. 
Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and 
infection of virtually every hepatocyte. J Virol, 68, 5792-803. 
 
KAMITANI, T., KITO, K., NGUYEN, H. P. & YEH, E. T. 1997. Characterization of NEDD8, a 
developmentally down-regulated ubiquitin-like protein. J Biol Chem, 272, 28557-62. 
 
KANEKO, S., KAKINUMA, S., ASAHINA, Y., KAMIYA, A., MIYOSHI, M., TSUNODA, T., NITTA, S., 
ASANO, Y., NAGATA, H., OTANI, S., KAWAI-KITAHATA, F., MURAKAWA, M., ITSUI, Y., 
NAKAGAWA, M., AZUMA, S., NAKAUCHI, H., NISHITSUJI, H., UJINO, S., SHIMOTOHNO, K., 
IWAMOTO, M., WATASHI, K., WAKITA, T. & WATANABE, M. 2016. Human induced pluripotent 
stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. 
Sci Rep, 6, 29358. 
 
KANN, M., SODEIK, B., VLACHOU, A., GERLICH, W. H. & HELENIUS, A. 1999. Phosphorylation-
dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol, 
145, 45-55. 
 
KAPOOR, D., GUPTAN, R. C., WAKIL, S. M., KAZIM, S. N., KAUL, R., AGARWAL, S. R., RAISUDDIN, 
S., HASNAIN, S. E. & SARIN, S. K. 2000. Beneficial effects of lamivudine in hepatitis B virus-
related decompensated cirrhosis. J Hepatol, 33, 308-12. 
 
KATEN, S. P., TAN, Z., CHIRAPU, S. R., FINN, M. G. & ZLOTNICK, A. 2013. Assembly-directed 
antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary 
and quaternary structure. Structure, 21, 1406-16. 
 
KING, R. W., LADNER, S. K., MILLER, T. J., ZAIFERT, K., PERNI, R. B., CONWAY, S. C. & OTTO, M. 
J. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide 
derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob 
Agents Chemother, 42, 3179-86. 
 
KLUMPP, K., LAM, A. M., LUKACS, C., VOGEL, R., REN, S., ESPIRITU, C., BAYDO, R., ATKINS, K., 
ABENDROTH, J., LIAO, G., EFIMOV, A., HARTMAN, G. & FLORES, O. A. 2015. High-resolution 
crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. Proc 
Natl Acad Sci U S A, 112, 15196-201. 
 
KLUMPP, K., SHIMADA, T., ALLWEISS, L., VOLZ, T., LUTGEHETMANN, M., HARTMAN, G., FLORES, 
O. A., LAM, A. M. & DANDRI, M. 2018. Efficacy of NVR 3-778, Alone and In Combination With 
Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. 
Gastroenterology, 154, 652-662 e8. 
 
KOCK, J., NASSAL, M., MACNELLY, S., BAUMERT, T. F., BLUM, H. E. & VON WEIZSACKER, F. 2001. 
Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey 
hepatitis B virus. J Virol, 75, 5084-9. 
 
KOCK, J., ROSLER, C., ZHANG, J. J., BLUM, H. E., NASSAL, M. & THOMA, C. 2010. Generation of 
covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a 
virus specific manner. PLoS Pathog, 6, e1001082. 
References 
 
 
134 
KONIG, A., YANG, J., JO, E., PARK, K. H. P., KIM, H., THAN, T. T., SONG, X., QI, X., DAI, X., PARK, 
S., SHUM, D., RYU, W. S., KIM, J. H., YOON, S. K., PARK, J. Y., AHN, S. H., HAN, K. H., GERLICH, 
W. H. & WINDISCH, M. P. 2019. Efficient long-term amplification of hepatitis B virus isolates 
after infection of slow proliferating HepG2-NTCP cells. J Hepatol, 71, 289-300. 
 
KONIGER, C., WINGERT, I., MARSMANN, M., ROSLER, C., BECK, J. & NASSAL, M. 2014. 
Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular 
DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A, 111, E4244-53. 
 
KUMAR, M., JUNG, S. Y., HODGSON, A. J., MADDEN, C. R., QIN, J. & SLAGLE, B. L. 2011. Hepatitis 
B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta 
interferon. J Virol, 85, 987-95. 
 
KUMAR, V., JAYASURYAN, N. & KUMAR, R. 1996. A truncated mutant (residues 58-140) of the 
hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci U S A, 93, 5647-
52. 
 
LADNER, S. K., OTTO, M. J., BARKER, C. S., ZAIFERT, K., WANG, G. H., GUO, J. T., SEEGER, C. & 
KING, R. W. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected 
hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. 
Antimicrob Agents Chemother, 41, 1715-20. 
 
LAHLALI, T., BERKE, J. M., VERGAUWEN, K., FOCA, A., VANDYCK, K., PAUWELS, F., ZOULIM, F. 
& DURANTEL, D. 2018. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of 
the Hepatitis B Virus Life Cycle. Antimicrob Agents Chemother, 62. 
 
LAI, C. L., CHIEN, R. N., LEUNG, N. W., CHANG, T. T., GUAN, R., TAI, D. I., NG, K. Y., WU, P. C., 
DENT, J. C., BARBER, J., STEPHENSON, S. L. & GRAY, D. F. 1998. A one-year trial of lamivudine 
for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 339, 61-8. 
 
LAI, C. L., GANE, E., LIAW, Y. F., HSU, C. W., THONGSAWAT, S., WANG, Y., CHEN, Y., HEATHCOTE, 
E. J., RASENACK, J., BZOWEJ, N., NAOUMOV, N. V., DI BISCEGLIE, A. M., ZEUZEM, S., MOON, Y. 
M., GOODMAN, Z., CHAO, G., CONSTANCE, B. F. & BROWN, N. A. 2007. Telbivudine versus 
lamivudine in patients with chronic hepatitis B. N Engl J Med, 357, 2576-88. 
 
LAI, C. L., RATZIU, V., YUEN, M. F. & POYNARD, T. 2003. Viral hepatitis B. Lancet, 362, 2089-94. 
LAI, C. L., WONG, D., IP, P., KOPANISZEN, M., SETO, W. K., FUNG, J., HUANG, F. Y., LEE, B., 
CULLARO, G., CHONG, C. K., WU, R., CHENG, C., YUEN, J., NGAI, V. & YUEN, M. F. 2017. 
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment 
in chronic hepatitis B. J Hepatol, 66, 275-281. 
 
LAMPERTICO, P., VIGANO, M., MANENTI, E., IAVARONE, M., LUNGHI, G. & COLOMBO, M. 2005. 
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic 
resistance to lamivudine. Hepatology, 42, 1414-9. 
 
LAN, Y. T., LI, J., LIAO, W. & OU, J. 1999. Roles of the three major phosphorylation sites of 
hepatitis B virus core protein in viral replication. Virology, 259, 342-8. 
 
LANFORD, R. E., NOTVALL, L., LEE, H. & BEAMES, B. 1997. Transcomplementation of nucleotide 
priming and reverse transcription between independently expressed TP and RT domains of the 
hepatitis B virus reverse transcriptase. J Virol, 71, 2996-3004. 
References 
 
 
135 
LANGLEY, D. R., WALSH, A. W., BALDICK, C. J., EGGERS, B. J., ROSE, R. E., LEVINE, S. M., KAPUR, 
A. J., COLONNO, R. J. & TENNEY, D. J. 2007. Inhibition of hepatitis B virus polymerase by 
entecavir. J Virol, 81, 3992-4001. 
 
LARAS, A., KOSKINAS, J., DIMOU, E., KOSTAMENA, A. & HADZIYANNIS, S. J. 2006. Intrahepatic 
levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically 
infected patients. Hepatology, 44, 694-702. 
 
LAVON, N., YANUKA, O. & BENVENISTY, N. 2004. Differentiation and isolation of hepatic-like 
cells from human embryonic stem cells. Differentiation, 72, 230-8. 
 
LE DUFF, Y., BLANCHET, M. & SUREAU, C. 2009. The pre-S1 and antigenic loop infectivity 
determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol, 
83, 12443-51. 
 
LE SEYEC, J., CHOUTEAU, P., CANNIE, I., GUGUEN-GUILLOUZO, C. & GRIPON, P. 1999. Infection 
process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 
domain. J Virol, 73, 2052-7. 
 
LE-TRILLING, V. T., MEGGER, D. A., KATSCHINSKI, B., LANDSBERG, C. D., RUCKBORN, M. U., TAO, 
S., KRAWCZYK, A., BAYER, W., DREXLER, I., TENBUSCH, M., SITEK, B. & TRILLING, M. 2016. Broad 
and potent antiviral activity of the NAE inhibitor MLN4924. Sci Rep, 6, 19977. 
 
LEMPP, F. A., MUTZ, P., LIPPS, C., WIRTH, D., BARTENSCHLAGER, R. & URBAN, S. 2016a. 
Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell 
dependency factor. J Hepatol, 64, 556-64. 
 
LEMPP, F. A., QU, B., WANG, Y. X. & URBAN, S. 2016b. Hepatitis B Virus Infection of a Mouse 
Hepatic Cell Line Reconstituted with Human Sodium Taurocholate Cotransporting Polypeptide. 
J Virol, 90, 4827-4831. 
 
LEMPP, F. A. & URBAN, S. 2014. Inhibitors of hepatitis B virus attachment and entry. 
Intervirology, 57, 151-7. 
 
LEMPP, F. A., WIEDTKE, E., QU, B., ROQUES, P., CHEMIN, I., VONDRAN, F. W. R., LE GRAND, R., 
GRIMM, D. & URBAN, S. 2017. Sodium taurocholate cotransporting polypeptide is the limiting 
host factor of hepatitis B virus infection in macaque and pig hepatocytes. Hepatology, 66, 703-
716. 
 
LENHOFF, R. J. & SUMMERS, J. 1994. Coordinate regulation of replication and virus assembly 
by the large envelope protein of an avian hepadnavirus. J Virol, 68, 4565-71. 
 
LEUPIN, O., BONTRON, S., SCHAEFFER, C. & STRUBIN, M. 2005. Hepatitis B virus X protein 
stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading 
to cell death. J Virol, 79, 4238-45. 
 
LEUPIN, O., BONTRON, S. & STRUBIN, M. 2003. Hepatitis B virus X protein and simian virus 5 V 
protein exhibit similar UV-DDB1 binding properties to mediate distinct activities. J Virol, 77, 
6274-83. 
 
LEVRERO, M., POLLICINO, T., PETERSEN, J., BELLONI, L., RAIMONDO, G. & DANDRI, M. 2009. 
Control of cccDNA function in hepatitis B virus infection. J Hepatol, 51, 581-92. 
References 
 
 
136 
LEWELLYN, E. B. & LOEB, D. D. 2011. The arginine clusters of the carboxy-terminal domain of 
the core protein of hepatitis B virus make pleiotropic contributions to genome replication. J 
Virol, 85, 1298-309. 
 
LI, B., WANG, Y., SHEN, F., WU, M., LI, Y., FANG, Z., YE, J., WANG, L., GAO, L., YUAN, Z. & CHEN, 
J. 2018a. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors 
via a Drug Repurposing Screen. Antimicrob Agents Chemother. 
 
LI, H. C., HUANG, E. Y., SU, P. Y., WU, S. Y., YANG, C. C., LIN, Y. S., CHANG, W. C. & SHIH, C. 
2010a. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS 
Pathog, 6, e1001162. 
 
LI, J., LIN, S., CHEN, Q., PENG, L., ZHAI, J., LIU, Y. & YUAN, Z. 2010b. Inhibition of hepatitis B 
virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear 
retention of pre-S/S RNAs. J Virol, 84, 6387-99. 
 
LI, J., ZONG, L., SUREAU, C., BARKER, L., WANDS, J. R. & TONG, S. 2016a. Unusual Features of 
Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor. J Virol, 90, 
8302-13. 
 
LI, M., SOHN, J. A. & SEEGER, C. 2018b. Distribution of Hepatitis B Virus Nuclear DNA. J Virol, 
92. 
 
LI, N., ZHANG, L., CHEN, L., FENG, W., XU, Y., CHEN, F., LIU, X., CHEN, Z. & LIU, W. 2012. MxA 
inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology, 
56, 803-11. 
 
LI, S. K., HO, S. F., TSUI, K. W., FUNG, K. P. & WAYE, M. Y. 2008. Identification of functionally 
important amino acid residues in the mitochondria targeting sequence of hepatitis B virus X 
protein. Virology, 381, 81-8. 
 
LI, T., ROBERT, E. I., VAN BREUGEL, P. C., STRUBIN, M. & ZHENG, N. 2010c. A promiscuous 
alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin 
ligase machinery. Nat Struct Mol Biol, 17, 105-11. 
 
LI, W., LI, M., LIAO, D., LU, X., GU, X., ZHANG, Q., ZHANG, Z. & LI, H. 2016b. Carboxyl-terminal 
truncated HBx contributes to invasion and metastasis via deregulating metastasis suppressors 
in hepatocellular carcinoma. Oncotarget, 7, 55110-55127. 
 
LI, W. & URBAN, S. 2016. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic 
insights and clinical implications. J Hepatol, 64, S32-s40. 
 
LI, Y., XIA, Y., HAN, M., CHEN, G., ZHANG, D., THASLER, W. E., PROTZER, U. & NING, Q. 2017. 
IFN-alpha-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against 
Hepatitis B Virus Infection. Sci Rep, 7, 12715. 
 
LIAO, W. & OU, J. H. 1995. Phosphorylation and nuclear localization of the hepatitis B virus 
core protein: significance of serine in the three repeated SPRRR motifs. J Virol, 69, 1025-9. 
 
LIAW, Y. F., SUNG, J. J., CHOW, W. C., FARRELL, G., LEE, C. Z., YUEN, H., TANWANDEE, T., TAO, 
Q. M., SHUE, K., KEENE, O. N., DIXON, J. S., GRAY, D. F. & SABBAT, J. 2004. Lamivudine for 
patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, 1521-31. 
References 
 
 
137 
LIEN, J. M., ALDRICH, C. E. & MASON, W. S. 1986. Evidence that a capped oligoribonucleotide 
is the primer for duck hepatitis B virus plus-strand DNA synthesis. J Virol, 57, 229-36. 
 
LIU, F., CAMPAGNA, M., QI, Y., ZHAO, X., GUO, F., XU, C., LI, S., LI, W., BLOCK, T. M., CHANG, J. 
& GUO, J. T. 2013. Alpha-interferon suppresses hepadnavirus transcription by altering 
epigenetic modification of cccDNA minichromosomes. PLoS Pathog, 9, e1003613. 
 
LIU, N., ZHANG, J., YANG, X., JIAO, T., ZHAO, X., LI, W., ZHU, J., YANG, P., JIN, J., PENG, J., LI, Z. 
& YE, X. 2017. HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability 
and Function. J Virol, 91. 
 
LIU, Y., LI, J., CHEN, J., LI, Y., WANG, W., DU, X., SONG, W., ZHANG, W., LIN, L. & YUAN, Z. 2015. 
Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate 
cytosolic DNA-sensing pathways. J Virol, 89, 2287-300. 
 
LIVINGSTON, C. M., RAMAKRISHNAN, D., STRUBIN, M., FLETCHER, S. P. & BERAN, R. K. 2017. 
Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6. 
Viruses, 9. 
 
LIZZANO, R. A., YANG, B., CLIPPINGER, A. J. & BOUCHARD, M. J. 2011. The C-terminal region of 
the hepatitis B virus X protein is essential for its stability and function. Virus Res, 155, 231-9. 
 
LO, A. O. & WONG, G. L. 2014. Current developments in nucleoside/nucleotide analogues for 
hepatitis B. Expert Rev Gastroenterol Hepatol, 8, 607-22. 
 
LOMONOSOVA, E., DAW, J., GARIMALLAPRABHAKARAN, A. K., AGYEMANG, N. B., ASHANI, Y., 
MURELLI, R. P. & TAVIS, J. E. 2017. Efficacy and cytotoxicity in cell culture of novel alpha-
hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antiviral Res, 144, 164-172. 
 
LONG, Q., YAN, R., HU, J., CAI, D., MITRA, B., KIM, E. S., MARCHETTI, A., ZHANG, H., WANG, S., 
LIU, Y., HUANG, A. & GUO, H. 2017. The role of host DNA ligases in hepadnavirus covalently 
closed circular DNA formation. PLoS Pathog, 13, e1006784. 
 
LOPEZ-CABRERA, M., LETOVSKY, J., HU, K. Q. & SIDDIQUI, A. 1990. Multiple liver-specific 
factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and 
repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci U S A, 87, 5069-73. 
 
LU, G., LOMONOSOVA, E., CHENG, X., MORAN, E. A., MEYERS, M. J., LE GRICE, S. F., THOMAS, 
C. J., JIANG, J. K., MECK, C., HIRSCH, D. R., D'ERASMO, M. P., SUYABATMAZ, D. M., MURELLI, R. 
P. & TAVIS, J. E. 2015. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking 
viral ribonuclease H activity. Antimicrob Agents Chemother, 59, 1070-9. 
 
LUCIFORA, J., ARZBERGER, S., DURANTEL, D., BELLONI, L., STRUBIN, M., LEVRERO, M., ZOULIM, 
F., HANTZ, O. & PROTZER, U. 2011. Hepatitis B virus X protein is essential to initiate and 
maintain virus replication after infection. J Hepatol, 55, 996-1003. 
 
LUCIFORA, J., ESSER, K. & PROTZER, U. 2013. Ezetimibe blocks hepatitis B virus infection after 
virus uptake into hepatocytes. Antiviral Res, 97, 195-7. 
 
LUCIFORA, J., XIA, Y., REISINGER, F., ZHANG, K., STADLER, D., CHENG, X., SPRINZL, M. F., 
KOPPENSTEINER, H., MAKOWSKA, Z., VOLZ, T., REMOUCHAMPS, C., CHOU, W. M., THASLER, 
W. E., HUSER, N., DURANTEL, D., LIANG, T. J., MUNK, C., HEIM, M. H., BROWNING, J. L., 
References 
 
 
138 
DEJARDIN, E., DANDRI, M., SCHINDLER, M., HEIKENWALDER, M. & PROTZER, U. 2014. Specific 
and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 343, 1221-8. 
 
LUO, N., CAI, Y., ZHANG, J., TANG, W., SLAGLE, B. L., WU, X. & HE, S. 2012. The C-terminal 
region of the hepatitis B virus X protein is required for its stimulation of HBV replication in 
primary mouse hepatocytes. Virus Res, 165, 170-8. 
 
LUTGEHETMANN, M., MANCKE, L. V., VOLZ, T., HELBIG, M., ALLWEISS, L., BORNSCHEUER, T., 
POLLOK, J. M., LOHSE, A. W., PETERSEN, J., URBAN, S. & DANDRI, M. 2012. Humanized chimeric 
uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug 
evaluation. Hepatology, 55, 685-94. 
 
LUTGEHETMANN, M., VOLZ, T., KOPKE, A., BROJA, T., TIGGES, E., LOHSE, A. W., FUCHS, E., 
MURRAY, J. M., PETERSEN, J. & DANDRI, M. 2010. In vivo proliferation of hepadnavirus-
infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology, 52, 
16-24. 
 
LUTWICK, L. I. & ROBINSON, W. S. 1977. DNA synthesized in the hepatitis B Dane particle DNA 
polymerase reaction. J Virol, 21, 96-104. 
 
MAC, C. F. 1946. Homologous serum hepatitis. Proc R Soc Med, 39, 655-7. 
 
MAO, R., NIE, H., CAI, D., ZHANG, J., LIU, H., YAN, R., CUCONATI, A., BLOCK, T. M., GUO, J. T. & 
GUO, H. 2013. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. 
PLoS Pathog, 9, e1003494. 
 
MARCELLIN, P., CHANG, T. T., LIM, S. G., SIEVERT, W., TONG, M., ARTERBURN, S., BORROTO-
ESODA, K., FREDERICK, D. & ROUSSEAU, F. 2008. Long-term efficacy and safety of adefovir 
dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 48, 
750-8. 
 
MARCELLIN, P., CHANG, T. T., LIM, S. G., TONG, M. J., SIEVERT, W., SHIFFMAN, M. L., JEFFERS, 
L., GOODMAN, Z., WULFSOHN, M. S., XIONG, S., FRY, J. & BROSGART, C. L. 2003. Adefovir 
dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 
348, 808-16. 
 
MARTIN-LLUESMA, S., SCHAEFFER, C., ROBERT, E. I., VAN BREUGEL, P. C., LEUPIN, O., HANTZ, 
O. & STRUBIN, M. 2008. Hepatitis B virus X protein affects S phase progression leading to 
chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology, 
48, 1467-76. 
 
MASON, W. S., ALDRICH, C., SUMMERS, J. & TAYLOR, J. M. 1982. Asymmetric replication of 
duck hepatitis B virus DNA in liver cells: Free minus-strand DNA. Proc Natl Acad Sci U S A, 79, 
3997-4001. 
 
MCCLAIN, S. L., CLIPPINGER, A. J., LIZZANO, R. & BOUCHARD, M. J. 2007. Hepatitis B virus 
replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic 
calcium levels. J Virol, 81, 12061-5. 
 
MEIER, A., MEHRLE, S., WEISS, T. S., MIER, W. & URBAN, S. 2013. Myristoylated PreS1-domain 
of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. 
Hepatology, 58, 31-42. 
References 
 
 
139 
MEIER, P., SCOUGALL, C. A., WILL, H., BURRELL, C. J. & JILBERT, A. R. 2003. A duck hepatitis B 
virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo 
growth characteristics to wild-type virus. Virology, 317, 291-8. 
 
MILLER, R. H. & ROBINSON, W. S. 1984. Hepatitis B virus DNA forms in nuclear and cytoplasmic 
fractions of infected human liver. Virology, 137, 390-9. 
 
MINOR, M. M. & SLAGLE, B. L. 2014. Hepatitis B virus HBx protein interactions with the 
ubiquitin proteasome system. Viruses, 6, 4683-702. 
 
MIRANDA, M. & SORKIN, A. 2007. Regulation of receptors and transporters by ubiquitination: 
new insights into surprisingly similar mechanisms. Mol Interv, 7, 157-67. 
 
MISRA, K. P., MUKHERJI, A. & KUMAR, V. 2004. The conserved amino-terminal region (amino 
acids 1-20) of the hepatitis B virus X protein shows a transrepression function. Virus Res, 105, 
157-65. 
 
MOLNAR-KIMBER, K. L., SUMMERS, J., TAYLOR, J. M. & MASON, W. S. 1983. Protein covalently 
bound to minus-strand DNA intermediates of duck hepatitis B virus. J Virol, 45, 165-72. 
 
MOLNAR-KIMBER, K. L., SUMMERS, J. W. & MASON, W. S. 1984. Mapping of the cohesive 
overlap of duck hepatitis B virus DNA and of the site of initiation of reverse transcription. J 
Virol, 51, 181-91. 
 
MUELLER, H., WILDUM, S., LUANGSAY, S., WALTHER, J., LOPEZ, A., TROPBERGER, P., 
OTTAVIANI, G., LU, W., PARROTT, N. J., ZHANG, J. D., SCHMUCKI, R., RACEK, T., HOFLACK, J. C., 
KUENG, E., POINT, F., ZHOU, X., STEINER, G., LUTGEHETMANN, M., RAPP, G., VOLZ, T., DANDRI, 
M., YANG, S., YOUNG, J. A. T. & JAVANBAKHT, H. 2018. A novel orally available small molecule 
that inhibits hepatitis B virus expression. J Hepatol, 68, 412-420. 
 
MURAKAMI, S. 2001. Hepatitis B virus X protein: a multifunctional viral regulator. J 
Gastroenterol, 36, 651-60. 
 
MURAKAMI, S., CHEONG, J. H. & KANEKO, S. 1994. Human hepatitis virus X gene encodes a 
regulatory domain that represses transactivation of X protein. J Biol Chem, 269, 15118-23. 
 
MURPHY, C. M., XU, Y., LI, F., NIO, K., RESZKA-BLANCO, N., LI, X., WU, Y., YU, Y., XIONG, Y. & 
SU, L. 2016. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV 
Replication. Cell Rep, 16, 2846-2854. 
 
NAG, A., DATTA, A., YOO, K., BHATTACHARYYA, D., CHAKRABORTTY, A., WANG, X., SLAGLE, B. 
L., COSTA, R. H. & RAYCHAUDHURI, P. 2001. DDB2 induces nuclear accumulation of the 
hepatitis B virus X protein independently of binding to DDB1. J Virol, 75, 10383-92. 
 
NASSAL, M. 1992. The arginine-rich domain of the hepatitis B virus core protein is required for 
pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus 
assembly. J Virol, 66, 4107-16. 
 
NASSAL, M. 2008. Hepatitis B viruses: reverse transcription a different way. Virus Res, 134, 
235-49. 
 
References 
 
 
140 
NASSAL, M. 2015. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of 
chronic hepatitis B. Gut, 64, 1972-84. 
 
NEWBOLD, J. E., XIN, H., TENCZA, M., SHERMAN, G., DEAN, J., BOWDEN, S. & LOCARNINI, S. 
1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a 
heterogeneous population of viral minichromosomes. J Virol, 69, 3350-7. 
 
NGUYEN, D. H., GUMMULURU, S. & HU, J. 2007. Deamination-independent inhibition of 
hepatitis B virus reverse transcription by APOBEC3G. J Virol, 81, 4465-72. 
 
NGUYEN, D. H. & HU, J. 2008. Reverse transcriptase- and RNA packaging signal-dependent 
incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol, 82, 6852-61. 
 
NI, Y., LEMPP, F. A., MEHRLE, S., NKONGOLO, S., KAUFMAN, C., FALTH, M., STINDT, J., KONIGER, 
C., NASSAL, M., KUBITZ, R., SULTMANN, H. & URBAN, S. 2014. Hepatitis B and D viruses exploit 
sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. 
Gastroenterology, 146, 1070-83. 
 
NI, Y., SONNABEND, J., SEITZ, S. & URBAN, S. 2010. The pre-s2 domain of the hepatitis B virus 
is dispensable for infectivity but serves a spacer function for L-protein-connected virus 
assembly. J Virol, 84, 3879-88. 
 
NI, Y. & URBAN, S. 2017. Stem cell-derived hepatocytes: A promising novel tool to study 
hepatitis B virus infection. J Hepatol, 66, 473-475. 
 
NIU, C., LIVINGSTON, C. M., LI, L., BERAN, R. K., DAFFIS, S., RAMAKRISHNAN, D., BURDETTE, D., 
PEISER, L., SALAS, E., RAMOS, H., YU, M., CHENG, G., STRUBIN, M., DELANEY, W. I. & FLETCHER, 
S. P. 2017. The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an 
Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. 
PLoS One, 12, e0169648. 
 
NKONGOLO, S., NI, Y., LEMPP, F. A., KAUFMAN, C., LINDNER, T., ESSER-NOBIS, K., LOHMANN, 
V., MIER, W., MEHRLE, S. & URBAN, S. 2014. Cyclosporin A inhibits hepatitis B and hepatitis D 
virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol, 60, 723-
31. 
 
NKONGOLO, S., NUSSBAUM, L., LEMPP, F. A., WODRICH, H., URBAN, S. & NI, Y. 2019. The 
retinoic acid receptor (RAR) alpha-specific agonist Am80 (tamibarotene) and other RAR 
agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Res. 
 
NOGUCHI, C., ISHINO, H., TSUGE, M., FUJIMOTO, Y., IMAMURA, M., TAKAHASHI, S. & 
CHAYAMA, K. 2005. G to A hypermutation of hepatitis B virus. Hepatology, 41, 626-33. 
 
OLSEN, S. K., CAPILI, A. D., LU, X., TAN, D. S. & LIMA, C. D. 2010. Active site remodelling 
accompanies thioester bond formation in the SUMO E1. Nature, 463, 906-12. 
 
ORI, A. & SHAUL, Y. 1995. Hepatitis B virus enhancer binds and is activated by the Hepatocyte 
nuclear factor 3. Virology, 207, 98-106. 
 
OU, J. H., LAUB, O. & RUTTER, W. J. 1986. Hepatitis B virus gene function: the precore region 
targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc 
Natl Acad Sci U S A, 83, 1578-82. 
References 
 
 
141 
OU, J. H., YEH, C. T. & YEN, T. S. 1989. Transport of hepatitis B virus precore protein into the 
nucleus after cleavage of its signal peptide. J Virol, 63, 5238-43. 
 
PARK, E. S., LEE, A. R., KIM, D. H., LEE, J. H., YOO, J. J., AHN, S. H., SIM, H., PARK, S., KANG, H. 
S., WON, J., HA, Y. N., SHIN, G. C., KWON, S. Y., PARK, Y. K., CHOI, B. S., LEE, Y. B., JEONG, N., 
AN, Y., JU, Y. S., YU, S. J., CHAE, H. B., YU, K. S., KIM, Y. J., YOON, J. H., ZOULIM, F. & KIM, K. H. 
2019. Identification of a quadruple mutation that confers tenofovir resistance in chronic 
hepatitis B patients. J Hepatol, 70, 1093-1102. 
 
PARK, I. H., BAEK, K. W., CHO, E. Y. & AHN, B. Y. 2011. PKR-dependent mechanisms of 
interferon-alpha for inhibiting hepatitis B virus replication. Mol Cells, 32, 167-72. 
 
PATTERSON, S. J., GEORGE, J., STRASSER, S. I., LEE, A. U., SIEVERT, W., NICOLL, A. J., DESMOND, 
P. V., ROBERTS, S. K., LOCARNINI, S., BOWDEN, S. & ANGUS, P. W. 2011. Tenofovir disoproxil 
fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic 
hepatitis B. Gut, 60, 247-54. 
 
PATZER, E. J., NAKAMURA, G. R. & YAFFE, A. 1984. Intracellular transport and secretion of 
hepatitis B surface antigen in mammalian cells. J Virol, 51, 346-53. 
 
PERNI, R. B., CONWAY, S. C., LADNER, S. K., ZAIFERT, K., OTTO, M. J. & KING, R. W. 2000. 
Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg Med Chem 
Lett, 10, 2687-90. 
 
PERSING, D. H., VARMUS, H. E. & GANEM, D. 1987. The preS1 protein of hepatitis B virus is 
acylated at its amino terminus with myristic acid. J Virol, 61, 1672-7. 
 
PETCU, D. J., ALDRICH, C. E., COATES, L., TAYLOR, J. M. & MASON, W. S. 1988. Suramin inhibits 
in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. 
Virology, 167, 385-92. 
 
PETERSEN, J., DANDRI, M., MIER, W., LUTGEHETMANN, M., VOLZ, T., VON WEIZSACKER, F., 
HABERKORN, U., FISCHER, L., POLLOK, J. M., ERBES, B., SEITZ, S. & URBAN, S. 2008. Prevention 
of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. 
Nat Biotechnol, 26, 335-41. 
 
POLARIS OBSERVATORY, C. 2018. Global prevalence, treatment, and prevention of hepatitis B 
virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 3, 383-403. 
 
POLLICINO, T., BELLONI, L., RAFFA, G., PEDICONI, N., SQUADRITO, G., RAIMONDO, G. & 
LEVRERO, M. 2006. Hepatitis B virus replication is regulated by the acetylation status of 
hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology, 130, 823-37. 
 
PRANGE, R. & STREECK, R. E. 1995. Novel transmembrane topology of the hepatitis B virus 
envelope proteins. Embo j, 14, 247-56. 
 
PROPST, T., PROPST, A., LHOTTA, K., VOGEL, W. & KONIG, P. 1998. Reinforced intradermal 
hepatitis B vaccination in hemodialysis patients is superior in antibody response to 
intramuscular or subcutaneous vaccination. Am J Kidney Dis, 32, 1041-5. 
 
QI, Y., GAO, Z., XU, G., PENG, B., LIU, C., YAN, H., YAO, Q., SUN, G., LIU, Y., TANG, D., SONG, Z., 
HE, W., SUN, Y., GUO, J. T. & LI, W. 2016. DNA Polymerase kappa Is a Key Cellular Factor for 
References 
 
 
142 
the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog, 12, 
e1005893. 
 
QU, B., NI, Y., LEMPP, F. A., VONDRAN, F. W. R. & URBAN, S. 2018. T5 exonuclease hydrolysis 
of Hepatitis B Virus replicative intermediates allows reliable quantification and fast drug 
efficacy testing of covalently closed circular DNA by PCR. J Virol. 
 
QUASDORFF, M. & PROTZER, U. 2010. Control of hepatitis B virus at the level of transcription. 
J Viral Hepat, 17, 527-36. 
 
RABE, B., DELALEAU, M., BISCHOF, A., FOSS, M., SOMINSKAYA, I., PUMPENS, P., CAZENAVE, C., 
CASTROVIEJO, M. & KANN, M. 2009. Nuclear entry of hepatitis B virus capsids involves 
disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog, 5, 
e1000563. 
 
RABE, B., GLEBE, D. & KANN, M. 2006. Lipid-mediated introduction of hepatitis B virus capsids 
into nonsusceptible cells allows highly efficient replication and facilitates the study of early 
infection events. J Virol, 80, 5465-73. 
 
RABE, B., VLACHOU, A., PANTE, N., HELENIUS, A. & KANN, M. 2003. Nuclear import of hepatitis 
B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A, 100, 9849-54. 
 
RADZIWILL, G., TUCKER, W. & SCHALLER, H. 1990. Mutational analysis of the hepatitis B virus 
P gene product: domain structure and RNase H activity. J Virol, 64, 613-20. 
 
RAMAKRISHNAN, D., XING, W., BERAN, R. K., CHEMURU, S., ROHRS, H., NIEDZIELA-MAJKA, A., 
MARCHAND, B., MEHRA, U., ZABRANSKY, A., DOLEZAL, M., HUBALEK, M., PICHOVA, I., GROSS, 
M. L., KWON, H. J. & FLETCHER, S. P. 2019. Hepatitis B Virus X Protein Function Requires Zinc 
Binding. J Virol, 93. 
 
RANEY, A. K., ZHANG, P. & MCLACHLAN, A. 1995. Regulation of transcription from the hepatitis 
B virus large surface antigen promoter by hepatocyte nuclear factor 3. J Virol, 69, 3265-72. 
 
RAVID, T. & HOCHSTRASSER, M. 2008. Diversity of degradation signals in the ubiquitin-
proteasome system. Nat Rev Mol Cell Biol, 9, 679-90. 
 
REHERMANN, B., FERRARI, C., PASQUINELLI, C. & CHISARI, F. V. 1996. The hepatitis B virus 
persists for decades after patients' recovery from acute viral hepatitis despite active 
maintenance of a cytotoxic T-lymphocyte response. Nat Med, 2, 1104-8. 
 
RESHETNYAK, V. I., KARLOVICH, T. I. & ILCHENKO, L. U. 2008. Hepatitis G virus. World J 
Gastroenterol, 14, 4725-34. 
 
ROEHL, I., SEIFFERT, S., BRIKH, C., QUINET, J., JAMARD, C., DORFLER, N., LOCKRIDGE, J. A., 
COVA, L. & VAILLANT, A. 2017. Nucleic Acid Polymers with Accelerated Plasma and Tissue 
Clearance for Chronic Hepatitis B Therapy. Mol Ther Nucleic Acids, 8, 1-12. 
 
ROST, M., MANN, S., LAMBERT, C., DORING, T., THOME, N. & PRANGE, R. 2006. Gamma-
adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B 
virus maturation. J Biol Chem, 281, 29297-308. 
 
References 
 
 
143 
RUNKEL, L., FISCHER, M. & SCHALLER, H. 1993. Two-codon insertion mutations of the HBx 
define two separate regions necessary for its trans-activation function. Virology, 197, 529-36. 
 
RUSSNAK, R. H. 1991. Regulation of polyadenylation in hepatitis B viruses: stimulation by the 
upstream activating signal PS1 is orientation-dependent, distance-independent, and additive. 
Nucleic Acids Res, 19, 6449-56. 
 
SACO, T. V., STRAUSS, A. T. & LEDFORD, D. K. 2018. Hepatitis B vaccine nonresponders: Possible 
mechanisms and solutions. Ann Allergy Asthma Immunol, 121, 320-327. 
 
SAHA, A. & DESHAIES, R. J. 2008. Multimodal activation of the ubiquitin ligase SCF by Nedd8 
conjugation. Mol Cell, 32, 21-31. 
 
SAKURAI, F., MITANI, S., YAMAMOTO, T., TAKAYAMA, K., TACHIBANA, M., WATASHI, K., 
WAKITA, T., IIJIMA, S., TANAKA, Y. & MIZUGUCHI, H. 2017. Human induced-pluripotent stem 
cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. Sci 
Rep, 7, 45698. 
 
SALISSE, J. & SUREAU, C. 2009. A function essential to viral entry underlies the hepatitis B virus 
"a" determinant. J Virol, 83, 9321-8. 
 
SCHIECK, A., MULLER, T., SCHULZE, A., HABERKORN, U., URBAN, S. & MIER, W. 2010. Solid-
phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. 
Molecules, 15, 4773-83. 
 
SCHLICKSUP, C. J., WANG, J. C., FRANCIS, S., VENKATAKRISHNAN, B., TURNER, W. W., 
VANNIEUWENHZE, M. & ZLOTNICK, A. 2018. Hepatitis B virus core protein allosteric 
modulators can distort and disrupt intact capsids. Elife, 7. 
 
SCHLUEP, T., LICKLITER, J., HAMILTON, J., LEWIS, D. L., LAI, C. L., LAU, J. Y., LOCARNINI, S. A., 
GISH, R. G. & GIVEN, B. D. 2017. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, 
an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus 
Infection, in Healthy Volunteers. Clin Pharmacol Drug Dev, 6, 350-362. 
 
SCHMITT, S., GLEBE, D., ALVING, K., TOLLE, T. K., LINDER, M., GEYER, H., LINDER, D., PETER-
KATALINIC, J., GERLICH, W. H. & GEYER, R. 1999. Analysis of the pre-S2 N- and O-linked glycans 
of the M surface protein from human hepatitis B virus. J Biol Chem, 274, 11945-57. 
 
SCHMITZ, A., SCHWARZ, A., FOSS, M., ZHOU, L., RABE, B., HOELLENRIEGEL, J., STOEBER, M., 
PANTE, N. & KANN, M. 2010. Nucleoporin 153 arrests the nuclear import of hepatitis B virus 
capsids in the nuclear basket. PLoS Pathog, 6, e1000741. 
 
SCHREIBER, A. & PETER, M. 2014. Substrate recognition in selective autophagy and the 
ubiquitin-proteasome system. Biochim Biophys Acta, 1843, 163-81. 
 
SCHULZE, A., GRIPON, P. & URBAN, S. 2007. Hepatitis B virus infection initiates with a large 
surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology, 46, 1759-
68. 
 
SCHULZE, A., MILLS, K., WEISS, T. S. & URBAN, S. 2012. Hepatocyte polarization is essential for 
the productive entry of the hepatitis B virus. Hepatology, 55, 373-83. 
References 
 
 
144 
SCHULZE, A., SCHIECK, A., NI, Y., MIER, W. & URBAN, S. 2010. Fine mapping of pre-S sequence 
requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J 
Virol, 84, 1989-2000. 
 
SEEGER, C., GANEM, D. & VARMUS, H. E. 1986. Biochemical and genetic evidence for the 
hepatitis B virus replication strategy. Science, 232, 477-84. 
 
SEEGER, C. & SOHN, J. A. 2014. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic 
Acids, 3, e216. 
 
SEEGER, C. & SOHN, J. A. 2016. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV 
cccDNA. Mol Ther, 24, 1258-66. 
 
SEITZ, S., IANCU, C., VOLZ, T., MIER, W., DANDRI, M., URBAN, S. & BARTENSCHLAGER, R. 2016. 
A Slow Maturation Process Renders Hepatitis B Virus Infectious. Cell Host Microbe, 20, 25-35. 
 
SEKIBA, K., OTSUKA, M., OHNO, M., YAMAGAMI, M., KISHIKAWA, T., SEIMIYA, T., SUZUKI, T., 
TANAKA, E., ISHIBASHI, R., FUNATO, K. & KOIKE, K. 2019a. Pevonedistat, a Neuronal Precursor 
Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a 
Potent Inhibitor of Hepatitis B Virus. Hepatology, 69, 1903-1915. 
 
SEKIBA, K., OTSUKA, M., OHNO, M., YAMAGAMI, M., KISHIKAWA, T., SUZUKI, T., ISHIBASHI, R., 
SEIMIYA, T., TANAKA, E. & KOIKE, K. 2019b. Inhibition of HBV Transcription From cccDNA With 
Nitazoxanide by Targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol, 7, 297-
312. 
 
SELLS, M. A., CHEN, M. L. & ACS, G. 1987. Production of hepatitis B virus particles in Hep G2 
cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A, 84, 1005-9. 
 
SELLS, M. A., ZELENT, A. Z., SHVARTSMAN, M. & ACS, G. 1988. Replicative intermediates of 
hepatitis B virus in HepG2 cells that produce infectious virions. J Virol, 62, 2836-44. 
 
SHEN, F., LI, Y., WANG, Y., SOZZI, V., REVILL, P. A., LIU, J., GAO, L., YANG, G., LU, M., SUTTER, 
K., DITTMER, U., CHEN, J. & YUAN, Z. 2018. Hepatitis B virus sensitivity to interferon-alpha in 
hepatocytes is more associated with cellular interferon response than with viral genotype. 
Hepatology, 67, 1237-1252. 
 
SHERAZ, M., CHENG, J., TANG, L., CHANG, J. & GUO, J. T. 2019. Cellular DNA topoisomerases 
are required for the synthesis of hepatitis B virus covalently closed circular DNA. J Virol. 
 
SHIMURA, S., WATASHI, K., FUKANO, K., PEEL, M., SLUDER, A., KAWAI, F., IWAMOTO, M., 
TSUKUDA, S., TAKEUCHI, J. S., MIYAKE, T., SUGIYAMA, M., OGASAWARA, Y., PARK, S. Y., 
TANAKA, Y., KUSUHARA, H., MIZOKAMI, M., SUREAU, C. & WAKITA, T. 2017. Cyclosporin 
derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J 
Hepatol, 66, 685-692. 
 
SHLOMAI, A., SCHWARTZ, R. E., RAMANAN, V., BHATTA, A., DE JONG, Y. P., BHATIA, S. N. & 
RICE, C. M. 2014. Modeling host interactions with hepatitis B virus using primary and induced 
pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A, 111, 12193-8. 
 
References 
 
 
145 
SHORT, J. M., CHEN, S., ROSEMAN, A. M., BUTLER, P. J. & CROWTHER, R. A. 2009. Structure of 
hepatitis B surface antigen from subviral tubes determined by electron cryomicroscopy. J Mol 
Biol, 390, 135-41. 
 
SLAGLE, B. L., ANDRISANI, O. M., BOUCHARD, M. J., LEE, C. G., OU, J. H. & SIDDIQUI, A. 2015. 
Technical standards for hepatitis B virus X protein (HBx) research. Hepatology, 61, 1416-24. 
 
SLAGLE, B. L. & BOUCHARD, M. J. 2016. Hepatitis B Virus X and Regulation of Viral Gene 
Expression. Cold Spring Harb Perspect Med, 6, a021402. 
 
SLAGLE, B. L. & BOUCHARD, M. J. 2018. Role of HBx in hepatitis B virus persistence and its 
therapeutic implications. Curr Opin Virol, 30, 32-38. 
 
SONG, M., SUN, Y., TIAN, J., HE, W., XU, G., JING, Z. & LI, W. 2018. Silencing Retinoid X Receptor 
Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. J Virol, 92. 
 
SOUCY, T. A., SMITH, P. G., MILHOLLEN, M. A., BERGER, A. J., GAVIN, J. M., ADHIKARI, S., 
BROWNELL, J. E., BURKE, K. E., CARDIN, D. P., CRITCHLEY, S., CULLIS, C. A., DOUCETTE, A., 
GARNSEY, J. J., GAULIN, J. L., GERSHMAN, R. E., LUBLINSKY, A. R., MCDONALD, A., MIZUTANI, 
H., NARAYANAN, U., OLHAVA, E. J., PELUSO, S., REZAEI, M., SINTCHAK, M. D., TALREJA, T., 
THOMAS, M. P., TRAORE, T., VYSKOCIL, S., WEATHERHEAD, G. S., YU, J., ZHANG, J., DICK, L. R., 
CLAIBORNE, C. F., ROLFE, M., BOLEN, J. B. & LANGSTON, S. P. 2009. An inhibitor of NEDD8-
activating enzyme as a new approach to treat cancer. Nature, 458, 732-6. 
 
SPRINZL, M. F., OBERWINKLER, H., SCHALLER, H. & PROTZER, U. 2001. Transfer of hepatitis B 
virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. 
J Virol, 75, 5108-18. 
 
STANAWAY, J. D., FLAXMAN, A. D., NAGHAVI, M., FITZMAURICE, C., VOS, T., ABUBAKAR, I., 
ABU-RADDAD, L. J., ASSADI, R., BHALA, N., COWIE, B., FOROUZANFOUR, M. H., GROEGER, J., 
HANAFIAH, K. M., JACOBSEN, K. H., JAMES, S. L., MACLACHLAN, J., MALEKZADEH, R., MARTIN, 
N. K., MOKDAD, A. A., MOKDAD, A. H., MURRAY, C. J. L., PLASS, D., RANA, S., REIN, D. B., 
RICHARDUS, J. H., SANABRIA, J., SAYLAN, M., SHAHRAZ, S., SO, S., VLASSOV, V. V., WEIDERPASS, 
E., WIERSMA, S. T., YOUNIS, M., YU, C., EL SAYED ZAKI, M. & COOKE, G. S. 2016. The global 
burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 
2013. Lancet, 388, 1081-1088. 
 
STANDRING, D. N., OU, J. H., MASIARZ, F. R. & RUTTER, W. J. 1988. A signal peptide encoded 
within the precore region of hepatitis B virus directs the secretion of a heterogeneous 
population of e antigens in Xenopus oocytes. Proc Natl Acad Sci U S A, 85, 8405-9. 
 
STAPRANS, S., LOEB, D. D. & GANEM, D. 1991. Mutations affecting hepadnavirus plus-strand 
DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear 
viral DNA. J Virol, 65, 1255-62. 
 
STEINAU, M., RAJEEVAN, M. S. & UNGER, E. R. 2006. DNA and RNA references for qRT-PCR 
assays in exfoliated cervical cells. J Mol Diagn, 8, 113-8. 
 
STRAY, S. J., BOURNE, C. R., PUNNA, S., LEWIS, W. G., FINN, M. G. & ZLOTNICK, A. 2005. A 
heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. 
Proc Natl Acad Sci U S A, 102, 8138-43. 
 
References 
 
 
146 
STRAY, S. J., JOHNSON, J. M., KOPEK, B. G. & ZLOTNICK, A. 2006. An in vitro fluorescence screen 
to identify antivirals that disrupt hepatitis B virus capsid assembly. Nat Biotechnol, 24, 358-62. 
 
STRAY, S. J. & ZLOTNICK, A. 2006. BAY 41-4109 has multiple effects on Hepatitis B virus capsid 
assembly. J Mol Recognit, 19, 542-8. 
 
SULLIVAN, G. J., HAY, D. C., PARK, I. H., FLETCHER, J., HANNOUN, Z., PAYNE, C. M., DALGETTY, 
D., BLACK, J. R., ROSS, J. A., SAMUEL, K., WANG, G., DALEY, G. Q., LEE, J. H., CHURCH, G. M., 
FORBES, S. J., IREDALE, J. P. & WILMUT, I. 2010. Generation of functional human hepatic 
endoderm from human induced pluripotent stem cells. Hepatology, 51, 329-35. 
 
SUMMERS, J. & MASON, W. S. 1982. Replication of the genome of a hepatitis B--like virus by 
reverse transcription of an RNA intermediate. Cell, 29, 403-15. 
 
SUMMERS, J., SMITH, P. M. & HORWICH, A. L. 1990. Hepadnavirus envelope proteins regulate 
covalently closed circular DNA amplification. J Virol, 64, 2819-24. 
 
SUN, D. & NASSAL, M. 2006. Stable HepG2- and Huh7-based human hepatoma cell lines for 
efficient regulated expression of infectious hepatitis B virus. J Hepatol, 45, 636-45. 
 
TAHAEI, S. M., MOHEBBI, S. R. & ZALI, M. R. 2012. Enteric hepatitis viruses. Gastroenterol 
Hepatol Bed Bench, 5, 7-15. 
 
TAKAHASHI, K. & YAMANAKA, S. 2006. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-76. 
 
TAN, Z., MAGUIRE, M. L., LOEB, D. D. & ZLOTNICK, A. 2013. Genetically altering the 
thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus 
replication in cell culture. J Virol, 87, 3208-16. 
 
TANG, H., DELGERMAA, L., HUANG, F., OISHI, N., LIU, L., HE, F., ZHAO, L. & MURAKAMI, S. 2005. 
The transcriptional transactivation function of HBx protein is important for its augmentation 
role in hepatitis B virus replication. J Virol, 79, 5548-56. 
 
TANG, H. M., GAO, W. W., CHAN, C. P., CHENG, Y., CHAUDHARY, V., DENG, J. J., YUEN, K. S., 
WONG, C. M., NG, I. O., KOK, K. H., ZHOU, J. & JIN, D. Y. 2014. Requirement of CRTC1 
coactivator for hepatitis B virus transcription. Nucleic Acids Res, 42, 12455-68. 
 
TANG, L., SHERAZ, M., MCGRANE, M., CHANG, J. & GUO, J. T. 2019. DNA Polymerase alpha is 
essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS 
Pathog, 15, e1007742. 
 
TATE, V. E. & PHILIPSON, L. 1979. Parental adenovirus DNA accumulates in nucleosome-like 
structures in infected cells. Nucleic Acids Res, 6, 2769-85. 
 
TAVIS, J. E., CHENG, X., HU, Y., TOTTEN, M., CAO, F., MICHAILIDIS, E., AURORA, R., MEYERS, M. 
J., JACOBSEN, E. J., PARNIAK, M. A. & SARAFIANOS, S. G. 2013. The hepatitis B virus 
ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H 
and integrase enzymes. PLoS Pathog, 9, e1003125. 
 
TAVIS, J. E. & LOMONOSOVA, E. 2015. The hepatitis B virus ribonuclease H as a drug target. 
Antiviral Res, 118, 132-8. 
References 
 
 
147 
TAVIS, J. E., ZOIDIS, G., MEYERS, M. J. & MURELLI, R. P. 2018. Chemical Approaches to Inhibiting 
the Hepatitis B Virus Ribonuclease H. ACS Infect Dis. 
 
TCHESNOKOV, E. P., OBIKHOD, A., SCHINAZI, R. F. & GOTTE, M. 2008. Delayed chain 
termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse 
transcriptase. J Biol Chem, 283, 34218-28. 
 
TENNEY, D. J., ROSE, R. E., BALDICK, C. J., POKORNOWSKI, K. A., EGGERS, B. J., FANG, J., 
WICHROSKI, M. J., XU, D., YANG, J., WILBER, R. B. & COLONNO, R. J. 2009. Long-term 
monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare 
through 5 years of therapy. Hepatology, 49, 1503-14. 
 
THOMAS, E., YONEDA, M. & SCHIFF, E. R. 2015. Viral hepatitis: past and future of HBV and HDV. 
Cold Spring Harb Perspect Med, 5, a021345. 
 
TOH, Q. C., TAN, T. L., TEO, W. Q., HO, C. Y., PARIDA, S. & CHEN, W. N. 2005. Identification of 
cellular membrane proteins interacting with hepatitis B surface antigen using yeast split-
ubiquitin system. Int J Med Sci, 2, 114-7. 
 
TROPBERGER, P., MERCIER, A., ROBINSON, M., ZHONG, W., GANEM, D. E. & HOLDORF, M. 2015. 
Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin 
organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A, 112, E5715-24. 
 
TRUJILLO, M. A., LETOVSKY, J., MAGUIRE, H. F., LOPEZ-CABRERA, M. & SIDDIQUI, A. 1991. 
Functional analysis of a liver-specific enhancer of the hepatitis B virus. Proc Natl Acad Sci U S 
A, 88, 3797-801. 
 
TU, T., BUDZINSKA, M. A., SHACKEL, N. A. & URBAN, S. 2017. HBV DNA Integration: Molecular 
Mechanisms and Clinical Implications. Viruses, 9. 
 
TUTTLEMAN, J. S., POURCEL, C. & SUMMERS, J. 1986. Formation of the pool of covalently 
closed circular viral DNA in hepadnavirus-infected cells. Cell, 47, 451-60. 
 
UNCHWANIWALA, N., SHERER, N. M. & LOEB, D. D. 2016. Hepatitis B Virus Polymerase 
Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial 
Targeting Signal. J Virol, 90, 8705-19. 
 
URBAN, S., BARTENSCHLAGER, R., KUBITZ, R. & ZOULIM, F. 2014. Strategies to inhibit entry of 
HBV and HDV into hepatocytes. Gastroenterology, 147, 48-64. 
 
URBAN, S., BREINER, K. M., FEHLER, F., KLINGMULLER, U. & SCHALLER, H. 1998. Avian hepatitis 
B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular 
receptor gp180. J Virol, 72, 8089-97. 
 
URBAN, S. & GRIPON, P. 2002. Inhibition of duck hepatitis B virus infection by a myristoylated 
pre-S peptide of the large viral surface protein. J Virol, 76, 1986-90. 
 
VAN BREUGEL, P. C., ROBERT, E. I., MUELLER, H., DECORSIERE, A., ZOULIM, F., HANTZ, O. & 
STRUBIN, M. 2012. Hepatitis B virus X protein stimulates gene expression selectively from 
extrachromosomal DNA templates. Hepatology, 56, 2116-24. 
 
References 
 
 
148 
VAN DE KLUNDERT, M. A., VAN DEN BIGGELAAR, M., KOOTSTRA, N. A. & ZAAIJER, H. L. 2016a. 
Hepatitis B Virus Protein X Induces Degradation of Talin-1. Viruses, 8. 
 
VAN DE KLUNDERT, M. A., ZAAIJER, H. L. & KOOTSTRA, N. A. 2016b. Identification of FDA-
approved drugs that target hepatitis B virus transcription. J Viral Hepat, 23, 191-201. 
 
VOLZ, T., ALLWEISS, L., BEN, M. M., WARLICH, M., LOHSE, A. W., POLLOK, J. M., ALEXANDROV, 
A., URBAN, S., PETERSEN, J., LUTGEHETMANN, M. & DANDRI, M. 2013. The entry inhibitor 
Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously 
infected with hepatitis B virus. J Hepatol, 58, 861-7. 
 
VOSOUGH, M., OMIDINIA, E., KADIVAR, M., SHOKRGOZAR, M. A., POURNASR, B., AGHDAMI, 
N. & BAHARVAND, H. 2013. Generation of functional hepatocyte-like cells from human 
pluripotent stem cells in a scalable suspension culture. Stem Cells Dev, 22, 2693-705. 
 
WALDEN, H., PODGORSKI, M. S., HUANG, D. T., MILLER, D. W., HOWARD, R. J., MINOR, D. L., 
JR., HOLTON, J. M. & SCHULMAN, B. A. 2003. The structure of the APPBP1-UBA3-NEDD8-ATP 
complex reveals the basis for selective ubiquitin-like protein activation by an E1. Mol Cell, 12, 
1427-37. 
 
WANG, G. H. & SEEGER, C. 1992. The reverse transcriptase of hepatitis B virus acts as a protein 
primer for viral DNA synthesis. Cell, 71, 663-70. 
 
WANG, J., CHEN, X., WU, Y., CAO, Z., WANG, L., HUANG, H., CHEN, X. & LU, F. 2018. Serum HBV 
RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion. Hepatol Commun, 2, 
1168-1171. 
 
WANG, J., QU, B., ZHANG, F., ZHANG, C., DENG, W., DAO THI, V. L. & XIA, Y. 2019. Stem Cell-
Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. Stem Cells Int, 2019, 
9605252. 
 
WANG, J., SHEN, T., HUANG, X., KUMAR, G. R., CHEN, X., ZENG, Z., ZHANG, R., CHEN, R., LI, T., 
ZHANG, T., YUAN, Q., LI, P. C., HUANG, Q., COLONNO, R., JIA, J., HOU, J., MCCRAE, M. A., GAO, 
Z., REN, H., XIA, N., ZHUANG, H. & LU, F. 2016. Serum hepatitis B virus RNA is encapsidated 
pregenome RNA that may be associated with persistence of viral infection and rebound. J 
Hepatol, 65, 700-710. 
 
WANG, J., SHENG, Q., DING, Y., CHEN, R., SUN, X., CHEN, X., DOU, X. & LU, F. 2017. HBV RNA 
virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-
deficient. J Hepatol. 
 
WANG, X., LI, Y., MAO, A., LI, C., LI, Y. & TIEN, P. 2010. Hepatitis B virus X protein suppresses 
virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated 
complex. Cell Mol Immunol, 7, 341-8. 
 
WANG, X. Y., WEI, Z. M., WU, G. Y., WANG, J. H., ZHANG, Y. J., LI, J., ZHANG, H. H., XIE, X. W., 
WANG, X., WANG, Z. H., WEI, L., WANG, Y. & CHEN, H. S. 2012. In vitro inhibition of HBV 
replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV 
mutations. Antivir Ther, 17, 793-803. 
 
WATASHI, K., SLUDER, A., DAITO, T., MATSUNAGA, S., RYO, A., NAGAMORI, S., IWAMOTO, M., 
NAKAJIMA, S., TSUKUDA, S., BORROTO-ESODA, K., SUGIYAMA, M., TANAKA, Y., KANAI, Y., 
References 
 
 
149 
KUSUHARA, H., MIZOKAMI, M. & WAKITA, T. 2014. Cyclosporin A and its analogs inhibit 
hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, 
sodium taurocholate cotransporting polypeptide (NTCP). Hepatology, 59, 1726-37. 
 
WEBER, M., BRONSEMA, V., BARTOS, H., BOSSERHOFF, A., BARTENSCHLAGER, R. & SCHALLER, 
H. 1994. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse 
transcription. J Virol, 68, 2994-9. 
 
WEBER, N. D., STONE, D., SEDLAK, R. H., DE SILVA FEELIXGE, H. S., ROYCHOUDHURY, P., 
SCHIFFER, J. T., AUBERT, M. & JEROME, K. R. 2014. AAV-mediated delivery of zinc finger 
nucleases targeting hepatitis B virus inhibits active replication. PLoS One, 9, e97579. 
 
WEBER, O., SCHLEMMER, K. H., HARTMANN, E., HAGELSCHUER, I., PAESSENS, A., GRAEF, E., 
DERES, K., GOLDMANN, S., NIEWOEHNER, U., STOLTEFUSS, J., HAEBICH, D., RUEBSAMEN-
WAIGMANN, H. & WOHLFEIL, S. 2002. Inhibition of human hepatitis B virus (HBV) by a novel 
non-nucleosidic compound in a transgenic mouse model. Antiviral Res, 54, 69-78. 
 
WEI, C., NI, C., SONG, T., LIU, Y., YANG, X., ZHENG, Z., JIA, Y., YUAN, Y., GUAN, K., XU, Y., CHENG, 
X., ZHANG, Y., YANG, X., WANG, Y., WEN, C., WU, Q., SHI, W. & ZHONG, H. 2010. The hepatitis 
B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling 
protein. J Immunol, 185, 1158-68. 
 
WEI, W., GUO, H., LIU, X., ZHANG, H., QIAN, L., LUO, K., MARKHAM, R. B. & YU, X. F. 2014. A 
first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting 
neddylation-dependent Vpx-mediated SAMHD1 degradation. J Virol, 88, 745-51. 
 
WELLS, M. J., HATTON, M. W., HEWLETT, B., PODOR, T. J., SHEFFIELD, W. P. & BLAJCHMAN, M. 
A. 1997. Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and 
interacts with thrombin-antithrombin complexes. J Biol Chem, 272, 28574-81. 
 
WENTZ, M. J., BECKER, S. A. & SLAGLE, B. L. 2000. Dissociation of DDB1-binding and 
transactivation properties of the hepatitis B virus X protein. Virus Res, 68, 87-92. 
 
WHITBY, F. G., XIA, G., PICKART, C. M. & HILL, C. P. 1998. Crystal structure of the human 
ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes. J Biol Chem, 
273, 34983-91. 
 
WILL, H., REISER, W., WEIMER, T., PFAFF, E., BUSCHER, M., SPRENGEL, R., CATTANEO, R. & 
SCHALLER, H. 1987. Replication strategy of human hepatitis B virus. J Virol, 61, 904-11. 
 
WINER, B. Y., HUANG, T. S., PLUDWINSKI, E., HELLER, B., WOJCIK, F., LIPKOWITZ, G. E., PAREKH, 
A., CHO, C., SHRIRAO, A., MUIR, T. W., NOVIK, E. & PLOSS, A. 2017. Long-term hepatitis B 
infection in a scalable hepatic co-culture system. Nat Commun, 8, 125. 
 
WOODDELL, C. I., ROZEMA, D. B., HOSSBACH, M., JOHN, M., HAMILTON, H. L., CHU, Q., HEGGE, 
J. O., KLEIN, J. J., WAKEFIELD, D. H., OROPEZA, C. E., DECKERT, J., ROEHL, I., JAHN-HOFMANN, 
K., HADWIGER, P., VORNLOCHER, H. P., MCLACHLAN, A. & LEWIS, D. L. 2013. Hepatocyte-
targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther, 
21, 973-85. 
 
WOODDELL, C. I., YUEN, M. F., CHAN, H. L., GISH, R. G., LOCARNINI, S. A., CHAVEZ, D., FERRARI, 
C., GIVEN, B. D., HAMILTON, J., KANNER, S. B., LAI, C. L., LAU, J. Y. N., SCHLUEP, T., XU, Z., 
References 
 
 
150 
LANFORD, R. E. & LEWIS, D. L. 2017. RNAi-based treatment of chronically infected patients and 
chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med, 
9. 
 
WU, G., LIU, B., ZHANG, Y., LI, J., ARZUMANYAN, A., CLAYTON, M. M., SCHINAZI, R. F., WANG, 
Z., GOLDMANN, S., REN, Q., ZHANG, F. & FEITELSON, M. A. 2013. Preclinical characterization 
of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother, 
57, 5344-54. 
 
WU, T. T., COATES, L., ALDRICH, C. E., SUMMERS, J. & MASON, W. S. 1990. In hepatocytes 
infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an 
intracellular pathway. Virology, 175, 255-61. 
 
XIA, Y., CARPENTIER, A., CHENG, X., BLOCK, P. D., ZHAO, Y., ZHANG, Z., PROTZER, U. & LIANG, 
T. J. 2017a. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, 
spreading and virus-host interactions. J Hepatol, 66, 494-503. 
 
XIA, Y., CHENG, X., BLOSSEY, C. K., WISSKIRCHEN, K., ESSER, K. & PROTZER, U. 2017b. Secreted 
Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. J Immunol Res, 2017, 
4828936. 
 
XIA, Y. & PROTZER, U. 2017. Control of Hepatitis B Virus by Cytokines. Viruses, 9. 
 
XIA, Y., STADLER, D., LUCIFORA, J., REISINGER, F., WEBB, D., HOSEL, M., MICHLER, T., 
WISSKIRCHEN, K., CHENG, X., ZHANG, K., CHOU, W. M., WETTENGEL, J. M., MALO, A., BOHNE, 
F., HOFFMANN, D., EYER, F., THIMME, R., FALK, C. S., THASLER, W. E., HEIKENWALDER, M. & 
PROTZER, U. 2016. Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells 
Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology, 150, 194-205. 
 
XIANG, C., DU, Y., MENG, G., SOON YI, L., SUN, S., SONG, N., ZHANG, X., XIAO, Y., WANG, J., YI, 
Z., LIU, Y., XIE, B., WU, M., SHU, J., SUN, D., JIA, J., LIANG, Z., SUN, D., HUANG, Y., SHI, Y., XU, J., 
LU, F., LI, C., XIANG, K., YUAN, Z., LU, S. & DENG, H. 2019. Long-term functional maintenance 
of primary human hepatocytes in vitro. Science, 364, 399-402. 
 
YAMOAH, K., OASHI, T., SARIKAS, A., GAZDOIU, S., OSMAN, R. & PAN, Z. Q. 2008. Autoinhibitory 
regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad 
Sci U S A, 105, 12230-5. 
 
YAN, H., PENG, B., LIU, Y., XU, G., HE, W., REN, B., JING, Z., SUI, J. & LI, W. 2014. Viral entry of 
hepatitis B and D viruses and bile salts transportation share common molecular determinants 
on sodium taurocholate cotransporting polypeptide. J Virol, 88, 3273-84. 
 
YAN, H., ZHONG, G., XU, G., HE, W., JING, Z., GAO, Z., HUANG, Y., QI, Y., PENG, B., WANG, H., 
FU, L., SONG, M., CHEN, P., GAO, W., REN, B., SUN, Y., CAI, T., FENG, X., SUI, J. & LI, W. 2012. 
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis 
B and D virus. Elife, 3. 
 
YAN, R., ZHAO, X., CAI, D., LIU, Y., BLOCK, T. M., GUO, J. T. & GUO, H. 2015. The Interferon-
Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. J Virol, 89, 9200-12. 
 
YANG, B. & BOUCHARD, M. J. 2012. The hepatitis B virus X protein elevates cytosolic calcium 
signals by modulating mitochondrial calcium uptake. J Virol, 86, 313-27. 
References 
 
 
151 
YANG, W. & SUMMERS, J. 1998. Infection of ducklings with virus particles containing linear 
double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. J Virol, 72, 
8710-7. 
 
YAO, F. Y., TERRAULT, N. A., FREISE, C., MASLOW, L. & BASS, N. M. 2001. Lamivudine treatment 
is beneficial in patients with severely decompensated cirrhosis and actively replicating 
hepatitis B infection awaiting liver transplantation: a comparative study using a matched, 
untreated cohort. Hepatology, 34, 411-6. 
 
YEH, C. T., LIAW, Y. F. & OU, J. H. 1990. The arginine-rich domain of hepatitis B virus precore 
and core proteins contains a signal for nuclear transport. J Virol, 64, 6141-7. 
 
YUEN, M. F., GANE, E. J., KIM, D. J., WEILERT, F., YUEN CHAN, H. L., LALEZARI, J., HWANG, S. G., 
NGUYEN, T., FLORES, O., HARTMAN, G., LIAW, S., LENZ, O., KAKUDA, T. N., TALLOEN, W., 
SCHWABE, C., KLUMPP, K. & BROWN, N. 2019. Antiviral Activity, Safety, and Pharmacokinetics 
of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. 
Gastroenterology, 156, 1392-1403 e7. 
 
YUEN, M. F., SETO, W. K., CHOW, D. H., TSUI, K., WONG, D. K., NGAI, V. W., WONG, B. C., FUNG, 
J., YUEN, J. C. & LAI, C. L. 2007. Long-term lamivudine therapy reduces the risk of long-term 
complications of chronic hepatitis B infection even in patients without advanced disease. 
Antivir Ther, 12, 1295-303. 
 
ZHANG, T. Y., CHEN, H. Y., CAO, J. L., XIONG, H. L., MO, X. B., LI, T. L., KANG, X. Z., ZHAO, J. H., 
YIN, B., ZHAO, X., HUANG, C. H., YUAN, Q., XUE, D., XIA, N. S. & YUAN, Y. A. 2019. Structural 
and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. 
Nat Commun, 10, 3192. 
 
ZHANG, Y. Y., ZHANG, B. H., THEELE, D., LITWIN, S., TOLL, E. & SUMMERS, J. 2003. Single-cell 
analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc 
Natl Acad Sci U S A, 100, 12372-7. 
 
ZHANG, Z. & TAVIS, J. E. 2006. The duck hepatitis B virus reverse transcriptase functions as a 
full-length monomer. J Biol Chem, 281, 35794-801. 
 
ZHAO, Y., MORGAN, M. A. & SUN, Y. 2014. Targeting Neddylation pathways to inactivate cullin-
RING ligases for anticancer therapy. Antioxid Redox Signal, 21, 2383-400. 
 
ZHOU, S. L. & STANDRING, D. N. 1991. Production of hepatitis B virus nucleocapsidlike core 
particles in Xenopus oocytes: assembly occurs mainly in the cytoplasm and does not require 
the nucleus. J Virol, 65, 5457-64. 
 
ZHOU, X., SHI, H., YANG, S. & SUN, P. 2017. An efficient rapid system for assaying HBx-mediated 
transactivation. Biotechnol Lett, 39, 1091-1099. 
 
ZHU, Y., YAMAMOTO, T., CULLEN, J., SAPUTELLI, J., ALDRICH, C. E., MILLER, D. S., LITWIN, S., 
FURMAN, P. A., JILBERT, A. R. & MASON, W. S. 2001. Kinetics of hepadnavirus loss from the 
liver during inhibition of viral DNA synthesis. J Virol, 75, 311-22. 
 
ZLOTNICK, A., LEE, A., BOURNE, C. R., JOHNSON, J. M., DOMANICO, P. L. & STRAY, S. J. 2007. In 
vitro screening for molecules that affect virus capsid assembly (and other protein association 
reactions). Nat Protoc, 2, 490-8. 
References 
 
 
152 
 
ZOULIM, F., SAPUTELLI, J. & SEEGER, C. 1994. Woodchuck hepatitis virus X protein is required 
for viral infection in vivo. J Virol, 68, 2026-30. 
 
ZUCKERMAN, A. J. 1996. Hepatitis Viruses. In: TH & BARON, S. (eds.) Medical Microbiology. 
Galveston (TX): University of Texas Medical Branch at Galveston 
The University of Texas Medical Branch at Galveston. 
 
